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 i 
Abstract 
 
Postmenopausal women experience an accelerated bone loss with 
increased fracture risk caused by oestrogen deficiency. Biomarkers of bone 
turnover assess the changes of bone metabolism in postmenopausal women; 
however, prediction of bone loss with these common biomarkers cannot be 
achieved because bone biomarkers might not reflect the bone microenvironment 
status. Thus, there is a need for discovering new bone biomarkers that can 
efficiently predict bone loss in postmenopausal women. Previous studies suggest 
that the ovariectomised sheep in combination with injected glucocorticoids may 
be a reliable model to evaluate the biological response to oestrogen withdrawal 
as well as the bone remodelling process.  
The purpose of this research programme was to test the following 
hypotheses: 1) ovariectomising sheep in combination with monthly injections of 
glucocorticoids would result in decreased bone mineral density (BMD) and 
increased plasma bone remodelling marker concentration over a shorter period 
of time; 2) the plasma metabolome and lipidome of ovariectomised sheep would 
be different, and the biochemical changes in plasma and bone remodelling would 
be associated with bone loss; 3) and finally, there would also be a difference in 
the plasma metabolome and lipidome of Singaporean–Chinese postmenopausal 
women according to their bone mineral density status. The hypotheses were 
evaluated using the OVX sheep in combination with glucocorticoids as a large 
animal model for postmenopausal osteoporosis, as well as comprehensive LC–
MS-based metabolomics as a diagnostic approach to identify lipids and 
metabolites associated with bone loss in postmenopausal women.  
 ii 
The OVX sheep model was successfully validated over five months of this 
study period, and bone mineral density was decreased and bone biomarkers 
increased after five months. Then, plasma samples from this animal model were 
analysed to measure the metabolome and lipidome of the OVX sheep. In the 
OVX sheep, metabolite and lipid alterations associated with bone loss included 
methionine, glutaric acid, tryptophan, 5-methoxytryptophan, CL and CerP, and 
these correlated with OC, CTx-1, femoral BMD and lumbar spine BMDThese 
studies revealed dynamic changes of the metabolite and lipid profiles from 
affected sheep, such as perturbation in multiple amino acids, metabolites, and 
fatty acid β-oxidation. Additionally, the results from the Singaporean–Chinese 
postmenopausal women showed alterations in proline, threonine, methionine, 4-
aminobutyric acid, aminopropionitrile, phosphatidic acid, diacylglycerol, CerP and 
phosphatidylinositol correlated with low femoral neck BMD. Methionine and CerP 
were the common compounds altered in OVX sheep and SC women with low 
BMD when compared with healthy groups. Those compounds, which are known 
to be involved in bone remodelling, have the potential for studying early bone 
loss in postmenopausal women, where identifying new bone-specific biomarkers 
may aid in clarifying novel molecular mechanisms of bone loss. 
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Chapter 1 
 
 
 
  
 
Thesis Introduction 
  
 2 
   
1.1 Thesis background 
 
Osteoporosis is a degenerative bone disease and a major health concern 
worldwide. Globally, 200 million people are affected, placing a considerable 
burden on financial healthcare systems (Reginster and Burlet, 2006). In women, 
oestrogen loss affects mainly the bone remodelling process, where 
overexpression of osteoclasts (bone resorbing cells) leads to bone loss (Riggs, 
2000). Deregulation of the bone remodelling process is often associated with 
bone diseases such as osteoporosis in women (Charatcharoenwitthaya et al., 
2007). Elucidation of the metabolic signals that regulate bone remodelling and 
mineralisation may allow the identification of new bone biomarkers to predict 
bone loss, as well as the development of new therapies to prevent bone loss in 
women. Specific metabolic pathways such as glycolysis, the tricarboxylic acid 
cycle (TCA), glutamine metabolism and fatty acid metabolism are regulated by 
oestrogen (Chen et al., 2009). Therefore, understanding the complex interactions 
of these metabolic pathways will not only improve the understanding of bone 
remodelling, but also could lead to the discovery of the relevant signalling 
pathways leading to bone metabolic alterations and osteoporosis in women. 
There has been an interest in developing accurate biomarkers that can 
predict bone loss, as well as interest in characterising cellular and extracellular 
components of the bone metabolism that are produced in health or disease 
states. Most of these biochemical biomarkers are used to monitor bone loss and 
measure the level of response to treatment for osteoporosis (Eastell and Hannon, 
2008). Bone biomarkers are released during bone remodelling and can be 
classified into two categories. Bone resorption markers reveal osteoclast activity, 
such as degradation of products of type 1 collagen. Bone formation markers 
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reflect osteoblast activity with products of collagen synthesis (Kuo and Chen, 
2017). There are many limitations involving these biomarkers, such as biological, 
exogenous and technical reasons, as well as both intra- and inter-laboratory 
variability. These current bone biomarkers can also not be used for early 
diagnosis of bone loss. The main function of these biomarkers is to aid in 
monitoring the response of treatments (drugs and diets), as an increase in the 
biochemical marker levels has been shown to be related to greater fracture risk 
(Hlaing and Compston, 2014). 
New biomarkers for improving the understanding of physiological 
interactions and metabolic responses to oestrogen loss need to be investigated. 
Novel technologies and bioinformatics tools offer the potential to investigate 
these complex interactions. Metabolomics aims to obtain the most relevant 
biochemical information from any health condition, as well as tracking the effects 
of drug or diet interventions (McNiven et al., 2011); however, metabolomics has 
not been used extensively to understand the association between the plasma 
metabolome and bone loss in postmenopausal women. Outcomes from 
metabolomics analyses would be expected to facilitate the discovery of new 
biomarkers associated with bone loss that aid an understanding how oestrogen 
loss influences the metabolic regulation of bone remodelling during menopause.  
 
1.2 Initial research questions  
This PhD project was part of a collaboration between Massey University, three 
institutes from Singapore's Agency for Science, Technology and Research, the 
University of Auckland and AgResearch. The project was funded via the bilateral 
agreement between the New Zealand Ministry of Business, Innovation and 
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Employment, and A*Star in Singapore. The aims of the overarching project were 
to identify and validate biomarkers using imaging and metabolic methods for 
clarifying the underlying mechanism of the diabetes risk in Singaporean–Chinese 
(SC) women. The project focused on the Chinese phenotype as it represents 
70% of the Singapore demographic. The project addressed two research 
questions in three objectives. 1) Can novel imaging and metabolic markers be 
identified and validated to improve the detection of SC women at increased 
diabetes risk? 2) Can appropriate dietary strategies improve metabolic health in 
SC women at increased diabetes risk?  
• Objective 1: improved body composition assessment of SC women for 
detection of early diabetes risk. 
• Objective 2: new metabolic markers in SC women for identification of early 
diabetes risk. 
• Objective 3: improved analyses of alterations in metabolic control in 
response to acute dietary interventions in SC women.  
During menopause, there are several changes associated with a variety 
of pathologies such as diabetes and bone loss, and postmenopausal women are 
also at increased osteoporosis risk, which increases with age (Karimifar et al., 
2012). The study cohort included a group of 97 postmenopausal women aged 
between 55 and 70 years. Thus, this PhD thesis was part of this project and was 
part of objective 2, where the aim was to provide rationale for gaining knowledge 
of the specific altered mechanisms and interactions between bone cells and bone 
remodelling in postmenopausal osteoporosis. The OVX sheep as a large animal 
model for postmenopausal osteoporosis was used to prove and explore how 
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these perturbed mechanisms and their interactions result in bone loss. The OVX 
sheep model has a faster rate of bone healing than in humans, but is still 
considered a suitable model for human bone turnover and remodelling activity 
(Pearce et al., 2007). There is, however, a lack of knowledge on the association 
between the metabolome and bone loss. 
 
The objectives of my project were to:  
 
1) optimise and characterise a sheep model for postmenopausal 
osteoporosis; 
2) identify novel biomarkers to improve our understanding of bone loss in 
women; 
3) acquire knowledge on how oestrogen loss influences the metabolic 
regulation of bone remodelling during menopause; 
4) determine the interaction between the plasma metabolome and lipidome 
of sheep and bone remodelling; and 
5) describe the association between the plasma metabolome and lipidome of 
postmenopausal SC women and bone loss. 
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1.3 Thesis introduction  
 
Chapter 2 defines the scope of the thesis and presents the current knowledge 
about postmenopausal osteoporosis and the recent findings on the plasma 
metabolome and bone health. Chapter 3 describes a sheep model for bone loss 
over a short period of time. Chapter 4 presents variations within skeletal sites and 
discusses bone loss at different anatomical areas in OVX sheep. Chapter 5 
employs the sheep model developed in Chapter 3 and presents for the first time 
results of a MS-based metabolomics approach, and discusses the association of 
the plasma metabolome with bone loss in the sheep model. Chapter 6 presents 
the results of altered plasma lipidome in the OVX sheep and discusses the 
relationship between the plasma lipid profiles and the bone remodelling process. 
Chapter 7 presents the findings in a human cohort of SC postmenopausal women 
using the same MS-based metabolomics approach, and discusses the 
association of the serum metabolome and lipidome with bone loss in women. 
Chapter 8 presents general discussions and then conclusions on all the findings 
obtained during this project. Future work and perspectives are also suggested. 
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Chapter 2 
 
 
 
 
 
 
 
Literature review 
 
 
 
This chapter reviews the current knowledge about the biology of bone tissue. In 
addition, the pathogenesis of osteoporosis and its current assessments are 
discussed. Next, a review of metabolomics approaches and recent findings on 
the plasma metabolome in models of osteoporosis are discussed. Finally, 
knowledge gaps are defined, where the aim was to evaluate whether LC–MS-
based untargeted metabolomics was suitable to identify lipids and metabolites 
associated with bone loss in postmenopausal women. 
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2.1 Bone 
 
2.1.1 Bone structure 
 
Bone is an active tissue undergoing a continuous remodelling process to 
preserve skeletal strength. Bone is a component of the skeletal system with 
several functions in the body; one of them is its structural function, which gives 
support and protection to vital organs such as the heart and lungs, and it also 
provides strength and rigidity. Further, bone stores minerals such as calcium and 
phosphates, and regulates these to maintain the levels in blood (Barrère et al., 
2006; Cohen Jr, 2006; Hadjidakis and Androulakis, 2006).  
The adult skeleton is formed out of more than 206 bones, including long 
bones (humerus, femur and tibia), short bones (wrist and ankle), flat bones 
(sternum and skull) and irregular bones (pelvis and lumbar spine). Bones can be 
classified into two categories depending on their structure, and the long bones 
can be used to describe the macrostructure of bone. A long bone has two 
cylindrical ends (epiphyses), which are formed out of trabecular bone and a 
central shaft (diaphysis) formed with cortical bone. The diaphysis and epiphysis 
are connected by a narrowed shape named metaphysis. Moreover, bone 
structure can be arranged either in a cortical (compact) or cancellous (trabecular) 
manner. Approximately 80% of the skeleton is formed by cortical bone, while 
cancellous bone is found in the interior of the end of long bones as well as within 
flat and irregular bones such as the sternum, skull, pelvis and lumbar spine, 
whose cavities are composed of blood vessels, marrow and adipose tissue 
(Barrère et al., 2006; Stevens, 2008; Brandi, 2009).  
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Bone consists of two types of structures: a mineral phase formed by 
crystals of hydroxyapatite [Ca10(PO4)6(OH)2] with carbonate, magnesium and 
acid phosphate (70–90% mineral/dry weight)  and ions such as Na+, Mg2+, HPO42-
, Cl-, F- and CO32+; and an organic part consisting of collagen fibres (90% type 1 
collagen) and noncollagenous proteins (Flynn, 2003; Clarke, 2008). Collagen 
plays a key role in the structure and function of bone tissue, where collagen type 
1 is the most abundant (Young, 2003). This has a repetitive amino acid sequence 
of glycine–X–Y, where X is proline and Y is hydroxyproline. Along this repetitive 
structure, three polypeptide chains are formed: two 1α chains and one 2α chain. 
This confers to the type 1 collagen a singular triple-helical structure, which is 
responsible for the crosslinking chemistry and structure given to the organic 
phase characterised by some properties such as strength and viscoelasticity 
(Fratzl et al., 2004) . 
Bones are adapted to changes in the mechanical loadings and physical 
activities of life without breaking (Liebschner, 2004). This adaptation is mainly 
due to bone materials and their relative amount, arrangement and molecular 
structure. These comprise minerals and proteins (type 1 collagen) both having 
different mechanical properties; the mineral confers strength and stiffness to the 
bone and the collagen is tough providing flexibility. Thus, the combination of these 
properties and the proportion of those in space provide the ability to disperse 
energy under mechanical deformation, stiffness and resistance to avoid fractures 
(Currey, 2003; Fratzl et al., 2004; Turner, 2006).  
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2.1.2 Bone cells  
 
Bone is a mineralised connective tissue containing three types of bone 
cells: osteoblasts, osteocytes and osteoclasts (Figure 2.1).  
 
Figure 2.1: Schematic of the bone remodelling process and the basic 
multicellular unit (BMU). The bone remodelling compartment consists of the cells 
compromising osteoblasts, osteocytes and osteoclasts. Osteoblasts and 
osteoclasts are derived from mesenchymal and hematopoietic precursors, 
respectively. Diagram is modified from (Kapinas and Delany, 2011).  
 
Bone is a dynamic organ that is continually formed by osteoblasts and 
reabsorbed by osteoclasts. The balance between bone formation and bone 
resorption cells, which are highly coupled to ensure that the bone mass is 
preserved,  depends on the actions of local and systemic factors, including 
hormones, cytokines and biochemical stimulation, that regulates bone cell 
differentiation and functions (Crockett et al., 2011).  
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2.1.2.1 Osteoblasts 
 
Osteoblasts are bone cells responsible for the formation of new bone. 
Osteoblasts are mononucleated cells, and their roles are in the formation of the 
organic matrix called osteoid, in calcification and in the synthesis of proteins. 
Osteoblasts develop from mesenchymal stem cells (MSCs); MSCs require the 
factor Sry HMG box protein 9-positive (SOX9+) to derive osteoblasts and 
chondrocytes, and the synthesis of bone morphogenetic proteins (BMPs) and 
members of Wingles (Wnt) (Calvi et al., 2001). Then, runt-related transcription 
factor 2 (RunX2+) is expressed and MSCs differentiate to osteoprogenitors. 
Simultaneously, the differentiation depends on some transcriptional factors such 
as SOX9+ to differentiate to chondrocytes; whilst osteoblasts develop when 
osterix (OSX+), RunX2+ and β-catenin are elevated (Gaur et al., 2005; Hill et al., 
2005). Wnts and Wnt pathway components affect early bone development 
stages. Wnts are cysteine-rich glycoproteins involved in cell differentiation, cell-
fate specification and cell survival. The Wnt/β-catenin pathway promotes RunX2+ 
expression to induce osteoblast differentiation (Bain et al., 2003; Gaur et al., 
2005). Then, the osteoblasts become activated and are located alongside the 
bone surface, where they form the bone matrix (osteoid) during bone formation. 
Mature osteoblasts may undergo apoptosis, differentiate into osteocytes or 
become lining cells. Osteoblasts produce type 1 collagen and noncollagenous 
proteins including osteocalcin and alkaline phosphatase. Total alkaline 
phosphatase activity is an indicator of osteoblast differentiation. Osteoblasts 
regulate osteoclast differentiation by expressing two cytokines, macrophage 
colony-stimulating factor (M-CSF) and receptor activator of nuclear factor-κB 
ligand (RANKL) (Capulli et al., 2014). Osteoblasts also inhibit osteoclastogenesis 
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by blocking the RANKL–RANK interaction via osteoprotegerin (OPG), a tumor 
necrosis factor (TNF) receptor expressed in osteoblasts (Proff and Römer, 2009; 
Yamashita et al., 2012).  
2.1.2.2 Osteocytes 
 
Mature osteoblasts that have finalised their role in the bone matrix become 
osteocytes. Among the bone cells, osteocytes are the most abundant (around 
95%). It is hypothesised that they detect alterations in skeletal bone such as 
microfractures, and maintain bone structure. The osteocytes are connected with 
osteoblasts from the surface and adjacent osteocytes in the bone matrix, and 
form long dendritic processes. These form a mechano-sensing network of 
signalling that evaluates the mechanical loading of bone. When a microfracture 
is present, a signal is generated which travels throughout this matrix until it 
reaches the bone surface, where it provokes the start of bone remodelling, 
although this has not been fully validated (Prentice, 2001; Young, 2003; 
Bonewald, 2007; Matsuo and Irie, 2008). Then, osteocytes appear to use the 
Wnt/β-catenin signalling pathway to send signals of mechanical loading to bone 
cells (osteoblasts) on the surface (Bonewald and Johnson, 2008). Osteocytes 
also secrete sclerostin to downregulate bone response to a mechanical loading. 
Hence, sclerostin inhibits bone formation through Wnt/β-catenin signalling in 
osteoblast differentiation by binding to the low-density lipoprotein-related protein 
5/6 (LRP5 and LRP6) and inhibiting canonical Wnt/β-catenin signalling (Li et al., 
2005). This is supported by  Wijenayaka et al. (2011), who found that sclerostin 
upregulates osteoclastogenesis. Further, osteocytes promote bone resorption 
due to expressing RANKL.  Nakashima et al. (2011) reported that mice lacking 
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this factor in osteocyte cells showed an osteopetrotic phenotype, which is 
characterised by an altered bone resorption and increased bone density.  
 
2.1.2.3 Osteoclasts 
 
Osteoclasts resorb bone through secretion of acid and proteases at a 
small compact and cortical bone area named a basic multicellular unit (BMU; 
Figure 1) (Proff and Römer, 2009). Osteoclasts have several morphological and 
phenotypic characteristics such as multinuclearity and expression of tartrate-
resistant acid and the calcitonin receptor (Teitelbaum and Ross, 2003). These 
cells develop from hematopoietic stem cells (Robling et al., 2006). Osteoclasts 
are multinucleated cells with apical and basolateral sides, each having different 
structures and functions (Clarke, 2008). Osteoclast differentiation is controlled by 
proteins, cytokines and growth factors that affect maturation of the monocyte–
macrophage lineage (Väänänen et al., 1998). The proteins involved are M-CSF 
and RANK, which are regulated by the cytokine TNF-α. The pre-monocyte 
produces M-CSF which allows the differentiation of the osteoclast precursor, and 
during this stage, the cells express RANK. Thus, it is possible to activate 
osteoclasts through RANK and colony stimulating factor 1 (CSF-1), which are 
cytokines needed for osteoclast differentiation and survival (Raggatt and 
Partridge, 2010). Additionally, some chemoattractants have been reported as 
being responsible for migration and targeting of the osteoclasts on the BMU, such 
as stromal cell-derived factor-1 (SDF-1). There are also other matrix 
metalloproteinases (MMPs), required by osteoclasts, such as MMP14, to move 
through the bone surface (Bar-Shavit, 2007). Active osteoclasts are highly 
polarised with specific membrane domains; one of them, the sealing zone, is 
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responsible for sealing the resorption area. In addition, adhesion molecules such 
as the integrin αvβ3 mediate the attachment of the osteoclast to the bone matrix 
(Ross and Teitelbaum, 2005).  
The activation of osteoclasts is regulated by osteoblastic lineage cells, as 
mentioned above. These cells of osteoblastic lineage express the factors 
receptor activator of nuclear factor-kappa ligand (RANKL), M-CSF and 
osteoprotegerin (OPG); while the pre-osteoclasts express RANK and c-Fms. 
RANKL on the osteoblastic lineage cells activates osteoclastogenesis by binding 
to and activating RANK on the osteoclast precursor. This activation by RANKL is 
controlled by three cytokines: interleukin-1 and -6 (IL-1 and IL-6) and TNF-α; as 
well as by vitamin D (1,25-dihydroxyvitamin D3). On the other hand, transforming 
growth factor β (TGF-β) and oestrogens may cause inhibition of 
osteoclastogenesis and bone resorption. M-CSF plays an important role in bone 
resorption due to being an important factor in the initiation of differentiation of the 
pre-osteoclasts. Finally, OPG is another key factor in this process because it has 
the ability to maintain a balance between bone resorption and formation, thereby 
blocking the effects of RANKL on osteoclasts. OPG expression is regulated by 
most of the factors that induce RANKL expression (Boyce and Xing, 2006). 
Further, oestrogen increases the levels of OPG (Riggs, 2000). In addition, 
Wnts/β-catenin controls osteoclastogenesis by enhancing the OPG-to-RANKL 
ratio in osteoblasts (Glass et al., 2005). The Wnt5 produced by osteoblasts 
promotes RANK expression in osteoclast precursors (Maeda et al., 2012). Thus, 
factors and hormones act in harmony, inducing the osteoclast formation directly 
and/or blocking activation via OPG to control and maintain the homeostasis of 
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bone remodelling (Christenson, 1997; Khosla, 2001; Robling et al., 2006; Proff 
and Römer, 2009; Kular et al., 2012; Rosenberg et al., 2012). 
 
2.1.3 Bone remodelling  
 
Bone is an active tissue with metabolic activity and the ability to grow and 
synthesise new bone through the activity of several types of bone cells. Bone 
remodelling is a complex process and depends on the synchronisation of bone 
resorption and subsequent bone formation, where osteoclasts are active early in 
this phase (Christenson, 1997). Bone remodelling is initiated in response to 
changing mechanical environments and to repair microcracks in the bone matrix. 
Bone remodelling occurs at the BMU, and multiple active BMUs are present in 
the skeleton at any one time. These processes are dependent on bone cells, 
mechanical demands, growth factors, enzymes and hormones (Flynn, 2003; 
Turner, 2006; Peacock, 2010). The bone cells play a key role in this metabolic 
process. Osteoclasts act on resorption and the osteoblasts on formation of bone 
and mineralisation, but only the osteocytes take part during all the processes 
(Marks and Popoff, 1988; Kular et al., 2012).  
The remodelling of the bone comprises resorption, reversal, formation and 
resting phases (Figure 2.2).  
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Figure 2.2: Bone remodelling stages. Simplified scheme of bone remodelling 
stages, where osteoclasts reabsorb old bone and stimulate osteoblasts to make 
new bone. Modified from (Bonjour et al., 2014). 
 
The production and differentiation of osteoclast precursors from the 
hematopoietic stem cells is known as the initiation phase, followed by a 
differentiation phase which turns them into mature osteoclasts, which then initiate 
erosion of bone. This phase is named resorption, and osteoclasts normally 
reduce the bone and form lacunae approximately 100 µm in diameter and 50 µm 
deep. During the first stage of resorption, calcium phosphate crystals are digested 
through their link to collagen by the osteoclasts in the bone matrix. Then, the 
collagen residues are digested by enzymes (collagenases) and these residual 
molecules are internalised or transported across the cells from the apical to the 
basolateral side. The apical side facing the bone secretes proteolytic enzymes 
such as acidic hydrolases, including cathepsin K, and MMPs, such as the MMP-
9 important for the degradation of the organic component of bone. While the 
basolateral side facing the vascular stream has receptors for hormones and other 
substances important for ion transport and response to signals (Christenson, 
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1997). During the reversal phase, osteoclasts are detached from the bone 
surface, and macrophage-like cells are thought to contribute to stimulating 
osteoblasts and removing old bone from the resorption phase. Once the eroded 
area has been cleaned, bone resorption changes to bone formation by osteoblast 
precursors. Then, new bone is formed by osteoblasts during the formation phase, 
where the osteoblasts lay down the osteoid matrix (mainly type 1 collagen). After 
this, when the BMU is filled with osteoid, the mineralisation phase takes place, 
and this matrix is mineralised with hydroxyapatite. Bone remodelling is a 
regulated process and therefore an imbalance may result in bone mass reduction 
with a subsequent bone loss. Factors such as parathyroid hormone  and gonadal 
steroids control bone remodelling, but cytokines and growth factors are also 
crucial to regulate bone cells (Christenson, 1997; Teitelbaum, 2000; Martin and 
Sims, 2005; Henriksen et al., 2009; Proff and Römer, 2009; Kular et al., 2012). 
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2.1.3.1 Systemic regulation of bone metabolism 
 
Bone metabolism is regulated mainly by several circulating hormones and 
growth factors, including PTH, vitamin D and oestrogen (Figure 2.3).  
Figure 2.3: Systemic regulation of bone remodelling. In osteoclasts, oestrogen 
prevents bone resorption by directly inducing apoptosis of osteoclasts. Oestrogen 
blocks RANKL/M-CSF, thus suppressing RANKL-induced osteoclast 
differentiation. In osteoblasts, oestrogen inhibits osteoblast apoptosis. Oestrogen 
controls the expression of RANKL, OPG and M-CSF. PTH induces differentiation 
of osteoblast precursors. PTH activates bone resorption through producing 
RANKL and M-CSF. Vitamin D enhances osteoblastogenesis through 
differentiation by mesenchymal stem cells (MSCs) to osteoblasts. Arrows and T-
bars indicate activating and inhibiting functions, respectively. Modified from 
(Tsartsalis et al., 2012). 
 
2.1.3.1.1 Parathyroid hormone (PTH) 
 
PTH regulates the commitment of mesenchymal stem cells to the 
osteoblast lineage, and has both anabolic and catabolic effects on bone 
metabolism (Silva and Bilezikian, 2015). PTH increases the number and activity 
of osteoclasts, and promotes both recovery of Ca2+ at the level of the kidney and 
production by the kidney of calcitriol, the active form of vitamin D. PTH is the main 
regulator of plasma calcium and plays a vital role in bone remodelling (Wein and 
Kronenberg, 2018). Thus, calcium homeostasis is maintained as a result of the 
release of PTH when there is a reduction of plasma calcium. Upon release, PTH 
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activates bone resorption, resulting in an enhancement of osteoclastogenesis 
through promoting MCP-1 and RANKL in osteoblasts (Poole and Reeve, 2005; 
Raggatt and Partridge, 2010); when PTH is administered constantly, it promotes 
bone resorption. As a result, high doses of PTH stimulate RANKL production by 
osteoblasts and suppress OPG levels, causing an increase in bone resorption 
(Ma et al., 2001; Hofbauer et al., 2004; Qin et al., 2004). PTH also controls 
osteoblastogenesis, osteoblast/osteocyte apoptosis and bone mineralisation 
(Isogai et al., 1996; Goltzman, 1999). Conversely, low PTH as a result of high 
plasma calcium enhances osteoblast formation and differentiation by activating 
RunX2+, promoting osterix expression and the β-catenin pathway, and the 
ultimate deposition of calcium in bone. Thus, bone formation is enhanced when 
PTH is administered intermittently or in low doses (Selvamurugan et al., 2000; 
Kim et al., 2003; Boumah et al., 2009). PTH blocks sclerostin expression in 
osteocytes and increases bone formation rate. Mechanical stimulation and the 
PTH signal via PTH receptors on osteocytes enhances the Wnt signalling 
pathway, allowing bone formation to occur and improving bone mineral density 
(Bellido et al., 2013).  
 2.1.3.1.2 Vitamin D (1,25-dihydroxyvitamin D3) 
 
Vitamin D impacts on bone metabolism, and the most active form of 
vitamin D promotes removal of calcium from the bone to control calcium 
metabolism. Vitamin D is changed to 25-hydroxyvitamin D in the liver, and is 
subsequently converted to 1,25-dihydroxyvitamin D3 (the active metabolite of 
vitamin D) in the kidneys. The synthesis of osteocalcin by osteoblasts is 
dependent on 1,25-dihydroxyvitamin D3 (Beresford et al., 1984). 1,25-
Dihydroxyvitamin D3 binds to a vitamin D receptor and osteoblasts to control the 
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calcium-specific nuclear hormone receptor, and thus there is an increase in 
intestinal calcium absorption and regulation of bone turnover (Holick, 2004). 
However, calcium absorption is regulated by a cytosolic calcium-binding protein, 
calbindin-D9k, and its synthesis is dependent on 1,25-dihydroxyvitamin D3. Thus, 
the diffusion of Ca2+ is facilitated by calbindin-D9k across the intestinal cell, where 
a Ca-ATPase at the basolateral membrane mediates the active extrusion of Ca2+ 
and takes place against an electrochemical gradient  (Bouillon et al., 2003; 
Cashman, 2007). It has been reported that 1,25-dihydroxyvitamin D3 enhances 
calbindin-D28k synthesis as well as osteocalcin and alkaline phosphatase 
activity. In in vitro studies, calbindin-D28k has been reported to have a role in 
mineralised matrix formation in bone marrow stromal cells. Hence, 1,25-
dihydroxyvitamin D3 is crucial for the intestinal absorption of calcium and is 
therefore essential for maintaining calcium homeostasis and mineralisation 
(Heaney, 2002).  
 2.1.3.1.3 Glucocorticoids and oestrogen  
 
Glucocorticoids are steroid hormones of the corticosteroid class, and are 
often used clinically to reduce inflammation. They can cause secondary 
osteoporosis, as a result of suppression of osteoblast function and bone 
formation, through increasing apoptosis of the osteoblasts (Rodan and Martin, 
2000; Canalis, 2003). Glucocorticoids increase the expression of RANKL and M-
CSF and OPG is suppressed, resulting in impaired bone remodelling (Hofbauer 
et al., 1999; Canalis, 2003). Growth factors are also affected by glucocorticoids. 
Principally insulin-like growth factors (IGFs) increase the formation of type 1 
collagen and mineral apposition rates, and reduce bone collagen degradation; 
however, glucocorticoids may have an effect on IGF I synthesis of mature 
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osteoblasts, where glucocorticoids may exert control by downregulation of 
osteoblastic IGF I expression, and this may lead to an uncoupling of bone 
remodelling (Delany et al., 2001). Glucocorticoids inhibit calcium absorption from 
the intestine by opposing vitamin D actions (Canalis et al., 2007). 
Oestrogen, the primary female sex hormone, plays a key role in the bone 
resorption on the BMUs by inhibiting osteoclast differentiation and promoting 
apoptosis of osteoclasts (Khosla et al., 2012). Oestrogen also increases bone 
formation activity of osteoblasts, and is directly involved in bone remodelling to 
reduce bone turnover rate and maintain the balance between osteoclast activity 
and osteoblasts (Harada and Rodan, 2003). Osteoclast formation is controlled by 
oestrogen due to the inhibition of cytokines, and RANKL is suppressed by this 
hormone while OPG secretion is stimulated (Rodan and Martin, 2000; Saika et 
al., 2001). Additionally, oestrogen promotes osteoclast apoptosis by promoting 
the Fas ligand (FasL) in osteoblasts, where oestrogen receptor-alpha (ERα) is its 
target gene (Nakamura et al., 2007; Krum et al., 2008). Oestrogen deficiency 
enhances TNF-α production by T cells. TNF-α increases osteoclastogenesis by 
increasing RANKL and M-CSF.  
The complex process of bone remodelling is controlled by oestrogen, PTH, 
vitamin D and cytokines (RANKL, OPG and M-CSF). The interaction between 
osteoblasts, osteoclasts and systemic regulators plays a significant role in 
regulation of physiological bone remodelling. Overall, an imbalance in the 
systemic regulators, as reflected by bone cells, involves several factors and their 
interactions. Currently the antiresorptive drugs for treatment of osteoporosis are 
well known to alter osteoclast functions, where those agents have shown a 
reduction in bone resorption but the effects of these in bone formation are still 
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under discussion. Better understanding of the mechanisms of bone remodelling 
will lead to the development of better treatments to target growth factors in 
osteoporosis or other bone pathologies.  
 
 2.2 Pathogenesis of osteoporosis 
 
Bone is maintained by the dynamic balance of bone formation and bone 
resorption, and imbalances in these bone processes are responsible for bone 
diseases. Osteoporosis is characterised by low bone mass and deterioration of 
bone tissue with the consequent increase in fracture risk. Osteoporosis 
represents a huge public health problem in the elderly population and results in 
high care costs for health systems (Holroyd et al., 2008). The most frequent 
fractures are in the proximal femur, lumbar spine and distal forearm, but before 
the fractures occur, osteoporosis can be diagnosed with noninvasive methods to 
measure bone mineral density (BMD) (Cosman et al., 2014).  
Osteoporosis is the most common metabolic bone disease and one of the 
most prevalent conditions associated with ageing. Osteoporosis can be classified 
as primary or secondary osteoporosis (Orimo et al., 2001). Primary osteoporosis 
can be classified into two different types. Type 1 affects postmenopausal women 
from the ages of 50–75 years, where higher trabecular bone loss occurs as a 
result of menopause (Riggs et al., 1998). This is mainly attributed to oestrogen 
deficiency, where the bone turnover cycle is impaired, and the amount of bone 
reabsorbed exceeds the amount of new bone deposited. Further, PTH 
overstimulates osteoclasts, and a reduced bone mass is the result (Raisz, 2005). 
Type 2 osteoporosis is age related and affects both men and women after the 
age of 70. Type 2 osteoporosis affects osteoblast function, where bone mass 
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decreases with microarchitectural alterations in bone as a result of a poor calcium 
absorption, an increase in PTH levels as well as a decreased intestinal 1,25-
dihydroxyvitamin D3 response (Riggs et al., 1998). Secondary osteoporosis bone 
loss occurs from diseases of the endocrine system, diseases of bone marrow, 
gastrointestinal diseases or treatment with corticoids, leading to fragility fractures 
and bone loss (Fitzpatrick, 2002).  
 
2.2.1 Current assessments of osteoporosis 
 
Postmenopausal women will exhibit bone loss and changes in their bone 
remodelling rate. Currently, several assessment methods are used to diagnose 
osteoporosis and it is frequently done through bone density measurements. 
These aid in the estimation of percentages of bone loss, prediction of the risk of 
fracture, and evaluation of the efficacy of treatments to prevent fractures (Bonnick 
and Shulman, 2006).  
 
2.2.1.1 Dual-energy x-ray absorptiometry (DXA) 
 
Dual-energy x-ray absorptiometry (DXA) is the gold standard for 
diagnosing osteoporosis. It measures bone mineral content and density, as well 
as fat mass and lean mass by using X-rays at two different energy levels, 40 and 
70 keV (Rothney et al., 2009). This technique is a recognised method for 
measuring bone mineral density (BMD), determining a treatment and observing 
its effects. Further, this equipment permits noninvasive and reproducible 
assessments of bone density with a low radiation exposure.  
The World Health Organisation (WHO) established criteria for diagnosis of 
osteoporosis. These criteria are used for assessments at the lumbar spine, hip 
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and forearm, which are the most common fracture sites in postmenopausal 
women. The bone mineral density measurements are reported in standard 
deviation (SD) values referred to as T-scores. Therefore, a T-score < –2.5 has 
been classified as osteoporosis, a T-score between –2.5 and –1.0 as osteopenia, 
and a T-score T ≥ –1.0 as normal BMD (Table 2.1) (World Health Organization, 
1994). The hip, posterior and anterior spine (L1–L4) measurements are 
performed in order to diagnose osteoporosis (Damilakis et al., 2007). Although 
DXA is the gold standard method for screening, monitoring and assessing the 
risk of bone fractures, it cannot predict bone loss. DXA scans can only identify 
bone loss in a patient when serial BMD assessment have been done over a 
period of years. Therefore, other methods that offer the opportunity of measuring 
the metabolic alterations in biofluids for fracture prediction should be investigated.  
 
Table 2.1: T-score scale. The WHO defines a T-score on the scale shown below. 
A BMD test compares the subject bone density to a “young normal” adult bone 
density. Results are given as a T-score. 
DXA BMD values Classification 
T score > –1.0 SD Normal BMD 
T score between –1.0 and –2.5 SD Osteopenia 
T score between –2.5 and –3.0 SD Osteoporosis 
T score < –3.0 SD with 1 or more fragility 
fractures 
Severe osteoporosis 
(WHO working group definition of osteoporosis.)  
 
2.2.1.2 Peripheral quantitative computed tomography (pQCT) 
 
Quantitative computed tomography is another method for the assessment 
of bone mass and densitometry. The method is based on computed tomography, 
provides a cross-sectional image slice and assesses volumetric BMD (vBMD) in 
the peripheral skeleton. Peripheral quantitative computed tomography (pQCT) 
can differentiate cortical and trabecular bone, and assesses geometric properties 
of bone tissue. This technique has the advantage of measuring accurately the 
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density, dimension and distribution of bone. Trabecular bone can easily be 
differentiated from cortical bone, and bone strength can also be predicted by this 
technique. The disadvantage is that it underestimates vBMD when the cortical 
bone thickness is low (Rüegsegger et al., 1976; Blake and Fogelman, 2001; 
Szabo et al., 2011). Thus, advanced imaging techniques are important to identify 
individuals at risk for fractures to predict bone loss, evaluate bone fragility and 
monitor response to treatments.  
 
2.2.2 Biochemical markers of bone turnover 
 
Biochemical markers can be used for aiding in osteoporosis diagnosis. 
The importance of bone remodelling is well established, and as bone is 
continually changing, specific biomolecules (markers) are released into 
circulation as a result of bone remodelling. Biochemical markers of bone turnover 
are normally classified according to a bone process. High-turnover bone 
biomarkers offer the clinical potential to assess changes in bone remodelling over 
short periods of time, to monitor treatment efficacy and to provide complementary 
information to BMD (Swaminathan, 2001). 
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2.2.2.1 Bone formation markers 
 
Markers of bone formation are by-products of active osteoblasts that are 
released during different phases of osteoblast development (Table 2.2).  
 
Table 2.2: Bone formation markers for bone remodelling. 
Marker Origin Advantages Disadvantages 
BAP Enzyme present on the outer 
cell surface of osteoblasts 
Indicator of osteoblast 
activity 
High cross-reactivity 
with liver alkaline 
phosphatase 
OC 
 
Osteoblasts synthesise this 
noncollagenous Gla protein 
Specific for bone 
formation 
Rapid degradation 
P1CP Cleavage of the carboxy 
terminal (N-terminal propeptide 
of type 1 collagen (P1CP)) 
Measure new 
deposition of type 1 
collagen 
Single protein; rapid 
degradation; regulated 
by thyroid and IGF-1 
 
P1NP Cleavage of the amino terminal 
(N-terminal propeptide 
of type 1 collagen (P1NP)) 
Measure new 
deposition of type 1 
collagen 
Affected by small 
circadian rhythm 
BPA = bone alkaline phosphatase, OC = osteocalcin, P1CP = procollagen type 1 carboxy-terminal propeptide, P1NP = 
procollagen type 1 amino-terminal propeptide.  
 
The most used bone formation markers are bone-specific alkaline 
phosphatase (BAP), carboxy- and amino-terminal procollagen type 1 propeptide 
and osteocalcin. BAP is a membrane isoenzyme with multiple isoforms including 
placental, intestinal, germ cell and tissue-nonspecific. The tissue-nonspecific 
enzyme is expressed in the liver, kidney and bone, and has been used as a 
marker of osteoblast activity (Langlois et al., 1994). Osteocalcin (OC) or bone 
GLA-protein (γ-carboxyglutamic acid (Gla) residues) is a noncollagenous protein 
and regulates calcium and bone formation. This noncollagenous protein accounts 
for up to 10% of total noncollagenous proteins. It is produced by osteoblasts, and 
vitamin 1,25-dihydroxyvitamin D3 regulates its expression (Risteli and Risteli, 
1993; Christenson, 1997; Allen, 2003). This small protein is vitamin K dependent, 
 27 
   
as this vitamin is a cofactor necessary for the formation of γ-carboxyglutamic acid 
(Gla) residues, which support the calcium binding characteristics of the protein 
(Risteli and Risteli, 1993). OC is released from bone cells during formation and 
from bone matrix during resorption (Swaminathan, 2001). 
Type 1 collagen is the most abundant form of collagen in the organic phase 
of the bone. Up to 90% is synthesised by osteoblasts as procollagen precursor 
molecules. The procollagen molecule has amino- and carboxy-terminal extension 
peptides. These peptides, named procollagen type 1 amino-terminal propeptide 
(P1NP) and procollagen type 1 carboxy-terminal propeptide (P1CP), are used as 
clinically relevant bone formation markers. P1NP has two major components with 
fragment sizes of 100 and 30 kDa. P1NP has been proposed to indicate bone 
turnover in postmenopausal women (Vasikaran et al., 2011b). P1CP is a protein 
with a molecular weight of 115 kDa, and contains mannose receptor chains of the 
hepatic cells (Melkko et al., 1990).  
 
2.2.2.2 Bone resorption markers 
 
During bone resorption, osteoclasts release collagen breakdown products 
such as collagen crosslinks, telopeptides and enzymes (Risteli and Risteli, 1993; 
Swaminathan, 2001; Seibel, 2005). These collagen breakdown products can be 
used as markers to measure the bone response to therapies (Table 2.3). 
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Table 2.3: Bone resorption markers for bone remodelling. 
Marker Origin Advantages Disadvantages 
TRAP5b Enzyme synthesised by 
osteoclasts 
Secreted by osteoclasts 
during bone resorption 
Enzyme is unstable to pH; 
current analytical methods 
lack specificity and sensitivity 
Cathepsin K Enzyme synthesised by 
osteoclasts 
Secreted by osteoclasts 
during bone resorption 
 
 CTx-1 Telepeptides of type 1 
collagen released 
during bone resorption 
by cathepsin-K 
Sensitive marker of 
bone resorption 
Affected by food intake and 
circadian rhythm 
NTx-1 Telepeptides of type 1 
collagen released 
during bone resorption 
by cathepsin-K 
Sensitive marker of 
bone resorption 
Not affected by food intake 
DPD Released when type 1 
collagen breaks down 
Measures degradation 
of mature collagen 
Nonspecific 24-h collection, 
needs to be corrected for 
creatinine 
PYD Released when type 1 
collagen breaks down 
Measures degradation 
of mature collagen 
Nonspecific 24-h collection, 
needs to be corrected for 
creatinine 
TRAP5b = tartrate-resistant acid phosphatase–isoform 5b, CTx-1= carboxy-terminal cross-linked telopeptides of type 1 
collagen, NTx-1 = amino-terminal cross-linked telopeptides of type 1 collagen, DPD = Deoxypyridinoline, PYD = 
Pyridinoline.  
 
Tartrate-resistant acid phosphatase–isoform 5b (TRAP5b) is a bone 
enzyme synthesised by osteoclasts and released into the circulation by leakage 
during resorption (Halleen et al., 2001). Similarly, cathepsin K is an enzyme 
synthesised by osteoclasts which is present in the outer membrane of these cells. 
During bone resorption, cathepsin-K is released by osteoclasts and its key role is 
the degradation of bone matrix composed of hydroxyapatite and proteins, 
especially type 1 collagen (Garnero et al., 2003). 
Crosslinks of collagens, such as pyridinoline (PYD) and deoxypyridinoline 
(DPD), are released during bone resorption when mature type 1 collagen is 
broken down by osteoclasts (Seibel, 2005). The concentrations of these 
crosslinks in the peripheral blood reflect the degradation rate of mature collagen. 
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PYD is found in cartilage, bone ligaments and vessels, whereas DPD is only 
found in bone and dentin (Eastell et al., 1993).  
Other degradation products of bone collagen are telopeptides of type 1 
collagen (NTx). Amino-terminal crosslinked NTx is released into circulation from 
the amino terminus of the mature type 1 collagen (NTx-1). NTx-1 is reported to 
be a sensitive marker of bone resorption (Christenson, 1997).  
Carboxy-terminal extension peptides of mature type 1 collagen (CTx-1) 
are also released during bone collagen resorption. The CTx-1 marker has a linear 
eight amino acid sequence (Garnero et al., 2003) and has been shown to be 
highly bone specific. Higher blood plasma levels of CTx-1 are correlated with risk 
of osteoporotic fracture (Garnero et al., 2000; Rosen et al., 2000). During early 
menopause there is an increase in bone resorption (Seifert-Klauss et al., 2002), 
and CTx-1 levels continue to increase during late menopause (Garnero et al., 
1996). Reginster et al. (2001) reported that CTx-1 can be used to establish a 
powerful discriminator in postmenopausal women with normal versus low BMD.  
Biochemical markers of bone turnover serve as indicators of bone 
remodelling activity. Biochemical marker analyses are relatively noninvasive 
methods to assess bone remodelling status, as blood or urine samples can be 
easily collected. Further, these bone turnover markers increase during 
menopause and the proportion of bone loss is dependent on the active bone 
metabolism (Garnero et al., 1996; Chen et al., 2005). It has been proposed that 
assessment of procollagen type 1 amino-terminal propeptide (P1NP) and 
crosslaps (CTx-1) levels are appropriate for approximating the rate of bone 
turnover in postmenopausal women (Łukaszkiewicz et al., 2008). However, 
 30 
   
current analytical methods have limitations in the detection of for whom treatment 
is suitable, or in the establishment of prognosis.  
The clinical parameters used in the diagnosis of bone loss in 
postmenopausal women, including bone densitometry by DXA and bone turnover 
markers, are often considered too insensitive to provide diagnostic information 
on disease onset, prognosis and fracture risk. Further research is needed to 
better understand the changes in biomarkers of bone turnover, monitor treatment 
efficacy and provide better treatment for diseases of bone metabolism and 
osteoporosis (Szulc, 2012). Therefore, the search for novel markers that indicate 
what is occurring in bone will aid our understanding and will lead to the 
development of novel dietary and physical interventions to improve quality of life 
by reducing the osteoporotic risk in postmenopausal women. 
 
2.2.3 Animal models of bone health 
 
In clinical research, the use of animal models is important due to the well-
known limitations associated with the use of humans as volunteers, including 
ethical challenges, specifically when the studies involve a novel therapy being 
tested in humans for the first time. Thus, to study osteoporosis, several animal 
models have been developed and tested in clinical research with the gold 
standard approach for osteoporosis being surgical ovariectomy (OVX) (Miller et 
al., 1995); however, comparing animal models to the human condition remains 
challenging. Clinical research in postmenopausal osteoporosis has been 
performed in mice, rats, rabbits, dogs, goats and sheep (Reichert et al., 2009). 
Rats are the animal model used most frequently due to their size and lower 
cost compared to large animals (Gomes and Fernandes, 2011). The rat model 
 31 
   
has been used more frequently in experimental procedures for induction of bone 
loss such as hormonal interventions, immobilisation and dietary manipulations 
(Lelovas et al., 2008). Bone metabolic disorders related to postmenopausal 
women require animal models that have similar phenotypes as humans in order 
to compare the findings from animal models to humans  (Egermann et al., 
2005). Further, the FDA has recommended the use of non-rodent models (large 
animal models) for osteoporosis and emphasised the study period, which should 
be long enough to obtain significant changes in the skeletal system of the animal 
model (Thompson et al., 1995).  
Sheep may provide a better animal model than rats in postmenopausal 
osteoporosis research, as sheep have more similarities to humans than the 
rodent models. Sheep are often used in biomedical research as their bone 
anatomy and metabolism are similar to those of humans (Newman et al., 1995; 
Reichert et al., 2009). The ovariectomised sheep has been explored more 
recently to examine the response of bone to OVX (Newton et al., 2004b). Several 
studies have been conducted using an OVX sheep model for osteoporosis with 
differences in bone mass and bone turnover (Lill et al., 2002c; Augat et al., 2003; 
Schorlemmer et al., 2005; Sigrist et al., 2007; Ding et al., 2010; Holland et al., 
2011).  Lill et al. (2002c) reported that glucocorticoids changed the bones of OVX 
sheep; however, the results did not reach statistical significance because of the 
small numbers per group. The sheep model therefore can be used to generate 
bone samples of a size approximating human bones for bone composition 
assessment by established or experimental methods, as well as to provide serial 
blood samples in sufficient volumes for measurement of known or novel bone 
markers. Finally, the sheep model is of interest for further exploration as recent 
 32 
   
data suggest that sheep may be able to reverse osteoporotic bone loss (Ding et 
al., 2010).  
 
2.3 The application of metabolomics to the study of postmenopausal 
osteoporosis 
 
In normal bone remodelling, bone homeostasis is maintained between 
bone formation and bone resorption, with this process being highly regulated. 
Studies are required to better describe the sequence of events that result in bone 
loss in postmenopausal women, and in particular to identify the specific 
alterations in molecular signalling, gene expression and bone cell physiology that 
occur due to oestrogen withdrawal and the subsequent changes in bone 
remodelling and bone loss. 
 
2.3.1 Metabolomics 
 
Metabolomics is a recent “omics” technique, which comprises the 
analyses of metabolites and their chemical reactions produced by the metabolic 
pathways (Wood et al., 2014). The term omics refers to a field of study in 
biological sciences that aims to characterise and measure biological molecules 
(e.g., genes, proteins and metabolites translate to genomics, proteomics and 
metabolomics) of an organism. Omics-based technologies have been used to 
unravel mechanisms involved in disease pathogenesis. According to the central 
dogma of molecular biology and the ‘omic’ cascade, where genomics and 
proteomics (which are the most established omics platforms) focus on regulatory 
processes and post-translational modifications, metabolomics provides 
information on downstream biochemical end-products that correlate with the 
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cellular phenotype and important biochemical alterations (Whitfield et al., 2004; 
Patti et al., 2012). 
Metabolomics studies the overall metabolome and the biochemical 
changes in biological samples (Mishur and Rea, 2012). Oliver et al. (1998) 
referred to the metabolome as “the characterisation and measurement of all small 
molecules (within a mass range of 50 – 1000 daltons) existent and detectable in 
a particular cellular condition or biological systems such as enzymes, cofactors, 
products and intermediates”. Metabolites can be divided into many classes based 
on their chemical properties, and are commonly separated and described based 
on their affinity for water as hydrophilic compounds (e.g., nucleotides, amino 
acids and carbohydrates) or hydrophobic compounds (e.g., mostly lipids).  
In any biological system, both intrinsic and extrinsic factors are responsible 
for chemical changes occurring in metabolism, and therefore the use of analytical 
methodologies is required to allow their full identification (Oliver et al., 1998). The 
use of mass spectrometry (MS) and nuclear magnetic resonance (NMR) is 
common in metabolomics analysis (Cubbon et al., 2010), with both aiming to 
profile hundreds of metabolites and obtain complex and comprehensive data 
sets. When these data are associated with other information, such as clinical 
measurements or those from other ‘’omics’’ techniques, for example, 
transcriptomics or proteomics, it becomes possible to obtain a better picture of 
the way in which metabolites are affected by factors such as phenotype or 
genotype in an organism (Dixon et al., 2006).  
Metabolomics is increasingly used to better understand the mechanisms 
of action, diagnosis and monitoring of disease (German et al., 2005). Additionally, 
metabolomics has the potential to develop non-invasive tests to quickly diagnose 
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diseases, and could influence progression from health research to clinical 
practice. Currently, diagnosis of pathologies such as osteoporosis is an important 
area of research, where the aim is to evaluate altered metabolic pathways and 
address early detection to prevent bone loss and osteoporosis-related fractures. 
Several metabolites are involved in bone metabolism; thus, the use of analytical 
technologies that allow the identification of those metabolites is required to detect 
and characterise novel bone biomarkers. The analytical methods can be applied 
for discovering early prognostic biomarkers to achieve the prediction of diagnosis 
and enhance treatment therapy for osteoporosis diseases. Currently, 
metabolomics is used to evaluate altered metabolic pathways of several diseases 
such as diabetes, cancer and cardiovascular diseases (Lindon et al., 2004; Zhang 
et al., 2012). 
 
2.3.1.2 Experimental approaches 
 
The metabolomics approach depends on the scope of the study, with both 
targeted analysis and metabolomics profiling (untargeted analysis) approaches 
being used.  
Targeted analysis detects and quantifies a particular number of known 
metabolites from a selected pathway or pathways. This approach only focuses 
on a small portion of the metabolome and all the other mechanisms are 
disregarded. The targeted metabolomics workflow is applied on studies where a 
hypothesis is tested and the metabolites to be analysed are usually isolated from 
the sample matrix with extensive sample preparation (Dunn et al., 2011a; Mishur 
and Rea, 2012). In contrast, metabolite profiling identifies and quantifies a large 
variety of metabolites under defined conditions. This approach is used to 
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generate an analytical database of a broad set of metabolites from a biological 
system or matrix component, which allows the identification of alterations in the 
metabolism induced by disease state or interventions (Theodoridis et al., 2008; 
Dunn et al., 2011a; Vuckovic, 2012).  
 
2.3.2 The workflow for untargeted metabolomics analysis 
 
The analytical aspects involved in typical untargeted metabolomics 
experiments are experimental design, sample collection and preparation, 
separation technique, analytical experiments, data analysis, and interpretation 
(Figure 2.4) (Büscher et al., 2009; Álvarez-Sánchez et al., 2010a).  
 
 
Figure 2.4: Scheme of a general metabolomics profiling workflow. 
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2.3.2.1 Sample preparation 
 
Sample preparation is a crucial step in the analytical process, as it impacts 
on the metabolites extracted. Biological samples collected for metabolomics 
analysis require careful sample handing to ensure a reproducible extraction is 
performed. The steps in the sample preparation begin with experimental design, 
where designing the study, deciding on the number of samples, and collecting 
and temporarily storing samples all require definition, and strict standard 
operating procedures should be implemented to ensure reduction of unwanted 
variation in the dataset. In addition, for nontargeted metabolomics, sample 
preparation is optimised to avoid metabolite loss during the extraction and 
analytical procedure, ensuring a wide overview of the metabolome will be 
analysed (Álvarez-Sánchez et al., 2010b; Gika and Theodoridis, 2011).  
After blood collection, in order to obtain a representative sample of the 
extracellular and intracellular reactions of the physiological state of interest, 
metabolism of the cells needs to be deactivated. Therefore, for sample collection 
factors such as the brand of vacutainer for blood collection, anticoagulant, 
temperature, velocity and duration of the centrifugation should be strictly 
monitored and controlled. Protocols for the extraction of metabolites will vary 
depending on the objective of the study. The most common methods for 
metabolite extraction include liquid-liquid extraction, solid-liquid extraction and 
solid phase extraction (Zhou et al., 2012). In general, metabolite extraction should 
be fast and with minimal handing to minimise metabolite degradation during 
preparation (Yin et al., 2013; Yin et al., 2015). The simultaneous extraction of the 
metabolome and lipidome can be achieved with a combination of solvents such 
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as aqueous methanol and chloroform for partitioning the polar and non-polar 
metabolites respectively. This allows the extraction of intracellular metabolites 
due to there is a disruption of the cell structure, while releasing the metabolites 
from the interior of the cell to the exterior (Bruce et al., 2009; Dunn et al., 2011b; 
Chen et al., 2013). In addition, to increase the permeability of the cells, freeze 
and low temperature cycles are included in the extraction process. Following 
extraction, freeze drying (lyophilisation) or evaporation using either vacuum or 
nitrogen blow-down are the most common methods for sample concentration. 
Freeze-drying samples is suitable for aqueous samples and with reduces the 
possibility of metabolite degradation as the solvent is evaporated without using 
heat. However, this approach is time consuming and it not suitable for organic 
solvents. Vacuum and nitrogen evaporation is more suitable for organic solvents 
than aqueous solvents, although the evaporation of the aqueous solvent takes 
longer and usually involves heating which is not suitable for thermally metabolites 
(Zou et al., 2013; Anton et al., 2015).  
 
2.3.2.2 Data acquisition  
 
The separation and description of all detectable metabolites in a sample 
is the aim of metabolomics. However, there is no single analytical method to 
cover the whole metabolome due to the wide range of molecular diversity within 
the metabolome, such as molecular weights, concentrations and polarities. NMR 
on the whole extract or MS coupled with a separation technique (usually liquid 
chromatography (LC) or gas chromatography (GC) on a small amount of the 
extract are the common analytical technologies used.  
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NMR has been one of the main approaches used in metabolomics and 
involves magnetic resonance fields and radio-frequency pulses in the nuclei of 
the atoms. When the atoms change from a low- to high-energy state, the radiation 
emitted when they return to low energy is measured. Little sample preparation is 
required for NMR and this technique provides highly reproducible results. 
However, NMR is relatively insensitive to metabolites present at low 
concentrations (Larive et al., 2015; Wolfender et al., 2015).  
In contrast, the principle of MS is to generate ions from organic or inorganic 
compounds and separate these ions by their mass-to-charge ratio (m/z). Hence, 
both the qualitative and quantitative detection of these ions is possible by 
measuring their m/z and abundance (Dunn et al., 2011a). MS allows one to 
characterise the molecular weight of molecules and obtain their chemical 
information(Zhang et al., 2012). Generation of the ions prior to detection by MS 
has been a rapidly developing area over the past 20–30 years, and there are now 
many ion sources available to ionise metabolites. The most commonly used for 
metabolomics with LC–MS is electrospray ionisation (ESI), which ionises the 
components eluting from the liquid chromatographic separation of molecules 
(Theodoridis et al., 2012). Moreover, ESI–MS systems utilising LC are the 
method of choice for the analysis of complex samples due to their ability to 
measure a wide range of compounds (e.g., from amino acids to triglycerides), 
often without the need to chemically alter/derivatise prior to analysis, as is often 
required for GC–MS. In ESI-MS the mobile phase solvent containing the 
separated analytes is evaporated during the ionisation step. ESI is performed by 
applying a high electric charge to the evaporating solvent droplet containing the 
analyte, enabling the ion formation of the analyte followed by the charged ion 
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entering to the mass analyser by an electric potential and pressure difference.  
The formation of the positive or negative ions depend on the polarity of the 
electrical field applied to the ESI probe needle. In general, in positive mode 
molecules will be protonated with a non-covalent addition, while in negative mode 
deprotonated molecules or loss of chemical species are generally detected 
(Allwood and Goodacre, 2010). After a sample has been ionised, the ions need 
to be separated according to their m/z, thus the type MS analyser must be 
considered depending again on the goal of the experiment. There are many types 
of mass analysers, and the most common are: 1) time of flight (TOF), in which 
the time of flight of the ion from the source to the detector is correlated to the m/z 
of the ion. In this way, the ions are separated according to their differential speed; 
2) the quadrupole (Q) uses the stability of the ions from the source to the detector 
to separate them per their m/z ratios by oscillating electric fields; and 3) the ion 
trap (IT), which uses an electrostatic field to trap ions and produce MS data (Dunn 
et al., 2011a). Quadruple-based MS analysers are recommended for quantitative 
profiling of metabolite concentrations and for the analyses of low concentration 
metabolites. For identification of metabolites, a mass analyser with MS/MS or 
high-quality tandem mass spectra (MS2) capabilities for structural fragmentation 
data is needed, such as an ion-trap or Q-TOF system. Advances in mass 
spectrometry have led to the manufacture of the Orbitrap mass analyser, which 
is an ion-trap instrument capable of collecting very high-resolution mass spectral 
data. The Orbitrap mass analyser is now widely used for identification, analyte 
characterisation (i.e. classification if ambiguous identification is not possible) and 
quantification of molecules in biological systems. An Orbitrap can maintain high 
mass accuracy, does not require the constant use of calibration standards in 
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every sample or scan. The Orbitrap mass analyser can be coupled to a linear ion 
trap, quadrupole mass filter or simply used directly to provide high resolution data. 
Orbitrap mass spectrometers are commonly used in proteomics and 
metabolomics studies (Lu et al., 2010; Xiao et al., 2012; Zhou et al., 2012; 
Zubarev and Makarov, 2013).  
MS systems can rapidly and accurately provide measurement of a diverse 
range of molecular ions and concentration ranges, then contribute data towards 
the identification of the molecules via the generation of MS fragments to obtain 
chemical composition in a comprehensive, selective and sensitive way.  MS can 
be applied with GC or LC separation before detection. GC allows the separation 
of complex samples with different stationary phases. GC-MS is performed to 
metabolites of low boiling points, and as many of the endogenous metabolites do 
not have sufficient volatility for GC analysis a chemical derivatisation is needed 
to detect those metabolites that can be made volatile enough to be resolved by 
GC (Begley et al., 2009). LC allows the separation as result of metabolite 
equilibration between a liquid mobile phase and a solid stationary phase. The 
reversed phase LC separation is compatible with the analysis of aqueous 
samples for metabolome characterisation and analysis. This reversed phase 
separation uses a solvent system with a high water content and a gradient elution 
increases the organic solvent such as methanol or acetonitrile. This reversed 
phase is ideal in the analysis of non-polar metabolite species such as lipids. 
Conversely, hydrophilic interaction chromatography (HILIC) uses gradient elution 
from high organic to high aqueous, which allows the analysis and separation of 
polar metabolites including amino acids, organic acids, sugar and carbohydrates 
(Cubbon et al., 2010). Given the complex nature of the untargeted metabolite 
 41 
   
profiling, both the highest resolution methods for the separation and identification 
of the complex array of metabolites in plasma is required. In addition, when the 
reversed phase is used with HILIC the coverage of the metabolome can be 
improved (Gika et al., 2014). Therefore, the use of this analytical technique is the 
best choice for detecting early prognostic biomarkers for bone health. For 
untargeted profiling, the preferred platform is LC–MS using electrospray 
ionisation (LC–ESI–MS), as this platform can resolve a wide range of chemical 
compounds into discreet individual peaks (Smith et al., 2006). 
 
2.3.2.3 Data analysis 
 
The main goals of data preprocessing are: 1) extraction of features from 
the LC-MS spectral data to determine identity and estimate relative abundance 
of possible metabolites; 2) alignment of multiple samples to correct retention time 
shifts within runs so that known and unknown metabolites can be compared 
correctly across the sample set; and 3) production of a table with the possible 
metabolites with their quantitative information for subsequent statistical analysis 
(Halket et al., 2005; Sugimoto et al., 2012).  
The feature extraction procedure aims to group several signals (detected 
m/z) into features. There are many algorithms on how to extract features but 
XCMS and CAMERA are the most commonly used packages for metabolomics 
data preprocessing (Smith et al., 2006; Kuhl et al., 2011). The first step in data 
processing is converting the LC-MS raw data in a numerical format that can be 
used for statistical analysis. For LC-MS data processing, peaks from each 
chromatogram are detected, aligned and grouped across samples. Each group 
of peaks has a unique m/z and retention time and are subsequently called a 
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feature. The XCMS package provides tools for peak detection, non-linear 
retention time alignment, visualisation and relative quantification. First, XCMS 
requires the LC-MS raw data to be converted into mzXML format. Then the data 
can be imported and processed in R. XCMS uses a series of different 
algorithms/functions to sequentially process the LC-MS data. The first step is to 
detect and filter ion peaks using a function ‘xcmsSet’ and a ‘minfrac’ command 
calculation which determines the minimum percentage of features present in a 
single sample group. The CentWave algorithm is used for performing peak 
detection of high resolution MS data, and it utilises two parameters, ppm and 
peakwidth. Ppm indicates the mass spectrometer accuracy across the 
experimental dataset while peakwidth indicates the range of the chromatographic 
peak width in the experiment. Thus, the xcmsSet method slices the data into 
predefined mass widths and then detects peaks in the chromatogram fitting within 
the peak width thresholds. The minfrac value determines if features are 
representative across a portion of the samples (usually a pooled quality control 
samples made using a small portion of each experimental sample) and are then 
thus classed as valid features within this experiment to be incorporated into the 
data matrix. The next step after filtration and peak detection is matching the same 
peak from each sample across the whole experimental sample set. Peaks with 
similar retention times across multiple samples must be placed into groups and 
use the similar peaks for the time alignment function group. The function ‘retcorr’ 
uses a single sample to identify (usually the sample with the most features 
detected in it) and realign the samples by correcting the retention time drifting to 
the single reference sample. Finally, the ‘fillpeak’ function re-examines the raw 
mzXML data files and fills the intensity values of each of the missing peaks. The 
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final data matrix output is a list of features with peak areas for each feature across 
the complete sample set, with the features identified with a mass (m/z) and 
retention time (Smith et al., 2006). In addition, CAMERA is another package 
developed in R that aids to extract compound spectra, annotate isotopes and 
adducts (originating from the same metabolite) while providing a reduction in data 
complexity (Kuhl et al., 2011; Perez de Souza et al., 2017).  
During data acquisition, quality control measurements are used to monitor 
the performance of metabolomics data collected, and these samples also provide 
a critical part of the data analysis workflow to detect problems such as injection 
problems, instrumentation failures, loss of sensitivity, noise and instrument 
chromatographic or mass drift. These quality control measurements include the 
use of internal standards of known metabolites, blanks samples and pooled 
samples. Internal standards for known metabolites are employed to review in real 
time the retention time and peak intensity during the analysis of large numbers of 
samples. The use of blanks aims to the identify system contaminants and batch-
batch accumulation of unwanted biological contaminants within the analytical 
system. Pooled quality control (QC) samples are regular and repeated 
measurements of a representative sample. Pooled QC samples are aliquots of a 
sample pooled from multiple subjects in an equal amount mixed homogeneously. 
Thus, during data processing, pooled QC samples are used to standardise data 
across datasets. In addition, pooled QC samples aid to evaluate the coefficients 
of variation for every feature detected and filter those ones with many missing 
values or features above a coefficient of variation threshold. Thus, periodic 
analysis of pooled QC samples evaluate the measurement of reproducibility for 
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all signals and standardise the data between batches (Dunn et al., 2012; 
Broadhurst et al., 2018).  
Then, data normalisation is used to reduce error in the data, such as 
decreasing sensitivity drift across the analytical batch of samples being analysed 
as the instrument becomes dirty/contaminated. There are two common 
normalisation methods used: 1) fitting an algorithm across all the samples based 
on the trends in the pooled QC samples within the experiment to subsequently 
adjust the peak areas of the samples (e.g., linear normalisation, locally weighted 
regression scatterplot smoothing (lowess) methods), or 2) using multiple internal 
standard compounds injected into the sample to correct the target compounds 
based on the internal standard response of the most similar internal standard in 
chemical structure/class (Katajamaa and Orešič, 2005; Sysi-Aho et al., 2007).  
After processing, the data matrix can be exported into an Excel file or 
similar and explored with other software such as SIMCA, Minitab and R or online 
databases such as Metaboanalyst, which have the ability to perform statistical 
analysis and process multivariate data (Smith et al., 2006; Xia et al., 2015). 
After loading the data matrix in MetaboAnalyst 4.0, two steps are followed 
to achieve consistency within the dataset prior to conducting the statistical 
analysis. Firstly, the quality control step, where the aims are to check the integrity 
and number of peaks, confirm the number of samples and treatment groups, and 
deal with missing values (Chong et al., 2018).  
Missing values are features that are below the limit of detection and can 
be replaced using imputation methods for handling missing values such as half 
minimum (HM), mean, median, random forest (RF) and k-nearest neighbour 
(kNN) (Xia and Wishart, 2002; Liland, 2011). Secondly, data is normalised to 
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remove variation between analytical conditions unrelated to the biological 
difference so that the mass intensities can be comparable. The normalisation can 
be done by sample or feature normalisation. Feature normalisation methods are 
auto-scaling (mean-centred and divided by standard deviation of each variable), 
range scaling and Pareto scaling. After normalisation peak intensities should 
follow a normal distribution, then univariate and multivariate analysis can be 
conducted (van den Berg et al., 2006).  
Multivariate analysis is used to find meaning in the whole dataset from the 
metabolome with the aim to identify changes of a metabolite between groups and 
find the correlation of the individual molecules. Principal component analysis 
(PCA), partial least squares (PLS) and orthogonal projections to latent structures 
discriminant analysis (OPLS-DA) are generally the most common multivariate 
analysis techniques applied in metabolomics (Liland, 2011).  
PCA plots create lower-dimensional data based on variation from original 
high-multidimensional data (Ringnér, 2008). PLS is a supervised multivariate 
linear regression method aiming to find the association between two variables (X 
and Y) by maximising their covariance. The objective of this is to understand 
which variables (features) of X are more correlated to a response Y to make 
predictions of new biomarkers (Zernicke et al., 2006; Indahl et al., 2007). OPLS-
DA is a multivariate linear model for classification and discrimination. The 
classification refers to the classification of new objects into one of two or more 
possible classes, and the discrimination is used for the two-class case, in which 
the objective is to maximise the separation between the two classes and highlight 
the key features contributing the most to the separation. The use of OPLS-DA 
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has been increasing for discrimination and biomarker development (Trygg and 
Wold, 2002).  
Univariate analysis measures metabolites that discriminate the treatments 
under comparison. Common univariate approaches such as those in 
MetaboAnalyst include fold-change (FC) analysis, t-tests, and the volcano plot, 
which is a combination of FC analysis and t-tests for comparison of metabolites 
from two treatment groups (Xia et al., 2015). 
There are two types of metabolite identification: putative identification and 
definitive identification. After performing statistical analysis the identification of 
the chemical composition of significant metabolic features identified by univariate 
methods and t-tests is based on: 1) a comparison of exact masses and retention 
times with those of compounds in internal libraries of chemical standards; 2) 
comparison with human metabolome database (HMDB) or MassBank; and 3) 
identification of peaks of the respective parent and potential fragment ions 
(Styczynski et al., 2007). The exact mass (m/z) of the selected peaks along with 
possible fragment mass data is used to identify compounds in databases. 
Databases such as HMDB contain metabolites with ESI and MS/MS spectra, 
where the identification of precursor ions is allowed followed by matching 
experimental MS/MS data against that one from the database. There are four 
levels for metabolite identification according to the metabolomics standard 
initiative. Level 1 requires at least two molecular properties of the putative 
metabolite to be corroborated with a pure standard analysed under identical 
analytical conditions. Identification of metabolites comparing against literature 
and database data is acceptable for level two and three of the metabolite 
identification. Finally, level four is for unknown metabolites (Vinaixa et al., 2016).  
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These levels of identification help standardise the annotation confidence of 
metabolomic data and assist in comparisons within the literature. 
 
2.3.3 Metabolomics approaches in bone health  
 
Osteoporosis is a common disease in the elderly. Treatment is focused on 
antiresorptive drugs, which generally shorten osteoclast formation and function, 
where the most common being selective oestrogen receptor modulator, 
bisphosphonates and calcitonin (Feng and McDonald, 2011). Despite the 
advancement in pharmacological treatments for the management of osteoporosis 
there is still a need to improve the existing therapies and find more effective 
therapeutic options for prevention of bone loss in postmenopausal women. 
During bone loss, there are changes in bone mass and these are associated with 
disturbed bone remodelling. Understanding signalling pathways in bone 
remodelling, specific to bone cells and systemic regulators, will aid in the 
development of new therapeutic options for osteoporosis.  
 
2.3.3.1 Altered metabolic pathways in bone cells post-menopause 
 
2.3.3.1.1 Bone cells and lipid metabolism 
 
Whilst osteoblastogenesis is reduced in menopause as a result of 
oestrogen deficiency, adipogenesis and osteoclastogenesis are increased, and 
as a result, bone loss occurs; this has been associated with higher lipid levels in 
bone marrow stromal cells (Rosen and Bouxsein, 2006). Adipocytes and 
osteoblasts are derived from a common bone marrow stromal cell. The balance 
between adipocyte and osteoblast differentiation is regulated by a signalling 
communication pathway that requires extracellular stimuli (Muruganandan and 
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Sinal, 2014). Cell membranes are complex bilayers formed of lipids and proteins 
that limit the interior from the exterior environment (Ingólfsson et al., 2014). Thus, 
lipid metabolism disorders may affect osteoblastogenesis by interfering with key 
signalling pathways. Lipid metabolism plays a key role in bone mineralisation and 
has been linked to pathological conditions including obesity, metabolic syndrome, 
cardiovascular diseases and bone loss (Cui et al., 2005). Lipids such as acidic 
phospholipids and phosphatidylserine may form matrix vesicles containing 
calcium ions that can be utilised in the initial mineral nucleation stages (Reid et 
al., 2012). During menopause, with oestrogen deficiency, cholesterol levels are 
associated with low BMD in postmenopausal osteoporosis (Tankó et al., 2003). 
This is related to the cholesterol biosynthetic pathway, which has a key role for 
osteoblastic differentiation of MSCs and determines cholesterol levels and bone 
resorption cell activity (Parhami et al., 2002; Ikonen, 2008). Sphingosine 1-
phosphate (S1P) levels are associated with lower femoral BMD and bone 
resorption markers in postmenopausal women. Here, S1P may stimulate bone 
resorption with a subsequent bone loss due to S1P interacting with the S1Pr in 
osteoblasts and T cells, and this interaction increases RANKL expression and 
osteoclastogenesis (Lee et al., 2012). 
In addition, changes in mitochondria are progressive with ageing and 
oestrogen deficiency, where a decrease in oxidation resistance could lead to 
bone loss in women.  Mitochondrial dysfunction leads to the generation of 
reactive oxygen species (ROS); studies indicate ROS act as mediators for 
osteoclast differentiation (Lee et al., 2005; Weitzmann and Pacifici, 2006). In vitro 
and animal models have shown that ROS have an impact on osteoclast 
differentiation and function as well as on osteoblast function. During ageing, ROS 
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lead to oxidative damage of macromolecules and mitochondrial DNA (mtDNA). 
Mutations of mtDNA decrease GH and IGF-1 concentrations (Garrett et al., 1990; 
Varanasi et al., 1999; Bai et al., 2004; Lean et al., 2005). This mtDNA dysfunction 
may impair IGF-1 action and lead to reduced BMD (Chan, 2006). Lipid oxidation 
products enhance intracellular oxidative stress in osteoblasts. Bioactive lipids and 
their intracellular molecular intermediates, and the associated increase of ROS 
production in ageing postmenopausal bone loss, remain to be fully elucidated 
(Tintut and Demer, 2014).  
 
2.3.3.1.2 Bone cells and amino acid metabolism 
 
Amino acids are involved in bone formation and they can improve BMD 
and bone strength; however, during menopause, changes in amino acids 
associated with oestrogen deficiency and ageing may affect bone mass. Amino 
acid pathways such as threonine, glutamine, arginine and proline metabolism 
have been reported to be altered in postmenopausal bone loss. Arginine 
increases GH and IFG-1 levels, reflecting an increased osteoblastic bone 
formation; arginine also releases nitric oxide, which is an inhibitor of bone 
resorption.  The glutamine metabolism pathway regulates cellular differentiation 
and proliferation in osteoblasts and produces proline and amino acids present in 
the collagen structure. Taurine has been shown to have a stimulatory effect in 
the bone anabolic phase (Hanaa and Hamza, 2009). 
During bone resorption, collagen is released into the circulation. Collagen 
is formed by three polypeptide chains, which gives it the triple-helical structure. 
Glycine (Gly) is needed to be present as every third residue in order for the chains 
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to form that triple helix; the sequence of collagen is a repeated Gly–X–Y, where 
X and Y are usually proline and hydroxyproline (Brodsky and Persikov, 2005).  
Glycan metabolism may also mediate bone mass during oestrogen 
deficiency. Proteoglycan and glycosaminoglycan are extracellular components 
which regulate the osteolytic process. Proteoglycans and glycosaminoglycans 
also contribute to stimulate bone remodelling and matrix mineralisation, and to 
control hydroxyapatite crystal formation in trabecular bone as a function of 
metabolic activity and tissue age (Gamsjaeger et al., 2013). A study showed that 
glycan regulates the bone turnover process as a response to oestrogen 
deficiency, where glycan increased trabecular bone turnover and bone loss in 
OVX mice (Allen, 2003).  
Further, histamine metabolism may be involved in trabecular bone loss in 
long bones of OVX rats, where histamine may be a first-line mediator of bone 
resorption.  Oestrogen depletion releases histamine, IL-6 and TNF-α from MCs 
and precursors in the osteoclastic pathway (Lesclous et al., 2006). 
Overall, lipids and amino acids are involved in crucial mechanisms by 
communicating among bone cells, and lately, there has been a growing interest 
in understanding their role in bone diseases. Therefore, the mechanistic links 
between adipogenesis, bone cell differentiation and amino acid metabolism may 
be the key findings to understand the mechanism of bone disease, and be useful 
as targets for the prediction of bone metabolism diseases.  
 
2.3.3.2 Metabolomics analyses in animal models for osteoporosis  
 
Several studies in rodent models have used serum metabolomics to 
identify non-invasive biomarkers of postmenopausal osteoporosis. The OVX rat 
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as an animal model of osteoporosis has shown an altered plasma metabolome 
after oestrogen depletion. A study analysed the OVX rat model for osteoporosis, 
where the relation between the metabolome and low BMD was the target 
analysed (Ma et al., 2013a). This study reported increased levels of arachidonic 
acid (AA, 20:4n-6), which stimulates RANK-L expression and blocks OPG 
secretion in osteoblasts (Coetzee et al., 2007), as well as reporting increased 
levels of cholesterol due to estrogen insufficiency, which blocks the activity of 
osteoblasts (Parhami et al., 2002), and increased levels of homocysteine, which 
promotes osteoclast formation. Another study reported that sphingolipid, ether 
lipid, glycerophospholipid and glycerolipid metabolisms were identified in OVX 
rats as novel biomarkers for oestrogen-deficient conditions induced by OVX 
(Vinayavekhin et al., 2016). Serum levels of AA, eicosapentaenoic acid (EPA), 
ergocalciferol and cholecalciferol in OVX rats were changed when compared to 
sham control by ultra-performance liquid chromatography–quadrupole time-of-
flight mass spectrometry (Zhu et al., 2010). Changes in pathways of lipids, energy 
and amino acid metabolism, some of which involved the oxidative system, were 
identified in OVX rats by using NMR (Xue et al., 2011). Another study reported 
the effects of menopause on lipid peroxidation, glycolysis, the TCA cycle, choline 
and amino acid metabolisms in OVX rats using NMR and GC–FID/MS methods 
(Zhang et al., 2014a). In OVX mice, the TCA cycle intermediates aspartate, 
taurine, glycine, glucose and 3-hydroxybutyrate were lower than in sham groups 
using NMR spectroscopy (Chen et al., 2014). Similarly, another study in OVX 
mice reported lower concentrations of amino acids, energy metabolites and 
intestinal microbial compounds in OVX mice compared with the sham group also 
using NMR (Chen et al., 2015). A recent study reported data from and integrative 
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bone metabolomics and lipidomics using UPLC-Q-TOF-MS, to generate a bone 
metabolism profile in a postmenopausal osteoporosis mouse model. Several 
metabolites were down-regulated including amino acids, purine and pyrimidine 
and lipids were up-regulated including glycerophospholipids, triacylglycerols, 
sphingolipids and sterol lipids once osteoporosis was established (Zhao et al., 
2018a). 
In summary, the existent literature suggests that perturbations in specific 
metabolic pathways such as the TCA cycle, glutamine metabolism, amino acid 
metabolism and fatty acid metabolism due to oestrogen deficiency might impact 
on bone remodelling in OVX rats and mice. All those findings may be used as 
biomarkers in diagnosis for postmenopausal osteoporosis. However, the clinical 
symptoms in these rodent models are poorly representative of the naturally 
occurring postmenopausal condition in humans (Chavassieux et al., 1997a). 
Bones and bone remodelling from rats differ from that of humans.  
Sheep are more similar to humans in their anatomical dimensions, and 
they possess metabolic and bone remodelling rates similar to those of humans 
(den Boer et al., 1999; McGovern et al., 2018). The sheep model therefore is a 
more optimal animal model to generate bone and blood samples for 
metabolomics analyses in the search of novel markers for bone health.  
 
2.3.3.3 Metabolomics analyses in postmenopausal women for osteoporosis  
 
Metabolomics has proven to be successful in measuring metabolite 
profiles in postmenopausal women using both NMR and LC–MS technologies. 
Two studies have reported metabolic alterations related to postmenopausal 
changes in Caucasian women. Auro et al. (2014) reported associations between 
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menopause and the plasma metabolome in Finnish and Estonian women. Using 
a NMR-based metabolomics technique, they found relationships between 
menopause status and glutamine, tyrosine, isoleucine and glycine, along with 
serum cholesterol measures and atherogenic lipoproteins, and total, 
monounsaturated and omega-7 and -9 fatty acids in the serum of Finns and 
plasma from Estonians.  
A recent study published findings from a metabolic characterisation of 
menopause in plasma samples of UK midlife women using an NMR-based 
metabolomics approach. Circulating lipids and metabolites from both cross-
sectional and longitudinal studies were associated with a variety of changes of 
metabolic markers in menopause. The altered metabolites were low-density 
lipoproteins (LDLs), intermediate-density lipoproteins, LDL remnants, LDL 
cholesterol and LDL particle size, glutamine and albumin (Wang et al., 2018). 
Sousa et al. (2018) reported the association between the plasma fatty acid profile 
and inflammatory metabolic markers among Portuguese Caucasian 
postmenopausal obese and overweight women using a GC–flame ionisation 
(FID) detector. Anti-inflammatory pathways were correlated with omega-3 and 
omega-6 fatty acids, unsaturated cis and polyunsaturated cis fatty acids, and 
short-chain fatty acids. Pro-inflammatory pathways were associated with omega-
9 fatty acids, polyunsaturated trans fatty acids, monounsaturated cis fatty acids, 
and saturated fatty acids. 
Another study reported the circulating changes of potential markers of 
menopause in plasma samples of Chinese women, including acylcarnitines, fatty 
acids, and lysophosphatidylcholines using an ultra-performance liquid 
chromatography–mass spectrometry (UPLC–MS) approach (Ke et al., 2015). 
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Yamatani et al. (2014) reported the metabolite profiling of adipose tissue between 
premenopausal and postmenopausal women using capillary electrophoresis 
(CE) ESI TOF–MS. Intermediate products of the pentose pathway increased in 
premenopausal women, while intermediate products of glycolysis and fatty acid 
metabolites increased after menopause. These changes in fatty acid metabolites 
where alterations of glycolysis and pentose phosphate pathways were also 
observed could be related to the metabolic syndrome (abdominal adiposity, 
insulin resistance, and dyslipidaemia) that emerges with oestrogen deficiency. 
Overall, the results from these studies show how menopause promotes 
substantial changes in diverse metabolites and these disturbances may have an 
impact on bone health by loss of oestrogen in women. 
Studies are limited in examining the associations between bone turnover 
markers and bone metabolism in postmenopausal women. You et al. (2014) 
reported a metabolomics study using NMR in plasma samples, where low BMD 
was related to elevated glutamine levels of Taiwanese postmenopausal women; 
simultaneously, metabolites that protected against low bone mineral density were 
lactate and acetone (You et al., 2014). Further, Qi et al. (2016), using GC–MS, 
reported that in the plasma of Chinese postmenopausal women, the levels of 
linoleic acid increased by 60% and 190% in the osteopenia and osteoporosis 
groups, respectively, and changes in the levels of tryptophan, 3-hydroxy-L-proline 
and fumaric acid were also noted.  
In another study using CE–TOF–MS, lower levels of the dipeptide Gly–Gly 
and of cysteine, and higher levels of hydroxyproline, were found in Japanese 
postmenopausal women with low versus normal BMD (Miyamoto et al., 2017). In 
a recent study Miyamoto et al. (2018) reported serum metabolomics profiles using 
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CE–TOF–MS in pre- and post-menopausal women Gly–Gly and of cysteine 
levels were lower in the post-menopausal women, confirming their previous 
findings. Levels of citrate and cis-aconitate, two metabolic intermediates seen 
early in the TCA cycle increased in the postmenopausal women. Hydroxyproline 
and branched chain amino acids (BCAAs), including valine, isoleucine and 
leucine concentrations significantly increased in post-menopausal women. The 
limitation of this study is that only focused in analysing polar metabolites and to 
have a full coverage of the metabolome, lipid species should be also investigated.  
Zhu et al. (2016) reported the study of the necrotic trabecular femoral head 
in humans based on UPLC–MS/MS. This study identified 67 differential 
metabolites and biomarkers, where lipid metabolism was associated with the 
necrotic period and disturbed protein metabolism may occur during all the 
disease stages.  
From the literature review, only one study has investigated the 
metabolomic profiles of young women with low and normal BMD. There were 
differential changes in the metabolism of amino acids (GABA, threonine, 
cysteine, taurine, and glutamic acid), bile acids (cholic acid, ursodeoxycholic acid, 
and tauroursodeoxycholic acid) and organic acids (succinate and N-
acetylneuraminic acid) in serum samples of young (pre-menopausal) Caucasian 
women with low and high BMD, suggesting those metabolites as candidates for 
developing biomarkers for early bone loss detection (Zhao et al., 2018b).  
Clearly, environmental, genetic and dietary differences between Western 
and Chinese populations may have produced conflicting results. There is limited 
information on this subject in the Chinese population. Therefore, metabolomics 
offers the potential to identify compounds for the prediction of osteoporosis, some 
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of which may even be specific to racial populations. Thus, metabolites and lipids 
might serve as candidate biomarkers to improve bone health in postmenopausal 
women. 
Even though metabolomics has been utilised to identify novel biomarkers, 
only a few studies have been reported using metabolomics in human studies for 
osteoporosis. Furthermore, no study has investigated whether the OVX sheep 
model is able to increase the knowledge of the mechanisms driving 
postmenopausal bone loss. Therefore, the present study will evaluate the relation 
between the metabolome and BMD in the OVX sheep model as well as in middle‐
aged women using a comprehensive untargeted LC–MS metabolomics 
approach. 
 
2.4 Problem statement 
 
Most of the studies reported to date have focused only in the analysis of 
the metabolite or lipid profiles in postmenopausal studies; however, both 
metabolite and lipid profiles should be analysed to have a better metabolome 
coverage for better understanding of the dynamic and complex interactions in 
bone remodelling. Little evidence exists to define the combined effect of OVX and 
glucocorticoid treatment on bone health and the association with the metabolome 
in sheep as a model of postmenopausal osteoporosis. There are also limited data 
available on the association of the plasma metabolome and BMD of 
postmenopausal women. In this research samples were utilised from 
Singaporean–Chinese women with varying bone densities as part of the 
overarching larger project. 
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2.5 Research questions 
 
1) Is there any association between the effect of loss of oestrogen and 
exposure to glucocorticoids and BMD and the plasma metabolome in OVX 
sheep? 
2) Is there any association between menopausal status, plasma metabolome 
and BMD in Singaporean–Chinese women? 
 
2.6 Research hypothesis 
 
The study hypotheses of this thesis are that the plasma metabolome and 
lipidome will differ between animals with induced osteoporosis and normal 
animals, and that the metabolome and lipidome will differ between Singaporean–
Chinese postmenopausal women with healthy bones and those with bone loss.  
 
The aims of this study were to: 
1) optimise and characterise a large animal model of postmenopausal 
osteoporosis; 
2) determine the interaction between the plasma metabolome and bone 
remodelling in sheep; 
3) describe the association between the plasma metabolome and bone 
remodelling in postmenopausal Singaporean–Chinese women; and 
4) compare between sheep and humans the metabolomic markers correlated 
with bone loss. 
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Chapter 3 
 
 
 
 
 
 
 
 
Glucocorticoids affect bone 
mineral density and bone 
remodelling in ovariectomised 
sheep: a pilot study 
 
This chapter employs the sheep to optimise and characterise a large animal 
model for postmenopausal osteoporosis. This chapter also evaluates the impact 
of short-term and long-term ovariectomy (OVX) and glucocorticoid hormonal 
interventions in the OVX sheep, and the relationship between bone mineral 
density measurements and bone turnover markers. 
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Abstract 
The aim of this study was to validate the combination of ovariectomy and 
glucocorticoid treatment in sheep as a large animal model for osteoporosis by 
measuring the concentration of specific biomarkers in the blood of the sheep and 
measuring bone loss over five months. Aged Merino ewes were randomly 
allocated into four groups: control, ovariectomy (OVX), and two OVX groups 
receiving glucocorticoids—one group once-monthly for five months (OVXG), and 
the other for two months followed by no treatment for three months (OVXG2). 
Parameters measured were biochemical markers of bone turnover, areal bone 
mineral density, volumetric bone mineral density, and total and trabecular bone 
parameters. Ovariectomy increased the concentrations of bone resorption 
marker C-terminal telopeptides of type 1 collagen (CTx-1) and bone turnover 
marker serum osteocalcin (OC) concentrations in the OVX group compared to 
control sheep. The combination of ovariectomy and glucocorticoid treatment 
increased the concentrations of CTx-1 and decreased serum OC concentrations 
in the OVXG group compared to OVXG2. Femur and lumbar spine bone density 
were lower in experimentally treated groups when compared with the control 
group. Total and trabecular volumetric bone mineral density (vBMD) in the 
proximal tibia were significantly lower in the treatment groups when compared 
with the control group. A significant negative correlation between femoral bone 
density and CTx-1 was found. The results of this study suggest that the 
combination of OVX and glucocorticoids induces bone loss in a short period of 
time in sheep. 
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3.1 Introduction 
 
Because of the increased aging population and the rise in the number of 
bone fractures in elderly people, osteoporosis is considered a major public health 
issue (Harvey et al., 2010). In women, low levels of oestrogen have effects on 
bone remodelling, causing loss of bone mass and bone strength due to increased 
bone resorption and decreased bone deposition (Snyman, 2014). Dual energy x-
ray absorptiometry (DXA) and peripheral quantitative computed tomography 
(pQCT) are useful to measure bone mineral density (BMD) in order to diagnose 
osteoporosis but cannot predict bone loss (Engelke et al., 2008). To reduce this 
disease worldwide, assist with understanding the mechanisms involved, and help 
with early diagnosis, more research must be conducted. 
Large animal models are approved by the US Food and Drug 
Administration for mimicking human osteoporosis in orthopaedic research 
(Reinwald and Burr, 2008). A well-known method used to induce osteoporosis is 
ovariectomy (OVX). This method has a direct effect on bone mass due to the 
induction of oestrogen deficiency. Oestrogen deficiency affects the bone 
remodelling process, and induces bone loss due to a direct effect on osteoblasts 
and osteoclasts (Klein-Nulend et al., 2015). Bone formation is inhibited while 
bone resorption is stimulated, resulting in bone loss (Khosla et al., 2011; Drake 
et al., 2015). In addition, treatment with glucocorticoids is known to cause 
secondary osteoporosis, due to increased bone resorption leading to a rapid 
initial bone loss, and decreased bone formation through suppression of 
osteoblasts and osteocytes (Compston, 2010; Andreasen et al., 2015). 
The OVX sheep is an established large animal model of osteoporosis. 
Sheep have the advantage that their bone structure and bone metabolism is 
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similar to humans (Newman et al., 1995; Wilke et al., 1997). The model has been 
used in several studies, and has shown that OVX will induce osteoporosis over 
six months (Hornby et al., 1995; Turner et al., 1995; Lill et al., 2002a; Wu et al., 
2008; Zhang et al., 2014b; Dias et al., 2018). These studies have reported 
increased bone turnover in OVX sheep, and all proposed that long periods of time 
were required for establishing osteoporosis in the sheep (Chavassieux et al., 
1993; Chavassieux et al., 1997b; MacLeay et al., 2004; Sigrist et al., 2007; Ding 
et al., 2010). Studies have indicated that when OVX is combined with 
glucocorticoids, further bone loss is induced (Lill et al., 2002a; Schorlemmer et 
al., 2005; Ding et al., 2010; Veigel et al., 2011). Therefore, a combination of OVX 
with glucocorticoids will increase bone loss in sheep; using both OVX and 
glucocorticoids could reduce the time needed to develop osteoporosis, and the 
trial time could be reduced. However, weekly treatment with glucocorticoids after 
long-term treatment has been shown to negatively impact the animals’ health with 
severe side effects such as infections and hair loss (Lill et al., 2002a; 
Schorlemmer et al., 2003). More importantly, how glucocorticoid withdrawal 
effects the rebound of bone is not yet fully understood in OVX sheep. Thus, 
strategies to reduce future complications of long-term glucocorticoid treatment in 
OVX sheep need to be considered. 
It was hypothesised that ovariectomising sheep in combination with monthly 
injections of glucocorticoids would result in decreased BMD and increased 
plasma bone remodelling marker concentration over a shorter period of time than 
previously reported, while eliminating the negative side effects. The aims of this 
study were to: 1) validate the OVX sheep model by measuring the concentration 
of serum biomarkers and bone loss over a five-month period; and 2) investigate 
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the effects of short- and long-term glucocorticoid administration on BMD in the 
lumbar spine, femur and tibia, as well as bone biomarkers, in the OVX sheep. 
3.2 Materials and methods 
 
3.2.1 Experimental animals 
 
Aged Merino ewes (7–9 years old, n = 28) were obtained from a 
commercial farm in the Whanganui region, New Zealand. The animals were 
housed in a barn and adapted to indoor pens with rubber mat flooring. Sheep had 
free access to water and were fed the control diet described below for 20 days. 
After adaptation, sheep were randomly allocated into groups: control group (n = 
10), the OVX group (n = 12), and two OVX groups receiving glucocorticoids, one 
group once a month for five months (OVXG) (n = 3) and the other group once a 
month for two months followed by no treatment for three months (OVXG2) (n = 
3) (Figure 3.1). 
  
 65 
   
 
 
Figure 3.1: Flow diagram of the experimental study. Merino ewes were randomly 
divided into groups, 10 underwent no treatment (control group), 12 ewes 
underwent ovariectomy (OVX), and the remaining 6 ewes underwent OVX and 
received an injectable suspension of 400 mg methylprednisolone (OVXG group). 
Half of the ewes in the OVXG group received the methylprednisolone treatment 
for five months, while the other half received this treatment for only two months 
(OVXG2 group). Blood samples were collected monthly. BMD measurements 
were done at baseline (month zero) by pQCT, and at post-cull (month two or 
month five) by pQCT and DXA. Half of the sheep in the control group and OVX 
group were euthanised after two months, and the remaining sheep for each group 
were euthanised after five months. All the sheep in the OVXG group and OVXG2 
were euthanised after five months. 
 
Control and low-calcium sheep pellet concentrate diets were formulated 
from soya, brollard and wheat to contain 11% protein, 34% starch, and 29% 
nondigestible fibre, as well as >2000 IU/kg vitamin D3/cholecalciferol and <200 
IU/kg vitamin D2 (ergocalciferol), which are required for calcium absorption. While 
2–4 g/kg calcium is sufficient for sheep under normal circumstances, the animals 
in the current study were housed indoors and had limited exposure to sunlight 
and no exposure to sun-cured forage. Under these circumstances, calcium 
absorption was likely to be impaired. It was considered undesirable to risk vitamin 
D toxicity by increasing the vitamin D levels to aid calcium absorption in the gut, 
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so the dietary calcium levels were increased to compensate. Ewes were fed at 
approximately 200 g/sheep/day. Wheat straw and water were available to all 
sheep ad libitum throughout the study. 
Sheep were anaesthetised using 0.5 mg/kg diazepam (Ilium, Troy 
Laboratories Pty Ltd., Glendenning, Australia) and 10 mg/kg ketamine (Phoenix 
Pharm Distributors Ltd., Auckland, New Zealand) intravenously, followed by 
endotracheal intubation and maintenance of anaesthesia with halothane. The 
distal tibia from each sheep was pQCT-scanned under general anaesthesia. The 
sheep, except for the control group, underwent bilateral OVX. The OVX was 
performed via a ventral abdominal incision. The linea alba and subcutaneous 
tissues were closed using 1 USP polydioxanone (PDS II, Ethicon Inc., USA) and 
the skin with 1 USP nylon suture (Kruuse A/S, Langeskov, Denmark), and the 
sutures were removed 14 d after the surgeries. Prior to extubation, each sheep 
was given 20 mg/kg meloxicam (Metacam, Boehringer Ingelheim GmbH, 
Ingelheim am Rhein, Germany) for pain. At the same time, the 10 sheep in the 
control group were anaesthetised but no surgery was performed. Post-surgery, 
until suture removal, sheep were examined twice daily. After suture removal, 
sheep were checked twice daily and food, water, activity and hair condition 
monitored. 
On day two after OVX, six OVX sheep were administered an injectable 
suspension of 400 mg methylprednisolone (Vetacortyl®, Vetoquinol SA, Lure 
Cedex, France) subcutaneously in the neck. Methylprednisolone treatment 
started before the sutures were removed. Three of the sheep were given four 
further treatments at the same dose once a month (OVXG). The remaining three 
sheep received the initial treatment and then an additional treatment was given 
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one month later, after which the treatment was discontinued in order to observe 
the effect on bone after glucocorticoid withdrawal (OVXG2). 
All experimental procedures were approved by the Massey University 
Animal Ethics committee (approval number 14/103) and performed according to 
the Code of Ethical Conduct for the use of live animals for research at Massey 
University, Palmerston North, New Zealand. 
 
3.2.2 Blood sampling 
 
Blood sample from each sheep was collected via jugular venepuncture 
into three different plain (serum), heparin and EDTA tubes (BD Vacutainer, 
Franklin Lakes, New Jersey, USA). Heparin and EDTA tubes for plasma samples 
were put on ice for 40 minutes and then centrifuged at 2000 g for 10 min, and 
plasma removed and stored at –80 °C for later analysis. The tubes designed for 
serum samples were left at room temperature for 45 minutes to clot prior to being 
processed as above. Blood samples were collected on the day of surgery (month 
0) and then monthly for the duration of the study until the animals were 
euthanised. Blood samples were taken between 08:00 and 10:00 hours to limit 
any circadian effect. 
 
3.2.3 Euthanasia and dissection  
 
Half of the ewes from the control group (n = 5) and half from the OVX 
group (n = 6) were euthanised using a captive bolt followed by exsanguination at 
two months. At the end of the study (five months), the remaining ewes from the 
control group (n = 5) and the OVX group (n = 6), and all of the ewes from the 
OVXG (n = 3) and the OVXG2 (n = 3) groups, were similarly euthanised. After 
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euthanasia, the femurs, lumbar spines (LSs) and tibias were collected and stored 
at 4 °C. Samples of ileum, liver, kidney, heart and lung were collected and stored 
in 10% neutral buffered formalin until processing for histology. Microscopic 
examination of 3 µm paraffin-embedded haematoxylin- and eosin-stained 
sections confirmed the absence of unrelated disease. 
 
3.2.4 Analysis of biochemical markers of bone 
 
Osteocalcin (OC) was measured in serum using an immunoassay kit 
(MicroVue Osteocalcin, San Diego, CA, USA) according to manufactures 
instructions. This The MicroVue immunoassay kit uses a monoclonal mouse 
antibody that recognises only intact (de novo) OC in serum. The MicroVue 
immunoassay used has cross-reactivity with sheep species (Dias et al., 2008).  
Serum C-terminal cross-linked telopeptides of type I collagen (CTx-1) was 
measured in heparinised plasma using CrossLaps ELISA kit (IDS, London, UK), 
which uses two highly specific monoclonal antibodies. The IDS immunoassay has 
been used for sheep (Wilkens et al., 2014). 
The quantification of OC serum CTx-1 were tested in duplicate according 
manufactures’ instructions. For the OC analysis the optical density was measured 
at 405 nm and for the CTx-1 at 450 nm using a ELx 808 ultra microplate reader 
(Bio-tek Instruments Inc., USA). A 4 parameter curve fitting was used to analyse 
the results and the sample absolute concentrations were extrapolated from the 
standard curves of each biochemical bone marker. OC and CTx-1 were 
measured in the sheep at baseline (month zero), two months and five months of 
the trial.  
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3.2.5 Analysis of bone parameters  
 
3.2.5.1 DXA 
 
Lumbar spine and femur were thawed at room temperature. Ex vivo 
measurements of bone mineral component (BMC) and areal BMD (aBMD) for the 
lumbar spine and femur were determined using the Hologic Discovery A Bone 
Densitometer (Hologic Discovery QDR 4500A densitometer, Hologic Inc., 
Bedford, Massachusetts, USA). 
 
3.2.5.2 pQCT 
 
Three-dimensional analyses of the left tibial bone were performed using 
pQCT. The first initial baseline scan was obtained after the sheep were 
anaesthetised for surgery. In vivo measurements were made of total volumetric 
BMD (vBMD), bone area, bone mineral content (BMC), cortical/subcortical and 
trabecular vBMD, cortical/subcortical and trabecular bone area, 
cortical/subcortical and trabecular BMC, and geometric variables of the mid-
metaphysis 10 mm from the distal surface of bone and at the mid-diaphysis 70 
mm from the distal end. 
Left tibias were thawed at room temperature. Ex vivo measurements were 
made of total vBMD, bone area, BMC, cortical/subcortical and trabecular vBMD, 
cortical/subcortical and trabecular bone area, cortical/subcortical and trabecular 
BMC and geometric variables of the proximal tibia, the mid-metaphysis and at the 
mid-diaphysis using the XCT2000 peripheral quantitative computed tomography 
(pQCT) scanner (Stratec Medizintechnik GmbH, Pforzheim, Germany). The 
measurement site was located at the proximal metaphysis 15 mm from the 
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proximal surface of bone. The pQCT scan for the in vivo and ex vivo 
measurements had a voxel size of 0.3 mm. 
Norland/Stratec XCT 5.50 software was used for scan imaging analysis. 
The trabecular compartment was obtained at the central 45% of bone at the 
trabecular sites. The manufacturer’s contour threshold was set at 280 mg/cm3 to 
separate soft tissue from the outer edge of bone. For cortical bone, the threshold 
was set at 710 mg/cm3. 
 
3.2.6 Statistical analyses 
 
Data for bone marker concentrations were analysed to report the effects 
of treatments at specified time points. For analysis of percentage of change from 
baseline, baseline results were included as covariate and the analysis was based 
on the results from month two and month five. Data for lumbar spine, femoral and 
tibial parameters were analysed to test the effect of the OVX plus glucocorticoid 
treatments after sacrifice at month two and month five. Data are expressed as 
mean and standard deviation (SD). Statistical analyses were performed with the 
nonparametric Kruskal–Wallis test to assess whether the treatment means were 
significantly different. The nonparametric Kruskal–Wallis test was followed by 
post-hoc comparisons of treatment means using Dunn’s post-hoc test. Statistical 
analyses on data were conducted using R (R 3.1.1, R Foundation for Statistical 
Computing, Vienna, Austria). Spearman rank-order correlation were performed 
to assess the association between BMDs of the lumbar spine, femur and tibia 
with bone biomarker concentrations. This test was done using Minitab 17.2.1 
(Minitab Inc., Pennsylvania, USA). In all statistical analyses, p-values < 0.05 were 
considered statistically significant. 
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3.3 Results 
 
3.3.1 Effect of OVX alone or combined with glucocorticoid on biochemical markers 
of bone in the sheep model  
 
During bone loss in osteoporosis, measurable metabolites are released in 
the blood, including OC and CTx-1. OC is a noncollagenous bone protein, which 
is released from osteoblasts during bone formation and from bone matrix during 
bone resorption. CTx-1 is a collagen breakdown product, which is released during 
bone resorption (Swaminathan, 2001; Allen, 2003; Garnero et al., 2003). 
Figure 3.2 and Table 3.1 show the changes in OC and CTx-1 markers over 
five months of treatment in OVX sheep. The percentage change from baseline of 
individual sheep is shown for each parameter (Figure 3.2). Sheep exhibited 
serum OC concentration mean values between 12 and 15 ng/mL at baseline 
(Table 3.1). Serum OC concentration in the control sheep increased by 22% at 
two months, and increased further by 40% at five months (Figure 3.2A). Similarly, 
serum OC increased by 35% (p-value = 0.337) within two months and by 43% (p-
value = 0.384) at five months compared to baseline in OVX sheep. On the other 
hand, serum OC concentration decreased by 24% (p-value = 0.040) at two 
months and remained at this decreased level (p-value = 0.099) at five months 
compared to baseline in the OVXG group. However, when the glucocorticoids 
were discontinued in the OVXG2 group at two months, the serum OC 
concentrations observed at five months increased by 26% (p-value = 0.209), 
compared to baseline in the OVXG2 group. 
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Figure 3.2: The concentrations of OC and CTx-1 in the serum of the OVX sheep. 
Percentage change in the bone turnover marker serum OC (A) and percentage 
change in the bone resorption marker CTx-1 (B) compared with the pretreatment 
baseline from Merino ewes that were either ovariectomised (OVX), 
ovariectomised and given five doses of glucocorticoid at monthly intervals 
(OVXG), ovariectomised and given two doses glucocorticoid at monthly intervals 
(OVXG2), or received no treatments (Control). OC and CTx-1 were measured at 
two months and five months after initiation of the treatments. The results are 
presented as serum OC and CTx-1 mean percent change from baseline. * p-
value < 0.05. Error bars denote standard error of mean. 
 
Table 3.1: Changes of OC and CTx-1 over five months in the OVX sheep. 
 
a Half of the ewes in the OVXG group received the methylprednisolone treatment for five months (OVXG group). b 
Half of the ewes in the OVXG group received the methylprednisolone treatment for only two months (OVXG2 group). 
Data are presented as serum OC and CTx-1 mean (SD). The resulting p-values obtained by Kruskal–Wallis are 
given. p-value < 0.05 was considered as statistically significant. 
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3.3.2 Effect of OVX alone or combined with glucocorticoid on bone parameters in 
the sheep model  
 
The results of DXA scans of the lumbar spine and femur are shown in 
Figure 3.3. After OVX, the lumbar spine and femur parameters did not differ 
between treatments compared with controls at two months (Figure 3.3). Lumbar 
spine aBMD was slightly reduced by 6% (p-value = 0.36) after OVX, but lumbar 
spine BMC was not affected two months after OVX. In addition, femoral aBMD 
did not vary between the control group and OVX group at two months. 
Similarly, the lumbar spine and femur did not show any significant 
differences in bone parameters compared with controls at five months. However, 
the lumbar spine and femoral aBMD of experimentally treated animals were 
decreased from controls at five months (Figure 3.3). The highest impact on aBMD 
was found in the OVXG group. Lumbar spine aBMD was reduced by 7%, 28% 
and 12% (p-value =0.06) in the OVX, OVXG and OVXG2 groups, respectively 
(Figure 3.3A). Lumbar spine BMC was decreased by 6.7%, 27% and 7% (p-value 
= 0.15) in the OVX, OVXG and OVXG2 groups, respectively (Figure 3B). Femoral 
aBMD was reduced by 10%, 21% and 6% (p-value = 0.06) in the OVX, OVXG 
and OVXG2 groups, respectively (Figure 3.3C). Femoral BMC was slightly but 
not significantly reduced after five months of treatment in all treated groups (p-
value = 0.19) (Figure 3.3D). 
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Figure 3.3: Bone parameters of lumbar spine and femur at month two and month 
five measured by DXA. (A) lumbar spine aBMD, (B) lumbar spine BMC, (C) 
femoral aBMD and (D) femoral BMC are shown for half of the ewes euthanised 
at month two in the control group (n = 5) and OVX group (n = 6), and for the 
remaining ewes at month five for each group. Data is presented as mean and 
95% confidence intervals. 
 
The results of pQCT scans of the proximal metaphysis of the tibia post-
cull are shown in Figure 3.4. The proximal metaphysis of the tibia at two months 
(Figure 3.4A, 3.4C, 3.4E) did not show significant differences between control 
and OVX treatment groups (p-value > 0.05). Total vBMD was reduced by 8% 
after two months of treatment (p-value = 0.1). Bone area and BMC did not vary 
between groups at two months. No difference could be found in trabecular vBMD 
(p-value = 0.72), trabecular area (p-value = 0.14) and trabecular BMC (p-value = 
0.58). 
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The proximal metaphysis of the tibia at five months (Figure 3.4B, 3.4D, 
3.4F) showed a significant treatment effect. Tibial vBMD was decreased by 8% 
(p-value = 0.052), 27% (p-value = 0.0009) and 13% (p-value = 0.057) in the OVX, 
OVXG and OVXG2, respectively (Figure 3.4B). BMC was decreased by 14% (p-
value 0.051), 28% (p-value = 0.001) and 1% (p-value = 0.293) in the OVX, OVXG 
and OVXG2, respectively (Figure 3.4F). Trabecular vBMD was reduced by 20% 
(p-value = 0.019) and 30% (p-value = 0.003) in the OVX and OVXG, respectively 
(Figure 3.4B). Trabecular BMC was reduced by 22% (p-value = 0.044) and 20% 
(p-value = 0.109) in the OVX and OVXG, respectively (Figure 3.4 F). 
The data were pooled from all the treatment groups at two months and five 
months, and further analyses performed to investigate any possible associations 
between parameters. Relationships of BMD of femur and tibia with OC and CTx-
1 concentrations in sheep at two months were not significant using Spearman’s 
rank-order correlations (Table 3.2). However, a significant correlation was 
observed between lumbar spine aBMD and OC (r = –0.636; p-value = 0.048). 
The correlations between biochemical markers and BMD of lumbar spine, femur 
and tibia at five months were positive for OC and negative for CTx-1, but not 
significant using Spearman’s rank-order correlation (Table 3.2). However, a 
strong and significant negative correlation between femoral aBMD and CTx-1 
was found (r = –0.505; p-value = 0.039). 
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Table 3.2: Correlation between biochemical markers and BMD of lumbar spine, 
femur and tibia in OVX sheep at month two and month five of the study. 
 OC  CTx-1  
 Spearman’s 
correlation 
p-value Spearman’s 
correlation 
p-value 
Month 2     
Lumbar spine aBMD –0.636 0.048 –0.345 0.298 
Femur aBMD –0.261 0.466 0.346 0.297 
Tibia     
vBMD –0.418 0.229 –0.336 0.312 
Trabecular vBMD –0.479 0.162 –0.409 0.212 
Month 5     
Lumbar spine aBMD 0.262 0.309 –0.212 0.414 
Femur aBMD 0.140 0.593 –0.505 0.039 
Tibia     
vBMD 0.130 0.619 –0.284 0.269 
Trabecular vBMD 0.184 0.480 –0.404 0.107 
 p-value < 0.05 was considered as statistically significant. 
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Figure 3.4: Bone variables at the proximal metaphysis of the tibia at month two 
and month five measured by pQCT. Total and trabecular tibial vBMD, area and 
BMC (A), (C) and (E), respectively, at month two. Total and trabecular tibial 
vBMD, area and BMC (B), (D) and (F), respectively, at month five are shown for 
half of the ewes euthanised at month two in the control group (n = 5) and OVX 
group (n =6); and the remaining ewes at month five for each group. Data is 
presented as mean and 95% confidence intervals. *p-value < 0.05 was 
considered as statistically significant.  
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3.4 Discussion 
 
In this study, we applied a combination of advanced age, OVX and 
glucocorticoid treatment to determine bone mass quantity, quality and bone 
markers using sheep as a large animal model for postmenopausal osteoporosis. 
A period of five months caused a decreased BMD in the glucocorticoid OVX 
sheep with a significant reduction of aBMD in the lumbar spine and femur as 
measured by DXA, and a significant decrease in tibial cortical and trabecular 
vBMD as measured by pQCT. The decreases in aBMD and vBMD were greater 
in the glucocorticoid-treated ovariectomised sheep compared with the control 
groups and those that only underwent OVX. Interestingly, after cessation of 
glucocorticoid administration, there was a recovery of bone mass in sheep treated 
with glucocorticoids for only two months. Serum biomarkers were increased in 
the ovariectomised sheep; however, those same serum markers were reduced in 
the glucocorticoid-treated OVX sheep. 
 
3.4.1 Effect of OVX on bone biomarkers and bone parameters in sheep  
 
Bone turnover markers can be used as measures of the status of bone 
remodelling. The bone remodelling depends on the synchronization of bone 
resorption cells—osteoclasts and subsequent bone formation cells—osteoblasts. 
During menopause, bone resorption increases as a result of oestrogen deficiency 
as well as bone formation to fill the bone cavities that have been destroyed 
(Vasikaran et al., 2011a). In this study, after five months of OVX on a diet 
providing the minimum required level of calcium, the bone resorption serum 
biomarker CTx-1 increased at two months in the OVX group and remained 
increased until the end of the study. Similarly, serum OC increased after OVX 
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and remained increased during the study. These results are in agreement with 
Kiełbowicz et al. (2015) that reported increased serum CTx-1 concentrations in 
OVX sheep. Other authors have reported an increase in urinary CTx-1 three 
months, and serum pyridinoline concentrations two months, after OVX 
(Chavassieux et al., 2001; Sigrist et al., 2007). Other studies also support these 
findings with regards to serum OC concentration; also showing that serum OC 
concentrations increased after OVX treatment in sheep (Chavassieux et al., 
2001; Johnson et al., 2002; Newton et al., 2004a). It was also observed that OC 
and CTx-1 concentrations were significantly negatively correlated with lumbar 
spine aBMD and femoral aBMD, respectively. These results suggest a possible 
association between bone turnover and bone density, where bone turnover is 
able to predict a reduction of BMD. These increased serum concentrations of OC 
and CTx-1 reflect increased bone resorption in lumbar spine and femur due to 
OVX promoting bone loss and increasing bone turnover (Yoon et al., 2012). 
These findings suggest that a two-month time point may be sufficient for 
assessing the early effects of OVX on bone resorption and can reliably predict 
changes in bone structure. 
In this study, a reduction of lumbar and femur BMD was found, as 
assessed by DXA, when compared with the control group that was not 
ovariectomised and was fed a diet with plentiful calcium. These results are similar 
to those reported by previous studies; with a decrease of aBMD reported in the 
spine at six months (Turner et al., 1995) and 12 months after OVX (Hornby et al., 
1995; Wu et al., 2008; Zhang et al., 2014b). 
In this study, tibia vBMD, trabecular vBMD and cortical/subcortical vBMD 
as assessed by pQCT showed a decrease in bone mass after five months of 
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OVX. However, published reports are controversial, as two of the few studies 
published to date reported no significant differences in trabecular vBMD in the 
proximal tibia after twelve months of OVX in sheep (Augat et al., 2003). However, 
Sigrist et al. (2007) observed a significant decrease in trabecular vBMD of the 
distal radius after four months of OVX. Taken together, these findings suggest 
that five months or less is a sufficient time period post-ovariectomy to reliably 
measure physical changes in BMD in the sheep model, where DXA and pQCT 
are suitable methods of measurement to assess BMD. 
 
3.4.2 Effect of glucocorticoid treatment on bone biomarkers and bone parameters 
in OVX sheep  
 
The combination of OVX, minimal dietary calcium, and glucocorticoid 
treatment caused a transient increase in the serum CTx-1 concentrations at two 
months, after which concentrations were lowered by the end of the study. This 
result is supported by previous studies, where serum CTx-1 concentrations 
increased during the first months in OVXG sheep but decreased thereafter 
(Zarrinkalam et al., 2009a; Ding et al., 2010; Andreasen et al., 2015). The bone 
resorption marker CTx-1 has been shown to increase during the administration 
of steroids. The direct effect of glucocorticoids may be in promoting 
osteoclastogenesis (Takuma et al., 2003) and having an anti-apoptotic effect on 
osteoclasts (Jia et al., 2006). 
In contrast, the serum OC concentration of sheep treated with 
glucocorticoids for five months decreased until the end of this study. This result 
is similar to some previous studies, where serum OC concentration rapidly 
decreased (Chavassieux et al., 1993; Chavassieux et al., 1997b; Ding et al., 
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2010) and remained suppressed in sheep (Andreasen et al., 2015) with the 
combination of OVX and glucocorticoid treatment. However, it is well known that 
glucocorticoids affect osteoblasts and osteocytes, decreasing their lifespan and 
bone formation, as reflected by the reduction of serum OC concentrations (Van 
Staa et al., 2002).  
An unexpected outcome of the current study is that the serum OC and 
CTx-1 concentrations in the group that received only two months of 
glucocorticoids were closer to the control group after cessation of glucocorticoid 
administration. This finding is supported by Ding et al. (2010), where serum OC 
recovered after the glucocorticoid treatment was discontinued at seven months 
in their study. 
In the present study, BMD decreased after five months of the combination 
of OVX and glucocorticoids in the lumbar spine, femur and tibia, although this 
reduction varied according to the skeletal site. Previous research reported 
decreased cortical and trabecular vBMD in the lumbar spine and distal radius with 
OVX plus glucocorticoids in sheep over a period of six months (Lill et al., 2002a), 
tibia (Schorlemmer et al., 2005) at 12 months and iliac bone (Andreasen et al., 
2015) over a period of seven months. Moreover, other studies reported the 
reduction of cortical and trabecular vBMD in the lumbar spine, distal radius and 
proximal tibia with OVX, glucocorticoids and diet in sheep (Lill et al., 2002a; Augat 
et al., 2003; Veigel et al., 2011). In this study, a significant reduction of trabecular 
compartment was detected during the administration of glucocorticoids, and this 
contributed to lower vBMD, which was observed after five months of treatment. 
Thus, the combination of OVX and glucocorticoids accelerates a profound bone 
loss in a short time, by inducing bone resorption and suppressing bone formation. 
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Sheep is recognised as a large animal model for studying human 
osteoporosis. The OVX sheep model is useful to understand the mechanisms 
that contribute to bone loss. However, there has been controversy about the 
optimal period of time for achieving bone loss due to there is no agreement within 
the literature of the time necessary to establish an osteoporotic (osteopenic) bone 
in OVX sheep. There have been several hypotheses proposed on the time 
required to induce measurable bone loss in sheep (Chavassieux et al., 2001; Les 
et al., 2005; Sigrist et al., 2007), although the duration required remains 
controversial due to the different breeds used in each study, the small number of 
animals per sampling, and the different approaches used to evaluate bone 
quantity and quality (Lill et al., 2002a; Ding et al., 2010; Veigel et al., 2011). 
However, in this study, it was found that a short-term ovariectomised 
glucocorticoid-treated model in Merino ewes can be used to induce bone loss 
without the side effects and complications of using glucocorticoids, such as hair 
loss, infections, and particularly, ethical concerns around animal welfare for the 
use of research animals as experimental units (Egermann et al., 2008). These 
results showed that five months was sufficient to induce bone loss using a 
combination of OVX and glucocorticoid treatment in Merino ewes, and that once-
monthly injections of glucocorticoids resulted in no clinical infections or negative 
dermatological effects. 
The limitations of this study include the small sample size and that bone 
mineral density was determined as a function of treatment evaluated in OVX 
sheep. Future studies such as mechanical properties of bone and changes in its 
extracellular matrix components are required to fully investigate bone quality in 
OVX sheep. However, the strengths are the induction of bone loss in a short 
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period of time and the assessment of bone mass during and after the cessation 
of glucocorticoids combined with OVX. Therefore, this present project should be 
considered a pilot study, where a combination of OVX and glucocorticoids was 
used to induce bone loss over a short period of time in sheep. A reduction in time 
may allow the sheep model to be used more frequently, to test novel therapies 
for postmenopausal women. 
3.5 Conclusions 
 
This pilot study suggested that the interaction of OVX and glucocorticoids 
plays a significant role and induces bone loss in sheep over five months, and this 
bone loss is similar to that seen in humans. The combination of OVX and length 
of glucocorticoid treatment should be carefully considered when designing 
studies using OVX sheep. Further, the use of experimental animal models for 
studying bone loss to test new experimental drug therapies and orthopaedic 
implants offers opportunities to enhance our understanding of bone diseases, 
particularly postmenopausal osteoporosis.  
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Chapter 4 
 
 
 
 
 
 
 
 
Bone changes in response to 
glucocorticoids in ovariectomised 
sheep: a peripheral quantitative 
computed tomography (pQCT) 
study 
 
Previous work in the ovariectomised (OVX) sheep model has been described in 
detail (Chapter 3), and these findings demonstrated that glucocorticoid-induced 
osteoporosis, where bone remodelling and bone loss occurred, was observed in 
OVX sheep over five months. In this section of my project, the results of pQCT 
measurements and the three-point bending test in left tibias in the OVX sheep 
are presented. There were three specific objectives of this study. First, to 
investigate the direct changes after OVX and glucocorticoid treatment on tibias 
of sheep. Second, to evaluate correlations between proximal and distal 
metaphyseal bone parameters of the left tibia. Third, to determine the tibial bone 
mechanical properties using the three-point bending test. 
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Abstract 
 
The main objectives of this study were to use pQCT to determine whether 
glucocorticoid treatment induces changes in the distal metaphysis of the tibia; to 
assess whether there is a relationship between proximal and distal metaphyseal 
bone parameters of the tibia; and to compare the effect of ovariectomy (OVX) 
and glucocorticoid treatments on mechanical properties in the mid-shaft tibial 
bone in sheep. Twenty-eight aged Merino ewes were selected and randomised 
into four groups: OVX, OVX plus glucocorticoid treatment for five months, OVX 
plus glucocorticoid treatment for two months, and untreated control. The left tibias 
were used for measurement of bone imaging by using pQCT at baseline, at two 
and five months. The left tibia was also processed for strength evaluation.  OVX 
alone did not affect bone parameters in the proximal and distal tibial metaphyses 
in OVX sheep at two months. The interaction of OVX plus glucocorticoids had a 
pronounced effect on volumetric bone mineral density in the group that received 
five months of this treatment. Conversely, when glucocorticoid treatment was 
discontinued after two months, a rebound effect was observed. Maximum load, 
stiffness, and energy to failure decreased over time. This study demonstrated 
that there are incremental bone changes at both distal and proximal metaphysis 
sites in OVX and glucocorticoid-induced osteoporosis over five months, some of 
which may be reversible in Merino ewes. 
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4.1 Introduction 
 
Bone loss occurs during oestrogen deficiency and is intensified with 
glucocorticoid treatments in postmenopausal women, which may lead to the 
development of osteoporosis. Osteoporosis is characterised by a decline in bone 
quantity and quality, as well as increased fracture risks. Despite the significant 
progress in diagnosis and treatment of osteoporosis, postmenopausal 
osteoporosis is still the most frequent cause of fractures in women. Worldwide, it 
is estimated that 200 million women are affected by osteoporosis, with 
approximately 1.6 million hip fractures occurring each year (Johnell and Kanis, 
2006; Kanis and Group, 2007).  
Dual energy x-ray absorptiometry (DXA) is the gold standard method to 
diagnose osteoporosis by assessing areal bone mineral density (aBMD) in a 
specific region of interest of clinically important sites of fracture risk. However, 
DXA only provides a two-dimensional image of apparent density, and this limits 
its ability to assess fracture risk. DXA also cannot differentiate between cortical 
or trabecular bone (World Health Organization, 1994). As osteoporosis induces 
rapid trabecular loss and structural changes, it is important to assess trabecular 
structure.  
pQCT provides a measurement of volumetric bone mineral density 
(vBMD), and can separate the cortical and trabecular compartments in the 
peripheral skeleton (Turner, 2002). There are skeletal site differences in bone 
loss as well as differences between locations within a single bone. In long bones, 
the trabecular compartment is higher in the metaphysis and epiphysis when 
compared with the diaphysis, where there is only cortical bone (Clarke, 2008). 
Thus, trabecular bone mass differs at skeletal sites, and fractures are commonly 
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observed in the distal radius, lumbar spine and the proximal femur (hip fracture) 
(Kanis et al., 1997). To date, the response to oestrogen loss of proximal sites has 
been well documented in postmenopausal women, but it is poorly understood 
whether there is a high correlation of bone loss between proximal and distal sites 
(Amstrup et al., 2016).  
Animal models have been used to understand osteoporosis and evaluate 
new treatments for bone loss. Rodent models have been widely used and 
trabecular bone loss occurs after OVX and glucocorticoid-induced osteoporosis 
in rats (Lelovas et al., 2008; Komori, 2015). Sheep are another suitable model, 
as the bone remodelling and response to oestrogen withdrawal approximates 
human bone biology. Trabecular bone loss has been reported after OVX (Turner 
et al., 1995; Augat et al., 2003; Newton et al., 2004b; Sigrist et al., 2007; Kennedy 
et al., 2009; Egermann et al., 2011) or OVX combined with glucocorticoid (Lill et 
al., 2002b; Goldhahn et al., 2005; Zarrinkalam et al., 2009b; Ding et al., 2010) in 
sheep models. The subsequent rate and magnitude of the reduction of BMD 
varies according to the skeletal site examined (Turner et al., 1995).  Few studies 
have reported either the distribution of, or the rate of reduction in, the trabecular 
and cortical bone in the distal radius in OVX sheep (Lill et al., 2002b; Goldhahn 
et al., 2005). Further, in sheep, a greater trabecular bone loss in the proximal 
limbs has been documented, but how OVX affects bone changes in the distal 
limbs has not been described in detail. These have a greater potential for serial 
sampling and therefore might be more useful to assess than proximal limbs  
(Oheim et al., 2016). In addition, there is no agreement within the literature of the 
time necessary to establish an osteoporotic animal model for bone loss in OVX 
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sheep. Thus, short-term studies are required to clarify how bone quality responds 
to oestrogen deficiency in different skeletal sites for evaluating bone status. 
A five-month study in OVX sheep was carried out to expand our knowledge 
of bone quality in postmenopausal osteoporosis. The aims of this study included: 
1) to use pQCT to examine whether glucocorticoid treatment induces changes in 
the distal metaphysis of the tibia; 2) to assess whether there is a correlation 
between proximal and distal metaphyseal bone parameters of the tibia after 
measuring these sites separately; and 3) to compare the effect of OVX and 
glucocorticoid treatments on mechanical properties in the mid-shaft tibial bone in 
sheep.  
 
4.2 Materials and methods 
 
4.2.1 Animals used and experimental design 
 
The animals used and the experimental design are described in Chapter 
3, Section 3.2.1. Briefly, 28 Merino ewes were first fed a basal diet for 10 days 
(adaptation period), then allocated at random to treatments, followed by OVX 
procedure. The study treatment groups were: OVX alone, OVX combined with 
glucocorticoid treatment for five months, OVX combined with glucocorticoids 
for two months, and untreated control. The study protocol aimed to mimic bone 
loss in postmenopausal osteoporosis. This study was performed in full 
compliance with the Massey University Animal Ethics committee (approval 
number 14/103) and performed according to the Code of Ethical Conduct for the 
use of live animals for research at Massey University, Palmerston North, New 
Zealand.  
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In total, bone samples from 28 ewes were examined: 10 from the control 
group, 12 from the OVX group, three from the OVX group receiving 
glucocorticoids once a month for five months (OVXG), and three from another 
OVX group receiving glucocorticoids once a month for two months (OVXG2).  
The initial baseline scan (in vivo pQCT, as described below) was obtained 
after the sheep were anaesthetised for surgery. Control animals were 
anaesthetised and scanned using the same procedure.   
At month two and at the end of the trial (five months), after sacrifice, the 
left tibias were harvested, stripped of muscle tissues and the bones wrapped in 
plastic bags, and stored at –20 °C. The tibias were thawed at room temperature 
before pQCT scans and biomechanical tests were performed (ex vivo pQCT, as 
described below).  
 
4.2.2 pQCT 
 
4.2.2.1 In vivo and ex vivo pQCT 
 
Three-dimensional analyses of the tibia from the left leg were performed 
using the XCT2000 scanner (Stratec, Pforzheim, Germany). The measurement 
protocol was performed in accordance with the manufacturer's instructions. Scout 
views were acquired to determine the standard measurements for the distal and 
proximal tibia. The thickness of the scan slice was 2 mm, voxel size 0.3 mm and 
a scan speed of 10 mm/s. A reference point line was set electronically at the 
midpoint of the most distal articulating surface of the distal tibia. From this 
reference line, two scans were performed unilaterally: one at the metaphysis (at 
10 mm, relative to the distal end), and one at a metaphyseal site, 15 mm from the 
proximal end. 
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4.2.2.2 Imaging analysis 
 
Norland/Stratec XCT 5.50 software was used for scan imaging analysis. 
For proximal and distal sites, the parameters of trabecular compartment were 
obtained as the central 45% of bone at trabecular sites. The manufacturer’s 
contour threshold was set at 280 mg/cm3 to separate soft tissue from the outer 
edge of bone. In addition, to determine cortical bone, the threshold was set at 
710 mg/cm3 (Neu et al., 2001; Firth, 2006). The following parameters were 
analysed for both the proximal and distal metaphysis: vBMD, bone area, bone 
mineral content (BMC), trabecular vBMD (Tb vBMD), trabecular bone area (Tb 
area), trabecular BMC (Tb BMC), cortical thickness, periosteal circumference, 
and endosteal circumference. 
 
4.2.3 Bone mechanical properties by three-point bending test of the tibias 
 
Left tibias were thawed and kept at room temperature during the test. Each 
bone sample was measured using an electronic vernier caliper (resolution 0.02 
mm, MitutoyoTM, Japan) and the midpoint of the tibia was marked with a pen. 
The mechanical properties of the tibia were determined after pQCT scans by a 
three-point bending test using a mechanical testing machine (Instron 1195 
Norwood, MA, USA) (Bozzini et al., 2012). Each tibia was placed on its anterior 
surface facing upward on two support bars 80 mm apart, centred, and the 
pressing force was directed vertically to its mid shaft. A compression load was 
applied at 25 kN load (50 mm/min) until breakage. The force at failure, energy, 
stress and stiffness were calculated for each sample and derived from the load–
deformation curve using the manufacturer’s built-in computer software: energy 
was calculated as the area under the load–deformation curve, stiffness calculated 
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as the slope of the linear part of the load–deformation curve, and stress was 
calculated as the area under the load–displacement curve (Gallant et al., 2013). 
 
4.2.4 Statistical analyses 
 
Data for tibial parameters were analysed to test the effect of OVX plus 
glucocorticoid treatments after sacrifice at two and five months. Data were 
expressed as mean and standard error of mean (SEM). Statistical analysis was 
performed with the nonparametric Kruskal–Wallis test followed by Dunn’s post-
hoc test (p-values < 0.05 were considered statistically significant). Statistical 
analyses on data were conducted using R (R 3.1.1, R Foundation for Statistical 
Computing, Vienna, Austria). The data were pooled from all the treatment groups 
at two and five months, and further analysis conducted to determine any possible 
correlation between parameters. Linear correlations and Spearman’s rank-order 
correlations were calculated for distal and proximal metaphysis of the tibia at 
months two and five using Minitab 17.2.1 (Minitab Inc., Pennsylvania, USA).  
4.3 Results 
 
4.3.1 Effect of OVX plus glucocorticoid on the distal tibial metaphysis over time  
 
At baseline, there were no significant differences between the control 
group and the OVX group for vBMD or any of the trabecular parameters (Table 
4.1 and Table 4.2). At both two and five months post-surgery, all the treated 
groups decreased in vBMD. Consistent with the effects in vBMD, bone area and 
BMC, periosteal and endosteal circumferences were similar at baseline but 
decreased only slightly over time (Table 4.1 and Table 4.2). However, trabecular 
vBMD was numerically reduced from baseline at both two and five months in all 
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groups, although statistical significance was not achieved (p-value > 0.05) (Table 
4.1). The trabecular area reduced only slightly; therefore, the decrease in vBMD 
was due to the decrease observed in BMC. Trabecular BMC was numerically 
reduced after five months and tended to be lower (p-value = 0.09) in the control 
group compared with the treated groups (Table 4.1). Similar to vBMD and 
trabecular vBMD, cortical thickness was lower at both two and five months in the 
treated groups (p-value = 0.06) (Table 4.2).  
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Table 4.1: Longitudinal bone measurements of the distal tibial metaphysis in 
OVX. 
    
Ovariectomy 
  
Ovariectomy + glucocorticoid treatment 
 
 
   Control 
(n = 5) 
OVX 
(n = 6) 
p- 
value 
Control 
(n = 5) 
OVX 
(n = 6) 
OVXG 
(n = 3) 
OVXG2 
(n = 3) 
p- 
value 
vBMD1 
(mg/cm3) 
Baseline  611.2 
(22.7) 
609.9 
(19.8) 
1 605.6 
(24.5) 
638.4 
(17.6) 
621.5 
(42.4) 
614.5 
(29.4) 
0.69 
 2 
Months 
 592.2 
(19.3) 
574.6 
(18.4) 
0.58 - - - - - 
 5 
Months 
 - - - 602.8 
(28.7) 
567 
(11.6) 
518.7 
(31.1) 
519.3 
(23.9) 
0.21 
           
Bone 
area 
(mm2) 
Baseline  466.1 
(17.8) 
477 
(41.2) 
0.58 483.5 
(10.2) 
461.7 
(17.9) 
498.2 
(22.3) 
512.1 
(20.2) 
0.56 
 2 
Months 
 411.2 
(27.6) 
440.1 
(27.5) 
0.47 - - - - - 
 5 
Months 
 - - - 430.1 
(14.7) 
394.9 
(12.2) 
415.5 
(21.2) 
448.5 
(28.6) 
0.43 
           
BMC2 
(g) 
Baseline  284.6 
(14.2) 
293.3 
(30.3) 
0.36 292.5 
(11.4) 
295.1 
(16.9) 
308.1 
(18.3) 
312.5 
(7.1) 
0.77 
 2 
Months 
 244.3 
(20.5) 
252.2 
(15.3) 
0.72 - - - - - 
 5 
Months 
 - - - 259.3 
(16.1) 
223.4 
(3.7) 
213.5 
(7.4) 
230.5 
(7.9) 
0.06 
           
Tb 
vBMD3 
(mg/cm3) 
Baseline  412.3 
(25.1) 
373.6 
(46.1) 
0.86 418.1 
(16.2) 
365.9 
(19.7) 
414.9 
(15.1) 
425.2 
(19.9) 
0.29 
 2 
Months 
 271.4 
(54.2) 
316.7 
(15.4) 
0.72 - - - - - 
 5 
Months 
 - - - 295.6 
(53.5) 
189.1 
(24.6) 
244.8 
(16.3) 
272.4 
(9.1) 
0.12 
           
Tb area4 
(mm2) 
Baseline  279.6 
(21.1) 
281.7 
(33.1) 
0.72 293.8 
(16.9) 
239.7 
(12.8) 
285.8 
(38.3) 
305.7 
(34.2) 
0.28 
 2 
Months 
 223.4 
(26.6) 
262.8 
(25.7) 
0.47 - - - - - 
 5 
Months 
 - - - 231.7 
(17.9) 
214.1 
(11.5) 
248.7 
(22.6) 
282.5 
(29.2) 
0.45 
           
Tb 
BMC5 
(mg/mm) 
Baseline  116.1 
(12.1) 
111.7 
(23.1) 
1 122.3 
(6.5) 
88.1 
(7.5) 
116.6 
(12.7) 
129.1 
(12.9) 
0.10 
 2 
Months 
 65.9 
(18.9) 
84.6 
(11.9) 
0.36 - - - - - 
 5 
Months 
 - - - 70.8 
(15.2) 
41.4 
(6.4) 
59.7 
(2.8) 
76.7 
(7.4) 
0.09 
1 Volumetric bone mineral density (vBMD). 
2 Bone mineral content (BMC). 
3 Trabecular volumetric bone mineral density (Tb vBMD). 
4 Trabecular area (Tb area). 
5 Trabecular bone mineral content (Tb BMC). 
Data expressed as mean (SEM). The resulting p-values obtained by Kruskal–Wallis are given.
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Table 4.2: Longitudinal geometric parameters of the distal tibial metaphysis in 
OVX sheep. 
   
Ovariectomy 
  
Ovariectomy + glucocorticoid 
treatment 
 
 
  Control 
(n = 5) 
OVX 
(n = 6) 
p- 
value 
Control 
(n = 5) 
OVX 
(n = 
6) 
OVXG  
(n = 3) 
OVXG2 
(n = 3) 
p- 
value 
Periosteal 
circumference 
 (mm) 
Baseline 76.4 
(1.4) 
77.1 
(3.4) 
0.58 77.9 
(0.8) 
76.1 
(1.5) 
79.1 
(1.7) 
80.1 
(1.5) 
0.56 
 2 
Months 
71.7 
(2.4) 
74.2 
(2.3) 
0.47 - - - - - 
 5 
Months 
- - - 73.4 
(1.2) 
70.4 
(1.1) 
72.1 
(1.8) 
74.9 
(2.41) 
0.43 
Endosteal 
circumference 
Baseline 62.7 
(2.1) 
62.4 
(3.4) 
0.86 64.3 
(1.7) 
58.6 
(1.5) 
63.3 
(3.8) 
65.1 
(3.4) 
0.24 
(mm) 2 
Months 
57.2 
(2.6) 
60.5 
(2.6) 
0.47 - - - - - 
 5 
Months 
- - - 58.3 
(1.5) 
55.3 
(1.3) 
59.5 
(2.4) 
62.5 
(3.1) 
0.41 
Cortical 
thickness 
(mm) 
Baseline 2.1 
(0.2) 
2.3 
(0.1) 
0.47 2.1 
(0.2) 
2.7 
(0.2) 
2.5 
(0.4) 
2.4 
(0.2) 
0.36 
 2 
Months 
2.3 
(0.1) 
2.1 
(0.1) 
0.47 - - - - - 
 5 
Months 
- - - 2.4 
(0.1) 
2.4 
(0.1) 
2 
(0.1) 
1.9 
(0.1) 
0.06 
Data expressed as mean (SEM). The resulting p-values obtained by Kruskal–Wallis are given. 
 
4.3.2 Effect of OVX plus glucocorticoid on the proximal tibial metaphysis at two 
and five months following treatments 
 
Table 4.3 shows the effect of glucocorticoid plus OVX on the proximal tibial 
metaphysis at two and five months. Sheep were euthanised at month two or 
month five post-surgery, and ex vivo measurements of proximal tibial sites were 
carried out. At month two after OVX, vBMD, trabecular vBMD and cortical 
thickness decreased by 8.7% (p-value = 0.050), 25% (p-value = 0.357) and 14% 
(p-value = 0.072), respectively, when compared with the control group. There was 
no difference in bone area, BMC, trabecular area, trabecular BMC, periosteal 
circumference and endosteal circumference (p-values > 0.05). 
After five months, there were marked differences between the control 
group and treated groups (Table 4.3). vBMD, bone area and BMC decreased by 
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8.2% (p-value = 0.052), 6.6% (p-value = 0.209) and 14% (p-value = 0.051), 
respectively. Trabecular vBMD, trabecular area and trabecular BMC decreased 
by 14% (p-value = 0.019), 20% (p-value = 0.435) and 4% (p-value = 0.044), 
respectively. Periosteal and endosteal circumference decreased by 3% (p-value 
= 0.209) and 2% (p-value = 0.343), respectively. Cortical thickness decreased by 
8% (p-value = 0.158). When glucocorticoids were administered for five months, 
vBMD, BMC and cortical thickness decreased by 20% (p-value = 0.034), 4% (p-
value = 0.056) and 23% (p-value = 0.038) when compared with the OVX group, 
whereas vBMD and cortical thickness decreased by only 5% (p-value = 0.407) 
and 19% (p-value = 0.038), respectively, in the OVXG2 group.  
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Table 4.3: Effect of OVX plus glucocorticoids treatment in the proximal 
metaphysis of the tibia in OVX sheep at two and five months. 
 2  
Months 
 5  
Months 
 
 Control 
(n = 5) 
OVX 
(n = 6) 
p-
value 
 
Control 
(n = 5) 
OVX 
(n = 
6) 
OVXG  
(n = 3) 
OVXG2  
(n = 3) 
p- 
value 
 
vBMD1 
(mg/cm3) 
476.1  
(13.7) 
434.6  
(17.3) 
0.10 490.7 
(14.2) 
450.1  
(11.6) 
358.7 
(14.3) 
426.3  
(17.1) 
0.02 
Bone area  
(mm2) 
695  
(30.7) 
774.2  
(50.2) 
0.20 702.2  
(31.4) 
655.9  
(20.8) 
695.8 
 (35.8) 
803.3  
(71.8) 
0.64 
BMC2 
(g) 
330.3  
(12.8) 
337  
(26.8) 
0.86 344.6 
 (18.8) 
294.3  
(6.5) 
248.1  
(9.7) 
339.9  
(30.5) 
0.03 
Tb vBMD3 
(mg/cm3) 
260.8 
(14.2) 
255  
(13.3) 
0.72 249.4  
(6.4) 
199.5  
(13) 
173.7 
(7.5) 
265.3  
(15.5) 
0.01 
Tb area4 
 (mm2) 
464.5 
(28.8) 
548.2  
(41.3) 
0.14 452.2  
(24.1) 
434  
(20.4) 
509.7  
(37.1) 
583.7  
(62.5) 
0.55 
Tb BMC5 
(mg/mm) 
122.3 
(12.2) 
141.35  
(15.7) 
0.58 113.2  
(8.3) 
87.5  
(8.1) 
89.5  
(9.7) 
156.7 
(21.52) 
0.10 
Periosteal 
circumference 
(mm) 
93.4  
(2.1) 
98.3  
(3.2) 
0.20 93.8  
(2.1) 
90.7  
(1.4) 
93.4 
 (2.3) 
100.1  
(4.6) 
0.64 
Endosteal 
circumference 
(mm) 
80.2 
(2.5) 
86.5  
(3.1) 
0.14 79.1 
 (2) 
77.1  
(1.8) 
83.4  
(2.9) 
89.1 
 (5.9) 
0.52 
Cortical 
thickness 
(mm) 
2.1 
(0.1) 
1.8 
(0.1) 
0.14 2.3 
 (0.1) 
2.1 
(0.1) 
1.6 
(0.1) 
1.7  
(0.1) 
0.02 
1 Volumetric bone mineral density (vBMD). 
2 Bone mineral content (BMC). 
3 Trabecular volumetric bone mineral density (Tb vBMD). 
4 Trabecular area (Tb area). 
5 Trabecular bone mineral content (Tb BMC). 
Data are shown for half of the ewes euthanized at baseline and month 2 in the control group and OVX group; and 
the remaining ewes at baseline and month 5 for each group. Data expressed as mean (SEM). The resulting p-
values obtained by Kruskal–Wallis are given.   p-value < 0.05 was considered as statistically significant. 
 
4.3.3 Relationship between distal and proximal metaphyseal parameters in OVX 
sheep at two and five months 
 
Table 4.4 shows the association between distal and proximal metaphyseal 
parameters of the tibia at two and five months. As there are local variations within 
a bone, these variations need to be assessed for understanding the relationship 
of bone loss in skeletal sites. The effect of OVX was more pronounced on 
trabecular bone in proximal sites in this study. However, when metaphyseal sites 
were examined, bone parameters in both distal and proximal sites correlated well. 
vBMD (r = 0.73, p-value < 0.01), bone area (r = 0.864, p-value < 0.01) and BMC 
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(r = 0.791, p-value < 0.01) were significantly correlated at both skeletal sites of 
the tibia. For trabecular vBMD, correlation between distal and proximal 
metaphyseal sites was significant only at five months (r = 0.528; p-value = 0.029). 
Considering other indices, both skeletal sites correlated well with periosteal and 
endosteal circumferences at two and five months, respectively.  
 
Table 4.4: Regression and correlation results between distal and proximal tibial 
metaphysis of the tibia at two and five months. 
 
1 Volumetric bone mineral density (vBMD). 
2 Bone mineral content (BMC). 
3 Trabecular volumetric bone mineral density (Tb vBMD). 
4 Trabecular area (Tb area). 
5 Trabecular volumetric bone mineral content (Tb BMC). 
p-value < 0.05 was considered as statistically significant.
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4.3.3 Effect of OVX plus glucocorticoids on biomechanics in mid-shaft of the tibia 
at two and five months following treatments 
 
A three-point bending test was used to assess bone strength at the mid-
diaphysis of the tibia (Figure 4.1). There were no significant differences in 
maximum load, stiffness and energy among the four groups determined from the 
three-point bending test in the mid-diaphysis of the tibia after sacrifice at months 
two and five (Figure 4.1). However, OVX plus glucocorticoids decreased all the 
mechanical property parameters of the tibial mid-diaphysis, where maximum 
load, stiffness and energy decreased after five months of the study in all groups. 
The decrease in mechanical properties may be affected by the decrease 
observed in distal and proximal tibial in vBMD.  
At two months, maximum load was slightly lower in the OVX group than in 
the control group (3.85 N vs 4.31 N; p-value = 0.228) (Figure 4.1A). Moreover, 
stiffness was lower in the OVX group than in the control group (1.75 N/mm vs 
2.96 N/mm; p-value = 0.089). Energy did not differ significantly between the OVX 
group and the control (2.65 N·mm vs 3.11 N·mm; p-value = 0.228).  
At five months, maximum load did not differ significantly between the OVX 
group and the control (4.39 N vs 4.41 N; p-value = 0.456). Compared to the OVX 
group, glucocorticoids decreased the maximum load in the OVXG group (3.57 N 
vs 4.39 N; p-value = 0.012), whereas the OVXG2 group showed an increase in 
the maximum load (4.64 N vs 4.39 N; p-value = 0.389).   
Stiffness was slightly higher in the OVX group compared with the control 
(2.45 N/mm vs 1.94 N/mm; p-value = 0.456) (Figure 4.1B). Compared to the OVX 
group, glucocorticoids decreased the stiffness in the OVXG group (1.6 N/mm vs 
2.45 N/mm; p-value = 0.115), whereas the OVXG2 group showed an increase in 
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stiffness (2.57 N/mm vs 2.45 N/mm; p-value = 0.389). Energy was lower in the 
OVX group than in the control group (2.57 N·mm vs 3.23 N·mm; p-value = 0.15) 
(Figure 4.1C). Compared to the OVX group, glucocorticoids showed a decrease 
in energy in the OVXG group (2.29 N·mm vs 2.57 N·mm; p-value = 0.241), 
whereas energy increased in the OVXG2 group (3.02 N·mm vs 2.57 N·mm; p-
value = 0.141). 
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Figure 4.1: Effect of OVX plus glucocorticoids treatment on bone mechanics 
measured by three bending points in tibia after sacrifice in OVX sheep. Maximum 
load (A), stiffness (B) and energy (C) at two months and five months in OVX 
sheep. Data are presented as mean and 95% confidence intervals. 
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 4.4 Discussion  
 
This study demonstrates the effect of OVX plus glucocorticoids on different 
skeletal sites in sheep. The key findings were that OVX combined with 
glucocorticoids in sheep resulted in decreased trabecular, cortical and strength 
parameters of the tibia. Changes in bone mass and strength parameters were 
consistent with changes in vBMD, but those differences were not significant in 
the strength parameters analysed using the three bending points. OVX sheep 
that received five months of glucocorticoid treatment had greater bone changes 
compared to the control and OVX groups over the five months.  
In this study, OVX alone did not affect bone parameters in the proximal 
and distal tibial metaphyses in OVX sheep at two months post-surgery. No 
significant differences were seen in any bone parameters between the control 
and OVX groups as change from baseline after two months. Similar to our 
findings, studies elsewhere reported that OVX alone did not decrease trabecular 
vBMD in OVX sheep after six or 12 months of study (Augat et al., 2003; Kennedy 
et al., 2009). These studies reported that at an early stage of oestrogen deficiency 
after OVX, oestrogen concentration increased at the tissue level as there were 
other extra-glandular sources of oestrogen, and this may result in the slow bone 
loss observed after OVX (Lesclous et al., 2001; Riggs et al., 2002; Oheim et al., 
2016). Sigrist et al. (2007) reported a 10% reduction of trabecular vBMD in sheep 
three months after OVX. Chavassieux et al. (2001) indicated that oestrogen 
deficiency after OVX increased cortical porosity, but no change was noted in 
trabecular bone.  
In this study, the interaction of OVX plus glucocorticoids had a pronounced 
effect on vBMD in the group that received five months of this treatment. Similarly, 
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Eschler et al. (2015) demonstrated the development of severe osteoporosis with 
OVX, corticosteroid treatment and calcium/phosphorus/vitamin D-deficient diet in 
sheep after five-and-a-half months of treatment. They reported a decrease in 
trabecular bone in the distal radius with significantly reduced vBMD in the 
glucocorticoid treatment group (0.19 g/cm³) as compared with the control animals 
(0.27 g/cm³). Other studies reported severe trabecular loss in the distal radius, 
lumbar spine and proximal tibia with glucocorticoid treatment alone over seven 
months (Ding et al., 2010), and with either OVX alone or a combination of OVX 
and glucocorticoid treatments over six and 12 months in sheep (Augat et al., 
2003).  
Glucocorticoid-induced osteoporosis has been reported to be reversible 
after six months of discontinued treatment (Van Staa et al., 2005). In this study, 
when glucocorticoid treatment was discontinued after two months, a rebound 
effect was observed, although this was not statistically significant in the OVXG2 
groups. A similar effect was reported by Ding et al. (2010), who indicated that 
three months after cessation of glucocorticoid treatment, the microarchitectural 
properties of trabecular bone were similar to those in the control group. 
Glucocorticoids affect bone remodelling directly by decreasing bone formation 
cells, altering bone remodelling and stimulating osteoclastogenesis (O’brien et 
al., 2004). Glucocorticoids can suppress expression of cytokines such as 
interferon-β and induce expression of M-CSF, which are essential molecular 
factors for osteoclastogenesis (Mazziotti et al., 2006).  
Interestingly, sheep in the control group showed a reduction in bone 
parameters as well over time. This could be attributed to a decline in physical 
activity which could have affected bone mass in the control group, as the sheep 
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were on a farm before the study and were kept in a barn during the study period. 
Studies in animals and humans support that long periods of inactivity will result 
in a reduction of bone mass and changes in bone structure (Goldhahn et al., 
2005; Roghani et al., 2013; Moreira et al., 2014). Bone strength of the long bone 
shaft predicts fracture risk during osteoporosis, and is associated with the 
mechanical properties of bone (Beck et al., 2001). Oestrogen modulates 
mechanical loading responses of bone cells and plays a role in bone 
homeostasis, but during menopause these responses change and there is an 
accelerated loss of bone mass and structure (Klein-Nulend et al., 2015). 
Bone provides mechanical and protective functions against fracture. In this 
study, bone maximum load, stiffness, and energy to failure decreased. There 
were no significant differences between the four groups, but OVX plus 
glucocorticoid treatment was more effective in deleteriously affecting the 
biomechanical properties of bone. In other studies, glucocorticoid treatment 
negatively affected the biomechanical properties of trabecular bone, resulting in 
reduced bone strength and increased risk of fractures (Lane et al., 2006). Thus, 
the efficacy of bone materials to protect against fracture is compromised as a 
result of long-term oestrogen depletion plus glucocorticoid treatment, making the 
bone vulnerable to mechanical damage. Ding et al. (2012) reported a decrease 
in cortical microarchitecture of the femoral shaft after seven months of 
glucocorticoids and malnutrition (low calcium and phosphorus) in sheep, where 
those changes may increase bone fragility. Lill et al. (2002c) reported a 70% 
reduction in load-bearing capacity of the lumbar spine, and a 50% reduction in 
the femoral head, in OVXG sheep. Similarly, results of the present study indicated 
that after OVX and glucocorticoid treatments, bone structural properties were 
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reduced, resulting in the observed greater decreased in vBMD in the OVXG 
groups (Lane et al., 2006). The reduction in bone biomechanical properties were 
consistent with the decrease in total and trabecular vBMD. During glucocorticoid-
induced osteoporosis reduction of trabecular bone has been reported, where 
there is decreased in trabecular thickness without reducing trabecular 
connectivity, affecting bone quality as there are changes in bone composition and 
strength (Carbonare et al., 2001; Tranquilli Leali et al., 2009). 
 Trabecular and cortical bone mass can be determined in the total 
skeleton, but prediction of fracture risk is complicated because bone mass differs 
between skeletal sites. In this study, vBMD and bone mass measurements 
between distal and proximal tibial metaphysis were correlated, although bone 
measurements were greater at proximal sites compared to distal sites. It has 
been reported that skeletal sites at both red and yellow marrows respond 
differently to oestrogen deficiency, and trabecular loss occurs mainly in proximal 
sites at red marrow rather than yellow marrow sites (Ma et al., 1994; Li et al., 
1996). Bone loss also occurs as a result of excess production of adipocytes in 
the marrow, and during menopause, bone loss is associated with lower 
osteoblastic and greater adipogenic lineage from the mesenchymal stem cells. 
Thus, after OVX, bone loss in these sites is associated with high bone 
remodelling in red marrow at proximal sites (Paccou et al., 2015).   
 
4.5 Conclusions 
 
OVX combined with glucocorticoid treatment did influence density and 
strength parameters of the tibia in OVX sheep over five months. This study 
showed that there are significant changes at the proximal tibial site, where 
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trabecular bone loss was observed. vBMD of the distal tibial metaphysis reflects 
vBMD of the proximal metaphysis, the location of clinically important fractures 
that occur in women with postmenopausal osteoporosis. This suggests that a 
relationship between both distal and proximal metaphysis sites does exist and is 
important for better understanding metaphyseal remodelling, with the potential to 
enhance the assessment and diagnosis of bone loss in postmenopausal 
osteoporosis. 
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Chapter 5 
 
 
 
 
 
 
 
 
 
Application of MS-based 
metabolomics approach in 
ovariectomised sheep as a model 
of osteoporosis 
 
 
 
This chapter employs the ewe as a large animal model of osteoporosis to 
investigate the impact of short-term and long-term ovariectomy and 
glucocorticoid hormonal interventions using a hydrophilic-interaction liquid 
chromatography–mass spectrometry (HILIC–MS)-based metabolomics 
approach. This is the first report to describe the effects of dynamic changes of 
osteoporosis progression on circulating metabolites in a longitudinal study. This 
chapter also evaluates the relationship between bone mineral density 
measurements, bone turnover markers and metabolite profiles in order to 
determine whether those significant features are linked to bone loss. 
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Abstract 
Understanding the early metabolic changes that accompany bone loss in 
postmenopausal osteoporosis will facilitate better targeting for developing new 
drugs or nutritional strategies for treatment of bone loss in postmenopausal 
women. Here, it was hypothesised that the metabolite profiles of ovariectomised 
sheep would be altered, and that the biochemical changes in plasma and bone 
remodelling would be correlated with bone loss. 28 skeletally mature ewes were 
divided randomly into four groups: an ovariectomy group, a group of ovariectomy 
in combination with five doses of glucocorticoids, a group of ovariectomy with 
only two doses of glucocorticoids, and a control group. Liquid chromatography–
mass spectrometry untargeted metabolomics analysis was applied to serial 
plasma samples from the sheep model to follow the progression of osteoporosis. 
To understand the mechanisms behind bone loss in these models, the plasma 
metabolome, bone turnover markers and bone mineral density of the sheep were 
evaluated. Separate statistical approaches were used to analyse the first two 
months (the short-term approach), and the five months (the long-term approach). 
Eight metabolites showed dynamic changes over time, including 5-
methoxytryptophan, valine, methionine, tryptophan, glutaric acid, 2-pyrrolidone-
5-carboxylic acid, indole-3-carboxaldehyde, 5-hydroxylysine and malic acid. In 
the short-term approach, metabolites had significant increases in relative 
intensities related to the early-onset changes that preceded the interventions. A 
negative correlation between methionine and osteocalcin was observed, and 
glutaric acid was negatively associated with femoral and lumbar spine bone 
mineral density. In the long-term approach, plasma metabolites appeared to be 
affected one month after initiating the hormonal interventions, where circulating 
metabolites decreased for a short time, and this decline remained steady 
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throughout the study. In the long-term study, 5-methoxytrytophan was negatively 
associated with the C-terminal telopeptide of type 1 collagen marker, and 5-
methoxytrytophan and methionine were associated with femoral bone mineral 
density. This study showed that oestrogen deficiency and glucocorticoid 
interventions generated changes in the metabolite profile of sheep. Further, the 
study revealed specific metabolites as possible bone formation and resorption 
markers, suggesting that 5-methoxytrytophan and methionine are potential 
targets for the prognosis of osteoporosis. 
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5.1 Introduction 
 
Bone metabolism requires intra- and extracellular factors to maintain 
balanced bone remodelling. During menopause, oestrogen deficiency induces 
bone loss. The mechanisms that contribute to bone loss are well understood. 
Oestrogen withdrawal stimulates bone resorption, resulting in unbalanced bone 
remodelling in which bone formation is unable to compensate for the amount of 
bone being resorbed by osteoclasts (bone cells) (Garnero et al., 1996; 
Manolagas, 2010). Imbalance in bone remodelling results in decreased BMD, 
micro-architectural deterioration, decreased bone strength and increased fracture 
risk (Kalervo Väänänen and Härkönen, 1996; Manolagas, 2000). In addition, 
bone loss is common in glucocorticoid-treated patients. Glucocorticoid-induced 
osteoporosis is characterised by an increased bone loss and increased fracture 
risk immediately after beginning the glucocorticoid treatment, leading to fractures 
in nearly 50% of people treated with long-term systemic glucocorticoids (Canalis 
et al., 2007; Briot and Roux, 2015).  
Currently, the diagnosis of osteoporosis is carried out by measuring BMD 
(Kanis et al., 1994; Kanis et al., 2008). Specific interest has been in the clinical 
potential of bone turnover biomarkers as a manner in which to assess fracture 
risk and to monitor treatment. Biochemical markers of bone metabolism are 
enzymes, protein fragments, or other molecules released into blood as a result 
of bone remodelling by osteoblasts and osteoclasts (Delmas et al., 2000). These 
bone turnover biomarkers represent bone metabolism, and include both bone 
formation and resorption markers (Vasikaran et al., 2011b; Glendenning et al., 
2018). Increased rates of bone turnover have been associated with increased risk 
of fractures and changes in BMD, but their predictive value is confounded by their 
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large biological and laboratory variability (Seibel, 2006; Wheater et al., 2013); 
therefore, more progress is needed towards the search for alternative biomarkers 
to be used for rapid and reliable early diagnostics of bone loss.  
Metabolomics is one of the novel techniques for investigating changes in 
the metabolome of biological systems. Metabolomics allows the measurement of 
all the small molecules in fluids or tissues that can be detected, and provides 
information on the final downstream products of gene expression, the 
phenotypes, which provides a better understanding of the disease mechanisms. 
The metabolome is highly dynamic, and changes in its metabolites and metabolic 
pathways can occur rapidly in response to specific physiological conditions or 
treatments. Thus, these metabolic alterations may have the potential for detecting 
early changes of specific metabolic pathways and discovering novel clinical 
biomarkers that can be associated with human diseases (Goodacre et al., 2004; 
Assfalg et al., 2008; Scalbert et al., 2009; Beger et al., 2016).  
Bone metabolism is a dynamic process, in which oestrogen regulates 
bone remodelling via osteocytes, osteoblasts, osteoclasts and T-cells. 
Osteoblasts express pro-inflammatory cytokines that stimulate 
osteoclastogenesis, including RANKL macrophage-colony stimulating factor, 
interleukin (IL)-1β, IL-6, IL-1 and leukemia inhibitory factor, both in normal and 
pathologic conditions. On the other hand, osteoblasts also enhance the 
production of anti-inflammatory cytokines such as osteoprotegerin, granulocyte–
macrophage-colony-stimulating factor, IL-3, IL-12 and IL-18, which inhibit 
osteoclastogenesis (Martin and Ng, 1994; Teti, 2013). In normal conditions, bone 
remodelling is coupled and formation and resorption are balanced, and oestrogen 
inhibits bone resorption by inducing osteoclast apoptosis. Oestrogen also inhibits 
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the secretion by T-cells of cytokines such as IL-1, IL-6 and RANKL, which at 
increased concentrations lead to increased osteoclastogenesis (Streicher et al., 
2017). Thus, undergoing menopause increases oxidative stress and pro-
inflammatory factors (Vaananen et al., 2000; Gerdhem et al., 2009). Therefore, 
circulating plasma compounds might reflect the biological processes in bone 
metabolism during menopause. Defining these metabolite perturbations during 
oestrogen deficiency may be useful to predict the onset of bone loss in 
postmenopausal women. 
Animal models are widely used to understand the processes and 
mechanisms that contribute to bone loss at different physiological stages. 
Ovariectomy (OVX), a surgical intervention, is an established method to induce 
bone loss in mammals for the study of postmenopausal osteoporosis (Lelovas et 
al., 2008). Sheep are accepted as one of the large animal models for 
osteoporosis. Most of the preclinical and translational studies have reported 
effective methods for inducing bone loss in sheep through OVX alone or by the 
combined treatment of OVX, a calcium- and vitamin D-deficient diet, and 
glucocorticoid treatments (Dias et al., 2018). Previous studies on sheep have 
documented the mechanisms underlying bone loss in postmenopausal 
osteoporosis (Lill et al., 2002c; Egermann et al., 2008; Zarrinkalam et al., 2012), 
but no research has been conducted to evaluate whether oestrogen deficiency 
and glucocorticoid interventions affect the plasma metabolite profile of OVX 
sheep as an animal model of bone loss. Hence, the purpose of this part of the 
study was to determine the impact of oestrogen deficiency and glucocorticoid 
hormonal interventions on tissue metabolism in an animal model of osteoporosis 
using a HILIC–MS untargeted metabolomics approach.  
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Here, it was hypothesised that OVX alone or combined with 
glucocorticoids, conditions reflective of osteoporosis, would produce biochemical 
and molecular changes in the plasma metabolite profile and bone remodelling in 
sheep that would be unique signatures of bone loss and osteoporosis. The 
present study employed Merino sheep, a widely used large animal model of 
osteoporosis. This breed was chosen because it has been proven that the sheep 
bone remodelling and fracture healing are similar to humans (Augat et al., 2003; 
Schorlemmer et al., 2005). The study comprised four different groups of 
animals: a control group, an OVX alone, and two OVX groups combined with 
glucocorticoids for a short-term or a long-term period. The study protocol aimed 
to mimic bone loss in postmenopausal osteoporosis, since it is known that 
oestrogen’s key role is to maintain a balanced bone metabolism. This chapter 
also evaluates the relationship between BMD measurements, bone turnover 
markers and metabolite profiles at specific time points, at month two and month 
five, in order to evaluate whether significant features are linked to bone loss in 
postmenopausal osteoporosis. Furthermore, in this chapter, the metabolic 
pathways altered by the disease progression were also investigated.  
  
 114 
   
5.2 Materials and methods 
 
5.2.1 Animals used and experimental design 
 
Animals used and experimental design have been described in Chapter 3, 
Section 3.2.1 (Figure 3.1). Briefly, twenty-eight Merino sheep (ewes) were used 
in this experiment, aged between 5–9 years, with hormonal interventions 
resulting from either OVX or OVX combined with glucocorticoids. The study 
comprised four groups of animals, OVX alone, OVX combined with 
glucocorticoids (OVXG) for a short-term or a long-term period, and a control 
group.  
 
5.2.2 Blood collection  
 
Blood samples were collected during the experiment described in Chapter 
3, Section 3.1.2. Blood samples were taken from the 28 ewes at the baseline time 
(pre-surgery), and through the period of this study at one, two, three, four and 
five months post-surgery. The sheep were given ad libitum water and straw, and 
measure-pelleted twice daily. Blood was collected by venepuncture of the jugular 
vein and the flow directed into EDTA-treated serum separator vacuum tubes. 
After centrifugation (2000 g, 15 min, 4 °C), the serum was removed and stored 
(–80 °C) until required. 
 
5.2.3 Bone turnover markers  
 
Bone turnover marker analyses for the experimental work have been 
described in Chapter 3, Section 3.1.4. 
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5.2.4 Bone mineral density 
 
Lumbar spine and femoral BMD assessments have been described in 
Chapter 3, Section 3.1.5.  
 
5.2.5 Metabolomics analysis 
 
5.2.5.1 Standards and reagents  
 
In this study, all standards and reagents used were analytical grade and 
supplied by Sigma-Aldrich Chemicals Co. (St Louis, MO, USA) unless specified. 
Ultrapure water was used for preparation of chemicals (Milli-Q-system, Millipore, 
Bedford, MA, USA). Acetonitrile (ACN), methanol and isopropanol were optima 
LC–MS grade, chloroform was high-performance liquid chromatography (HPLC) 
grade, and all were purchased from Thermo Fisher Scientific (Auckland, New 
Zealand). 
 
5.2.5.2 Sample preparation 
 
Briefly, for the metabolic profiling, samples were collected at baseline, 
month one, two, three, four and five and stored at –80 °C until experimental 
analysis. Methods for metabolite extraction were as have been described 
previously (Xu et al., 2016). The plasma samples were thawed at 4 °C and 
immediately vortexed for 1 min. Then, a total of 100 μL of plasma was transferred 
to a microcentrifuge tube and a total of 800 μL of precooled chloroform:methanol 
(1:1 v/v, containing 0.8 mg ML-1 of internal standards, D4-Citric acid, 13C6-D-
fructose, D5-L-tryptophan, D7-L-alanine, D35-stearic acid, D5-benzoic acid, D10-
leucine, D2-Tyrosine) at –20 °C was added to each tube. The tubes were mixed 
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by hand for 1 min and the samples incubated for 30 min at –20 °C. Following 
incubation, 400 µL of water was added to each sample and they were then 
vortexed for 30 s. The samples were centrifuged for 15 min at 11,000 rpm at 4 
°C. Thereafter, 250 µL aliquots of the supernatants were collected for metabolite 
analysis and transferred into new microcentrifuge tubes. Each tube was placed 
under a stream of nitrogen to evaporate the samples to dryness. Thereafter, 300 
µL of ACN:water (1:1 v/v) containing formic acid (0.1%) was added to each tube 
to reconstitute the samples. Then, the samples were vortexed for 1 min, 
centrifuged for 10 min at 11,000 rpm at 4 °C, and 100 µL was transferred to a vial 
containing an insert and stored at 4 °C for immediate metabolite analysis. Blank 
samples were prepared using the same protocol but using 100 µL of water 
instead of plasma. The pooled quality control (QC) samples were prepared by 
adding 60 µL of each sample, and were placed in a tube to be pooled and 
processed in exactly the same manner as the rest of the samples The pooled QC 
samples were used to compare the analytical performance of the instrument data 
based on the total number of detected peaks, to detect reproducibility and 
consistency of detected features through all the analysis.  
 
5.2.5.3 Metabolite analysis  
 
For the LC-MS analysis the order of the sequence runs was blanks, QC 
samples and individual samples. Pooled QC samples were also injected every 
ten samples throughout the analytical batch. Data quality was monitored using 
retention time and signal to intensity ratios during all the analysis.  
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Metabolites were analysed by hydrophilic-interaction liquid 
chromatography–mass spectrometry (HILIC–MS) with positive and negative 
mode electrospray ionisation.  
Metabolomics was performed on a Thermo Exactive LC–MS system 
(Thermo Fisher Scientific, Waltham, MA, USA) that consisted of an Accela 1250 
quaternary pump, a Thermo-PAL autosampler fitted with a 15,000 psi injection 
valve (CTC Analytics AG., Zwingen, Switzerland) and a 2 μL injection loop and 
an Exactive Orbitrap mass spectrometer.  
Metabolites were separated on a ZIC-pHILIC column (100 mm × 2.1 mm, 
5 μm; Merck, Darmstadt, Germany) with a gradient elution program at a flow rate 
of 250 μL/min. The mobile phase was a mixture of ACN:formic acid (99.9:0.1 v/v) 
(solvent A) and water–ammonium formate (16 mM, pH 6.3) (solvent B). The 
gradient elution programme was: held at 97% A (0–1 min), 97–70% A (1–12 min), 
70–10% A (12–14.5 min), held at 10% A (14.5–17 min), returned to 97% A (17–
18.5 min) and allowed to equilibrate for a further 5.5 min prior to the next injection. 
Samples were run in both positive and negative electrospray ionisation mode 
separately. Data were collected in profile data acquisition mode over a mass 
range of m/z 55–1100 at a mass resolution setting of 25,000 with a maximum trap 
fill time of 100 ms using the Xcalibur v2.1 software (Thermo Scientific, Hemel 
Hemstead, UK) provided by the manufacturer. Positive ion mode parameters 
were as follows: spray voltage, 2.7 kV; capillary temperature, 275 °C; capillary 
voltage, 29.1 V; tube lens, 108.8 V. Negative ion mode parameters were as 
follows: spray voltage, −3.0 kV; capillary temperature, 325 °C; capillary voltage, 
−90 V, tube lens −100 V. 
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Each raw datafile consisted of LC–MS spectral features characterised by 
m/z, retention time and ion signal relative intensity. Peak picking, alignment and 
integration of the LC-MS data set from the plasma metabolites was performed 
with the open-source software XCMS (Figure 5.1). The metabolomics data 
preprocessing workflow started by first importing the raw datafiles to MSconvert 
(ProteoWizard; Software Foundation, San Diego, CA, USA) and converting them 
to mzXML files using MSconvert file conversion tool. Then, the next step was to 
extract the features of the spectra, assign them to molecular ions, align peaks 
across samples and quantify their relative intensity using the open-source 
program XCMS (Figure 5.1) (Smith et al., 2006). These programming steps 
consisted of 1) peak detection and filtration using the ‘xcmsSet’ function 2) 
Xcms.group to group features together across samples using m/z bins to 
calculate peak distributions in the chromatographic time, 3) retention time 
correction using ‘retcor’ function from xcms R package, 4) Annotation of isotope 
peaks, adducts and fragments with CAMERA.annotate (Kuhl et al., 2011) and 
finally 5) a ‘diffreport’ obtained . Table 5.1 summarises the extraction parameters 
applied for this untargeted LC-MS spectral data. 
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Figure 5.1: Preprocessing workflow in untargeted metabolomics. XCMS 
functions to preprocess LC-MS data for relative quantification and statistical 
analysis.  
 
Table 5.1: XCMS main parameters applied for untargeted LC-MS-based 
metabolomics spectral processing. 
 
*signal to noise threshold 
 
After data extraction, cleaning of the detected feature table using the 
quality control samples was performed. The data matrix generated with the 
‘diffreport’ function was used to compare QC samples and blank samples and 
remove all those features with a p-value > 0.05 (i.e. peaks that were not 
significantly different from the blank to the pooled QC sample were classed as 
blank features and removed). A QC sample to samples comparison was 
performed and then each extracted ion chromatogram was visually inspected to 
verify that peak picking, alignment, and integration was performed adequately 
Parameters Related to Settings
ppm m/z 10
peakwidth Retention time 20,60
Prefilter intensity 3, 1000
Snthresh* intensity 10
noise intensity 200
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and those failing visual inspection were remove (generally misaligned features 
and baseline noise). 
Thereafter, peak intensities of each sample were corrected for run-order 
signal correction by using a locally quadratic (loess) regression model to fit the 
QC values (Giacomoni et al., 2015). Metabolites with a coefficient of variation of 
their QC values greater than 30% after run-order correction were removed from 
the peak table. Missing values in the peak tables were replaced using the k-
nearest neighbour method.  
 
Putative identification of metabolites was achieved using an in-house 
library of authentic standards to their respective ionisation mode. Identification 
were based on m/z and experimental precursor mass match and retention time 
match to the library of authentic standards. METLIN and the Human Metabolome 
Database were also used for matching against standard metabolite compounds 
based on accurate mass and MS2 spectra (Smith et al., 2006; Wishart et al., 
2013). 
 
5.2.6 Statistical analyses  
 
The metabolite profiles obtained from HILIC–MS positive and negative 
ionisations were analysed by two main statistical approaches to assess group 
differences by either multivariate or univariate analysis (Figure 5.2). The separate 
approaches were analysed to investigate the effects of short-term and long-term 
glucocorticoid treatment on metabolite profiles in OVX sheep. In the short-term 
approach, three treatments (n = 28), OVX, OVXG and control groups were 
analysed at the first two time points. In the long-term approach, four treatment 
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groups (n = 17), OVX, OVXG, OVXG2 and control groups were analysed at all 
six-time points. 
 
5.2.6.1 Multivariate analysis 
 
PCA is an unsupervised multivariate method and was used to explore and 
visualise the effect of OVX plus glucocorticoid treatments in ewes. The main 
objective of PCA is the reduction of the high dimensionality of a dataset, while 
preserving its variability. PCA reduces a set of possible high-dimensional 
variables into a lower-dimensional set of uncorrelated variables through a linear 
transformation that preserves as much of the variance in the original data as 
possible. In this sense, PCA analyses a smaller set of components called 
principal components that are organised into decreasing order of relevance, 
where the first components account for most of the variation in the original data. 
In this statistical analysis, R2 and Q2 are parameters necessary for evaluating 
the models. R2 represents the percentage of variation explained by the model 
(the goodness of fit), Q2 is a parameter to assess the quality of the model, a 
significant value of 0.5 is generally accepted, and a large discrepancy between 
R2 and Q2 indicates overfitting of the model (Wheelock and Wheelock, 2013; 
Triba et al., 2015). In the present study, PCA was performed on plasma samples 
to explore differences among samples from different time points.  The 
metabolomics data were mean centered, log transformed and autoscaled prior 
to performing data analysis. 
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Figure 5.2: Overview of the study design and specific statistical analyses. 
Short-term study: Plasma metabolite profiles of 28 sheep, control group n = 10, 
OVX group n = 12, OVXG n = 6, were analysed by multivariate and univariate 
analyses from baseline to two months. Long-term study: Plasma metabolite 
profiles of 17 sheep, control group n = 5, OVX group n = 6, OVXG n = 3, OVXG2 
n = 3, were also analysed by multivariate and univariate analyses from baseline 
(month zero) to five months.  
 
5.2.6.2 Univariate analysis 
 
A linear mixed model was used to analyse for treatment effects over time 
in the metabolite profiles in OVX sheep. Homogeneity of group variances was 
estimated using Levene’s test. Changes in the sheep plasma over time were 
analysed with a linear mixed effect (lme) model for comparison of means, a 
procedure from R for fitting linear mixed models, using as fixed effects the 
treatment and time, and animal as random effect (Pinheiro et al., 2015). The 
differences between the group means of treated sheep were compared using 
one-way ANOVA, followed by post-hoc Fisher's least significant difference (LSD) 
test for pair-wise multiple comparison of the group means. Significance was 
considered at p-value < 0.05, and predicted means from the model with standard 
error of the means were obtained using the PredictedMeans package of R. 
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Metabolites that did not show significant differences between the interaction and 
treatments were not further analysed. 
The data were pooled from all the treatment groups at month two and 
month five, and further analyses performed to investigate any possible 
associations between bone clinical parameters. Correlations between bone 
turnover markers (OC and CTx-1), and BMD (lumbar spine and femur) and 
metabolite profiles were obtained, and values of Pearson’s correlation 
coefficients are presented. P-values less than 0.05 were considered statistically 
significant. Statistical data analysis was performed by SIMCA 14.1 (Umetrics, 
Umea, Sweden), Minitab 17 statistical software (Minitab Inc., 2008, USA) and 
the platform R 3.3.3 (R Foundation for Statistical Computing). 
 
5.3 Results 
 
OVX alone or combined with glucocorticoids caused changes of 
metabolite profiles in plasma samples as revealed by HILIC–MS-based 
metabolomics. The metabolite profiles of the untreated control group and OVX 
sheep treated with or without glucocorticoids were obtained at baseline, and one, 
two, three, four and five months. Overall, 193 features, including positive and 
negative ions were detected in plasma samples taken over five months of the 
study period.  
Both statistical approaches highlighted changes in detected variations of plasma 
metabolites related to the time of the study. PCA failed to identify separation 
between the experimental groups. To analyse the polar metabolites in detail, a 
linear mixed model approach was then performed. The metabolite profiles 
revealed significant differences in the plasma metabolome of OVX sheep and 
OVXG when compared with the control group by univariate analysis. Twenty-six 
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features were significantly affected by treatment and time in the short-term 
approach and twenty-four in the long-term approach with p-values less than 0.05. 
Unfortunately, in this study only nine metabolites could be identified. These 
metabolites included 5-methoxytryptophan, valine, methionine, tryptophan, 
glutaric acid, 2-pyrrolidone-5-carboxylic acid, indole-3-carboxaldehyde, 5-
hydroxylysine and malic acid. 
 
5.3.1 Effect of OVX on the plasma metabolome of sheep: short-term approach 
 
5.3.1.2 PCA: short-term approach 
 
PCA was used to analyse the distribution of polar metabolites among all 
treatments over two months of the study. PCA was conducted on all the 193 
detected features in positive and negative modes. Overall, the PCA models 
showed no separation, and R2 and Q2 values were lower. Furthermore, in the 
PCA a few samples could be considered outliers according to the 95% Hotelling’s 
T2 confidence range. However, outliers could be part of a huge variation among 
samples, so in this study all the outliers were retained for the analyses. 
Due to individual variability, it was difficult to directly observe changes in 
the metabolite profiles among the three groups (see Appendix B, Figure B.1). 
Thus, all time points for each group were analysed individually to obtain global 
information regarding the metabolite changes. 
The distribution of all the serum samples from the control group at baseline 
(month zero), and one and two months, is shown in Figure 5.3A. No noticeable 
differences can be observed in the PCA over the period of time. At baseline, the 
resulting scatter plot of PC1 and PC2, which explain 28.1% of the variance, 
showed that over time, samples were clustered in the middle of the plot. Two 
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outliers were observed in the control group, one at baseline and the other at 
month one. Moreover, in the OVX group (Figure 5.3B), PC1 and PC2 explained 
34.2% of the total variance, showing that plasma samples of OVX at three time 
points changed; whereas OVX samples at month one exhibited a different pattern 
with respect to OVX samples from baseline and month two. Two outliers from 
month one were identified. Similarly, for the OVXG group shown in Figure 3C, 
PC1 and PC2 explained 30% of the variance, and consistent with the OVX group, 
the OVXG samples changed over time. Surgical intervention (OVX) combined 
with glucocorticoid treatment changed the metabolic profiling over time when 
compared to baseline measurements when samples from all time points were 
analysed together.  
 
Figure 5.3: Inter-animal variation in the plasma metabolome of sheep over two 
months of the study period. PCA scatter plots derived from HILIC–MS spectra 
dataset based on normalised and autoscaled data.  Each data point represents 
the metabolite profile of a single ewe. PCA scoring plot showing the variation of 
control group (A) (● baseline (month zero), ● month one, ● month two) R2 = 
54.2% and Q2 = –5.5%; (B) R2 = 53.8% and Q2 = 16%; and (C) R2 = 30% and 
Q2 = 1.86%. 
  
 126 
   
5.3.1.2 Linear mixed model: short-term approach 
 
To identify individual dynamic metabolite changes, all features were 
analysed by using a linear mixed model, and only those features that showed 
significance based on the interaction of treatment and time were further analysed. 
Twenty-six features were significant and of these, eight were identified. In this 
chapter, the eight identified metabolites are described and all the remaining 
unidentified features are shown in a complementary section of this chapter (see 
Appendix B, Table B.1). 
Changes in the plasma metabolites of the OVX group were observed with 
a decrease in the relative intensities of all the identified metabolites at month one 
after OVX, with the exception of 5-methoxytryptophan, methionine and 
tryptophan (Table 5.2). However, all plasma metabolites increased relative 
intensities at month two of this study, with the exception of methionine and 
tryptophan. In contrast, for the OVXG group, a trend for most of the metabolite 
relative intensities to be higher after OVX plus glucocorticoid treatments was 
observed. At month one, methionine was the only amino acid with decreased 
intensity (Table 5.2), while at month two, all metabolite relative intensities 
decreased, with the exception of valine.  
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Table 5.2: Effect of OVX and glucocorticoids on the metabolite profile of sheep in the short-term approach. Relative intensities 
were measured in plasma samples of control group (n = 10), OVX group (n = 12) and OVXG (n = 6). Using a linear mixed model, 
the relative intensities of the metabolite profiles were found to significantly change over two months.  
 
Data presented are predicted means, standard error of the difference (SED) and p-values.  
Sec (seconds). Trt (Treatment). Int (Interaction treatment and time)
Mean
RT (Relative intensity, E+05) p -value
mz (sec) Metabolite Trt 0 1 2 SEM Trt Time Int
233.803 493.615 5-Methoxytryptophan Control 0.259 0.526 0.433 0.132 <0.0001 <0.0001 <0.0001
OVX 0.608 1.019 1.279 0.121
OVXG 0.249 1.656 1.538 0.171
148.039 506.035 Methionine Control 0.373 0.970 0.448 0.136 0.005 <0.0001 0.028
OVX 0.467 0.875 0.526 0.124
OVXG 0.473 1.364 1.411 0.176
161.903 622.743 5-Hydroxylysine Control 1.090 1.126 1.094 0.092 0.086 0.275 0.012
OVX 1.189 0.892 1.214 0.084
OVXG 1.132 1.450 1.376 0.119
144.044 635.951 Indole-3-carboxaldehyde Control 0.344 0.492 0.394 0.069 0.006 0.386 0.001
OVX 0.518 0.362 0.452 0.063
OVXG 0.484 0.839 0.779 0.089
116.070 686.643 L-Valine Control 0.651 0.559 0.558 0.192 0.015 0.096 0.007
OVX 0.556 0.420 0.589 0.175
OVXG 0.576 0.733 0.748 0.248
128.034 818.824 2-Pyrrolidone-5-carboxylic acid Control 1.409 1.609 1.530 0.109 0.445 0.4 0.009
OVX 1.646 1.251 1.574 0.100
OVXG 1.512 1.732 1.707 0.141
131.081 851.654 Glutaric acid Control 22.371 32.187 25.471 3.222 0.074 0.241 0.008
OVX 36.051 28.746 29.239 2.942
OVXG 30.731 42.420 35.211 4.160
203.138 926.230 D-Tryptophan Control 0.772 1.482 1.028 0.153 0.042 <0.0001 0.042
OVX 0.820 1.077 0.987 0.140
OVXG 0.610 1.756 1.179 0.198
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To identify the individual changes between treatments, the fold change 
(FC) was calculated. The FC ranks the metabolites in order of greatest change 
within a dataset. Using plasma samples, a 2-FC cut-off for metabolomics studies 
has been reported which minimises the effect of biological variation in individuals 
(Crews et al., 2009; Vinaixa et al., 2012). In this study, the corresponding changes 
of metabolite profiles are presented in Table 5.3. Overall, the metabolite profile 
indicated early alterations during oestrogen deficiency, and glucocorticoid 
treatments were significantly different between treated and control groups in 
plasma samples. Comparing OVX versus control group, the FC values of only 
5-methoxytryptophan were significantly greater than 1 at month one and month 
two. 2-Pyrrolidone-5-carboxylic acid and tryptophan fold changes were 
significantly lower than 1 only at month one. However, comparing OVXG vs 
OVX, the FCs of all the metabolites were significantly greater than 1 at month 
one, while at month two only the fold changes of indole-3-carboxadehyde and 
valine were significant. These results suggest that all the metabolites in the 
OVXG had an immediate response to OVX combined with glucocorticoid 
interventions.   
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Table 5.3: FC of the metabolite abundance between the OVX and control 
groups and between the OVXG and the OVX groups at month one and month 
two. 
 
FC value was calculated by dividing the value of the relative intensities of metabolites in the OVX group by the control 
group, and the OVXG group by the OVX group. FC with a value >1 indicated a relatively higher intensity present in treated 
animals, whereas a value <1 indicated a relatively lower intensity compared with their respective control animals. All FC 
values, which are in bold, are significant (p-value < 0.05). p-value calculated using post-hoc Fisher's least significant 
difference (LSD) test for pair-wise multiple comparison of the group means. 
 
To assess the relationship between bone clinical parameters, serum 
osteocalcin (OC) (a bone turnover marker), serum C-terminal telopeptide of type 
1 collagen (CTx-1), the BMDs of OVX sheep, and the selected metabolites, 
Pearson correlations were calculated. The correlation coefficient values 
between the metabolites and bone clinical parameters are shown in Table 5.4. 
Overall, plasma metabolites were more frequently negatively associated with 
OC, while positive associations were noted with CTx-1. Similarly, negative 
associations were observed with lumbar spine and femoral BMD. The 
associations between bone turnover biomarkers, serum OC and CTx-1, and for 
all the selected metabolites in sheep at month two, were not significant, with 
the exception of methionine. A negative correlation between methionine and 
serum biomarker OC (r = –0.384, p-value = 0.044) was observed. This study 
also did not show significant associations between BMD measurements, femur 
and lumbar spine, and all the selected metabolites, with the exception of 
glutaric acid. Negative correlations with glutaric acid and femoral (r = –0.738, 
Metabolite OVX vs OVXG vs 
Control OVX
FC FC FC FC
1 month 2 months 1 month 2 months
5-Methoxytryptophan 1.938 2.955 1.625 1.203
Methionine 0.902 1.172 1.559 2.684
5-Hydroxylysine 0.792 1.111 1.626 1.133
Indole-3-carboxaldehyde 0.736 1.146 2.317 1.725
L-Valine 0.752 1.055 1.746 1.271
2-Pyrrolidone-5-carboxylic acid 0.778 1.029 1.384 1.084
Glutaric acid 0.893 1.148 1.476 1.204
D-Tryptophan 0.727 0.960 1.631 1.195
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p-value = 0.015) and lumbar spine BMD (r = –0.747; p-value = 0.013) were 
observed. 
 
Table 5.4: Correlation coefficients between metabolites selected by univariate 
analysis in the short-term approach. Pearson correlation between bone 
formation marker (OC), bone resorption marker (CTx-1), femoral BMD and 
lumbar spine BMD and selected metabolites at month two.  
 
 Bolded numbers indicate statistically significant correlation (p-value < 0.05)  
 
5.3.2 Effect of OVX on the plasma metabolome of sheep: long-term approach 
 
5.3.2.1 PCA: long-term approach 
 
The results from the PCA did not reveal a clear separation among groups. 
It was difficult to observe the variance in the metabolite profiles among the four 
groups when analysing all treatments per individual time point (see Appendix B, 
Figure B.2). Thus, each group and all its time points were analysed individually 
to obtain global information regarding the metabolite changes. 
PCA plots of the metabolite profiles obtained from the analysis of OVX 
sheep over five months are shown in Figure 5.4. The resulting scatter plots 
showed clearly that animals were clustered in the middle of the plot, suggesting 
there were only modest differences between the treated animals.  
A modest disease progression can be noticed in the OVX sheep (Figure 
5.4 B); PC1 and PC2 explained 26.8% of the variance) when compared with the 
control group (Figure 5.4A); PC1 and PC2 explained 26.2%). However, the 
glucocorticoid-treated ewes (Figure 5.4C); PC1 and PC2 explained 33.4%) 
OC CTx-1 Femoral BMD Lumbar spine BMD
n  = 28 n  = 28 n  = 11 n  = 11
Pearson Pearson Pearson Pearson
Metabolite correlation p -value correlation p -value correlation p -value correlation p -value
5-Methoxytryptophan 0.041 0.834 0.075 0.705 -0.112 0.758 -0.232 0.519
Methionine -0.384 0.044 0.296 0.126 -0.151 0.676 -0.342 0.333
5-Hydroxylysine -0.225 0.25 -0.056 0.776 0.1 0.783 0.054 0.883
Indole-3-carboxaldehyde -0.273 0.16 0.147 0.454 -0.678 0.031 -0.233 0.517
L-Valine 0.225 0.249 0.2 0.307 -0.178 0.623 -0.359 0.308
2-Pyrrolidone-5-carboxylic acid -0.151 0.443 0.017 0.932 -0.301 0.399 -0.288 0.42
Glutaric acid 0.25 0.2 0.227 0.246 -0.738 0.015 -0.747 0.013
D-Tryptophan 0.239 0.221 0.134 0.498 -0.202 0.576 -0.284 0.427
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showed a different plasma metabolite profile in comparison with the OVXG2 
group and OVX group. A smaller difference in OVXG2 (Figure 5.4 (D); PC1 and 
PC2 explained 28.3%) was observed from month three to month five when 
compared with OVXG. Furthermore, two outliers from month one were noted in 
the OVX group and one from month three in the OVXG group.  
 
 
Figure 5.4: Inter-animal variation in the plasma metabolome of sheep over five 
months of the study period. PCA scatter plots derived from HILIC–MS spectra 
dataset based on normalised and autoscaled data. Each data point represents 
the metabolite profile of a single ewe. PCA scoring plot showing the variation of 
control group (A) (● baseline (month zero); ● month one; ● month two; ● month 
three; ● month four; and ● month five) R2 = 48.1% and Q2 = –5.1%; OVX group 
(B) R2 = 52.6% and Q2 = 21.4%; OVXG group (C) R2 = 43.7% and Q2 = –2.2%; 
and OVXG2 group (D) R2 = 28.3% and Q2 = –1.2%. 
 
5.3.2.2 Linear mixed model: long-term approach 
 
Overall, the metabolites selected by the linear mixed model presented a 
significant interaction between treatment and time (Table 5.5). At month one, the 
OVX group showed decreased relative intensities of all amino acids, with the 
exception of 5-methoxytryptophan and methionine. In contrast, OVXG and 
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OVXG2 groups showed increased relative intensities of all metabolites, with the 
exception of malic acid.  
At month three, the OVX group also showed decreased relative intensities 
of all metabolites, with the exception of methionine. Further, all the relative 
intensities of the metabolites in the OVXG decreased. Similarly, the metabolite 
profile of OVXG2 showed a decrease in the relative intensities of all the amino 
acids, with the exception of methionine and phenylalanine.  
At month five, OVX increased the relative intensities of 5-
methoxytryptophan, methionine, hydroxylysine, phenylalanine, tryptophan and 
valine in the OVXG, with the exception of indole-3-carboxaldehyde and malic 
acid. In addition, OVXG animals showed increased relative intensities of all amino 
acids, with the exception of hydroxylysine. Ewes in the group that only received 
two doses of glucocorticoids had decreased concentrations of 5-
methoxytryptophan, methionine, phenylalanine, indole-3-carboxaldehyde and 
valine, and increased levels of hydroxylysine, tryptophan and malic acid. 
The OVX group showed a significant FC of six metabolites over time 
(Table 5.6). The FC of 5-methoxytryptophan was greater than 2 at all the time 
points, with the exception of month one when compared with control. 5-
hydroxylysine, phenylalanine and tryptophan fold changes were lower than in 
month one. Methionine and malic acid FC values were higher than 1 only at 
month five. The OVXG group showed higher FC values than 1 for all the 
metabolites in month one. Phenylalanine and indole-3-carboxadehyde had 
greater FC values than 2 at month one, while the FC value was greater than 2 for 
5-hydroxylysine, tryptophan and valine. Interestingly, the FC value of 5-
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hydroxylysine was lower than 1 at month three. Methionine’s FC value was 
higher than 3 only at month two.  
Similarly, the OVXG2 group showed higher FC values than 1 in all the 
metabolites in month one. Interestingly, at month three, 5-hydroxylysine and 
phenylalanine remained steady at the same level, but 5-methoxytryptophan 
and malic acid were lower than 1. In addition, methionine’s FC value was lower 
at month five.  
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Table 5.5: Effect of OVX and glucocorticoids on the metabolite profile of sheep in the long-term analysis. Relative intensities were 
measured in plasma samples of control group (n = 5), OVX group (n = 6), OVXG (n = 3) and OVXG2 (n = 3). Using a linear mixed 
model, the relative intensities of the metabolite profiles were found to significantly change over time.  
 
Data presented are predicted means, standard error of the difference (SED) and p-values.  
Sec (seconds). Trt (Treatment). Int (Interaction treatment and time).   
Mean
RT (Relative intensity, E+05) p -value
m/z (sec) Metabolite Trt 0 1 2 3 4 5 SEM Trt Time Int
233.803 493.615 5-Methoxytryptophan Control 0.1596 0.4888 0.47 0.5068 0.3829 0.5287 0.1934 0.001 <0.0001 0.015
OVX 0.6922 1.0302 1.5665 1.2696 1.0824 1.1867 0.1766
OVXG 0.1801 1.4326 1.7105 1.3698 0.9956 1.261 0.2497
OVXG2 0.3187 1.88 1.3663 0.5425 0.7875 0.5672 0.2497
148.039 506.035 Methionine Control 0.3362 0.9287 0.4989 0.859 1.0658 0.5777 0.2149 0.098 0.003 0.012
OVX 0.6955 0.8981 0.3958 0.6952 0.9834 1.1463 0.1962
OVXG 0.2878 1.0584 1.354 0.7628 0.9625 1.671 0.2775
OVXG2 0.6576 1.6706 1.4673 1.1644 1.609 0.5964 0.2775
161.903 622.743 5-Hydroxylysine Control 0.9798 1.1285 1.0556 1.2217 1.054 1.2502 0.1177 0.335 0.374 0.007
OVX 1.368 0.7656 1.2021 1.1741 0.9816 1.3272 0.1074
OVXG 1.1355 1.3303 1.3193 0.7909 1.1707 1.105 0.152
OVXG2 1.1276 1.5694 1.4322 1.3247 1.2472 1.2686 0.152
164.071 623.132 L-Phenylalanine Control 0.6805 0.7464 0.7365 0.8559 0.6208 0.7922 0.0983 0.057 0.229 0.003
OVX 0.8212 0.4408 0.8315 0.6666 0.7328 0.892 0.0897
OVXG 0.8886 0.9784 0.9917 0.4641 0.799 0.8578 0.1269
OVXG2 0.7656 1.2565 1.0843 0.9174 0.8883 0.8842 0.1269
144.044 635.951 Indole-3- Control 0.29 0.4752 0.4332 0.4199 0.3145 0.2523 0.0959 0.493 <0.0001 <0.0001
carboxaldehyde OVX 0.4873 0.2687 0.4611 0.4091 0.3995 0.3841 0.0876
OVXG 0.4423 0.8541 0.6486 0.2666 0.3479 0.3945 0.1238
OVXG2 0.5258 0.8238 0.91 0.3708 0.2901 0.1729 0.1238
116.070 686.643 L-Valine Control 0.6234 0.5386 0.5874 0.6117 0.5247 0.5492 0.25 0.418 0.136 0.011
OVX 0.5314 0.3769 0.618 0.5058 0.6096 0.6322 0.2282
OVXG 0.5509 0.7335 0.6612 0.3747 0.4982 0.6388 0.3227
OVXG2 0.6011 0.7335 0.8346 0.5967 0.6438 0.5057 0.3227
133.043 767.096  Malic acid Control 2.0082 1.6814 1.6442 1.5266 1.7401 1.2604 0.1713 0.643 0.027 0.03
OVX 1.761 1.5331 1.9866 1.7873 1.6098 1.9203 0.1563
OVXG 1.9592 1.6821 2.0199 1.8405 1.3172 1.9708 0.2211
OVXG2 2.0405 1.8404 1.9864 1.0289 1.6596 1.8711 0.2211
203.138 926.230 D-Tryptophan Control 0.7264 1.3593 0.9804 1.1351 0.8683 1.0072 0.1618 0.673 <0.0001 0.001
OVX 0.7721 0.7741 1.0454 0.7909 0.9119 0.9933 0.1477
OVXG 0.6178 1.4953 1.2982 0.6536 0.7189 0.7432 0.2089
OVXG2 0.6025 2.0175 1.0603 0.8138 0.6444 0.792 0.2089
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Table 5.6: FC of the metabolite abundance between the OVX and control 
groups, between the OVXG and the OVX groups and between the OVXG2 and 
the OVXG groups from month one to month five. 
 
FC was calculated by dividing the value of relative intensities of metabolites in the OVX group by the control group, the 
OVXG group by the OVX group and OVXG2 by OVXG. All FC values in bold are significant. FC with a value >1 indicates 
a relatively higher intensity present in treated ewes, whereas a value <1 indicates a relatively lower intensity compared 
with their respective control animals. p-value < 0.05. p-value calculated using post-hoc Fisher's least significant difference 
(LSD) test for pair-wise multiple comparison of the group means. 
 
Metabolite OVX vs 
Control
FC FC FC FC FC
1 month 2 months 3 months 4 months 5 months
5-Methoxytryptophan 2.108 3.333 2.505 2.827 2.245
Methionine 0.967 0.793 0.809 0.923 1.984
5-Hydroxylysine 0.678 1.139 0.961 0.931 1.062
L-Phenylalanine 0.591 1.129 0.779 1.180 1.126
Indole-3-carboxaldehyde 0.565 1.064 0.974 1.270 1.522
L-Valine 0.700 1.052 0.827 1.162 1.151
Malic acid 0.912 1.208 1.171 0.925 1.524
D-Tryptophan 0.569 1.066 0.697 1.050 0.986
Metabolite OVXG vs 
OVX
FC FC FC FC FC
1 month 2 months 3 months 4 months 5 months
5-Methoxytryptophan 1.391 1.092 1.079 0.920 1.063
Methionine 1.178 3.421 1.097 0.979 1.458
5-Hydroxylysine 1.738 1.097 0.674 1.193 0.833
L-Phenylalanine 2.220 1.193 0.696 1.090 0.962
Indole-3-carboxaldehyde 3.179 1.407 0.652 0.871 1.027
L-Valine 1.946 1.070 0.741 0.817 1.010
Malic acid 1.097 1.017 1.030 0.818 1.026
D-Tryptophan 1.932 1.242 0.826 0.788 0.748
Metabolite OVXG2 vs 
OVXG  
FC FC FC FC FC
1 month 2 months 3 months 4 months 5 months
5-Methoxytryptophan 1.312 0.799 0.396 0.791 0.450
Methionine 1.579 1.084 1.526 1.672 0.357
5-Hydroxylysine 1.180 1.086 1.675 1.065 1.148
L-Phenylalanine 1.284 1.093 1.977 1.112 1.031
Indole-3-carboxaldehyde 0.965 1.403 1.391 0.834 0.438
L-Valine 1.000 1.262 1.592 1.292 0.792
Malic acid 1.094 0.983 0.559 1.260 0.949
D-Tryptophan 1.349 0.817 1.245 0.896 1.066
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The correlation coefficient values between the metabolites and bone 
clinical parameters at month five are shown in Table 5.7. After five months of 
oestrogen deficiency and glucocorticoid treatments, plasma metabolites were 
positively associated with serum OC and CTx-1, with the exception of malic acid. 
However, more negative associations were observed with femoral BMD and 
lumbar spine. The associations between bone turnover biomarkers, serum OC 
and CTx-1, and all the identified metabolites in sheep at month five were not 
significant, with the exception of 5-methoxytryptophan with serum CTx-1 (r = 
0.482, p-value = 0.05). The associations between all the metabolites and BMD 
measurements, femur and lumbar spine BMD, were not significant with the 
exception of 5-methoxytryptophan (r= –0.658, p-value = 0.004) and methionine 
(r = –0.482, p-value = 0.05). 
 
Table 5.7: Correlation coefficients between metabolites selected by univariate 
analysis in the long-term approach. Pearson correlation between bone 
formation marker (OC), bone resorption marker (CTx-1), femoral BMD and 
lumbar spine BMD and selected metabolites at month five.  
 
Bolded numbers indicate statistically significant correlation (p-value < 0.05)  
 
5.4 Discussion  
 
The study described in this chapter applies a HILIC–MS untargeted 
metabolomics approach to identify changes in the metabolome of OVX sheep. 
This is the first longitudinal study that presents results on the plasma metabolite 
OC CTx-1 Femoral BMD Lumbar spine BMD
n  = 17 n  = 17 n  = 17 n  = 17 
Pearson Pearson Pearson Pearson
Metabolite correlation p -value correlation p -value correlation p -value correlation p -value
5-Methoxytryptophan 0.156 0.551 0.482 0.05 -0.658 0.004 -0.399 0.113
Methionine 0.019 0.943 0.412 0.101 -0.482 0.05 -0.319 0.213
5-Hydroxylysine 0.279 0.279 0.025 0.925 0.139 0.596 0.203 0.435
L-Phenylalanine 0.321 0.21 0.115 0.661 -0.283 0.272 -0.184 0.479
Indole-3-carboxaldehyde 0.25 0.333 0.364 0.151 -0.436 0.08 -0.328 0.199
L-Valine 0.253 0.327 0.181 0.488 -0.442 0.076 -0.345 0.175
Malic acid -0.108 0.68 0.385 0.127 -0.238 0.357 -0.175 0.501
D-Tryptophan 0.366 0.149 0.089 0.735 0.112 0.67 0.079 0.763
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profile of OVX sheep treated with glucocorticoids in an animal model of 
postmenopausal osteoporosis, and their metabolite profiles were compared with 
those of the control group. The preliminary results obtained demonstrate the 
metabolites’ changes in response to hormonal interventions, and OVX alone or 
in combination with glucocorticoid treatments over time. Furthermore, in the 
short-term approach (two months), methionine was found to be negatively 
associated with bone turnover, and glutaric acid was found negatively associated 
with femoral and lumbar spine BMD. In the long-term approach (five months), 5-
methoxytryptophan and methionine were found to be negatively associated with 
femoral BMD. This suggests that combining OVX and glucocorticoids affects 
bone remodelling leading to bone loss in ewes by regulating osteoclast 
differentiation and apoptosis of osteoblast bone cells involved in bone 
remodelling.  
Initially, the results from the treated groups were examined using PCA. 
However, due to the relatively large number of animal groups, with small sample 
size and unbalanced design, the separation was difficult to visualise. 
Nevertheless, it could be seen that the ewes responded to the surgical or 
hormonal interventions, which resulted in a metabolic change over time. 
Subsequently, the results of both the short-term and long-term approach from the 
linear mixed models showed features that changed over the two- or five-month 
study period.  
Osteoporosis was associated with early changes in the plasma metabolite 
profile, including amino acids and other metabolites. Overall, circulating 
metabolites were accumulated in plasma after OVX in sheep. On the other hand, 
compared to the OVX animals, OVXG2 animals could reverse the impacts of 
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glucocorticoids on the plasma metabolites at month four and month five. The 
results suggest that long administration of glucocorticoid treatment to the OVX 
sheep (OVXG) affects their metabolite profile. This dynamic change observed in 
the metabolite profile of the OVX sheep may reflect the increased bone turnover 
observed in oestrogen deficiency models, where an imbalance within the bone 
remodelling process suggests enhanced bone resorption and a reduced bone 
formation. In addition, due to uncoupling of the bone turnover cycle in the 
presence of low oestrogen, bone resorption increases at basic multicellular units 
of bone, and the rate of bone loss is greater than the formation of new bone 
(Kalervo Väänänen and Härkönen, 1996; Greendale Gail et al., 2011). On the 
other hand, in the glucocorticoid-induced osteoporosis model, bone resorption 
markers have been associated with a decreased BMD as a result of an excessive 
bone resorption rate and reduced osteoblast activity (Mazziotti et al., 2006).  
Amino acids are not only part of the building blocks of proteins, but also 
are derivatives of many secondary metabolites and are involved in the process 
of cell signalling and signal transduction of key metabolic pathways. Amino acids 
enhance immunity by upregulating pro-inflammatory and downregulating anti-
inflammatory cytokines (Zhang et al., 2007). Menopause is associated with the 
risk of developing a number of chronic diseases including cardiovascular disease, 
diabetes and osteoporosis, among others. Osteoporosis is accompanied by 
oxidative stress and inflammation, and changes of amino acid levels may indicate 
which key metabolic pathways may be altered in postmenopausal women 
(Jousse et al., 2004; Obayashi et al., 2004; Bellanti et al., 2013; Grygiel-Górniak 
et al., 2014). Thus, the analysis of all the detectable metabolites in serum may be 
a method for discovering biomarkers for early detection of bone loss in women.  
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Although this is the first study that reports the metabolite profile in OVX 
sheep, previous metabolomics analyses have shown altered metabolism in OVX 
rats, another common animal model for postmenopausal osteoporosis. A study 
using nuclear magnetic resonance (NMR) reported that six months after OVX, 
serum levels of alanine, asparagine, glutamine, isoleucine, leucine, valine, 
tryptophan, lysine, proline, serine and threonine increased, and glutamate, 
glycine, phenylalanine and tyrosine were decreased (Assadi-Porter et al., 2015). 
Another study reported increased concentrations of isoleucine, valine and leucine 
after OVX using gas chromatography time-of-flight mass spectrometry (GC–
TOF–MS) (Ma et al., 2011). Similarly, branched-chain amino acids (valine, 
leucine and isoleucine), homocysteine, hydroxyproline and ketone bodies (3-
hydroxybutyric acid) were elevated, while levels of lysine decreased in the OVX 
group compared to the sham group (Ma et al., 2013a). 
The relationship between bone markers and BMD with the identified 
metabolites was assessed. In this study, we found negative associations between 
methionine and serum OC, lumbar spine and femoral BMD in OVX sheep. 
Furthermore, methionine was found to be associated with bone loss. A previous 
study on methionine reported changes in bone turnover in 
hyperhomocysteinemia aged rats, where OC decreased and urine N-terminal 
type 1 collagen, a marker of bone resorption, increased (Ozdem et al., 2007). 
Herrmann et al. (2005a) reported a significant correlation between 
hyperhomocysteinemia and urinary deoxypyridinoline crosslinks in peri- and 
postmenopausal women; however, no significant correlations were observed 
between hyperhomocysteinemia and OC. In another study, 
hyperhomocysteinemia levels were associated with higher bone turnover and 
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lower BMD (Gerdhem et al., 2009). Methionine plays key roles in cell metabolism. 
Methionine as one of the essential amino acids is required for cellular 
proliferation, protein synthesis, RNA synthesis and transamination. Further, 
methionine can be catabolised into homocysteine and cysteine (Brosnan and 
Brosnan, 2006; Tyagi et al., 2011). This suggests that methionine levels may alter 
bone remodelling and could possible explain the reduced BMD observed in 
treated ewes by upregulating osteoclast development induced by OVX and 
glucocorticoid treatments.  
Homocysteine, a metabolite of methionine, has been reported to increase 
oxidative stress, inducing increased production of reactive oxygen species of 
inflammation, and these can elevate the risk factor for fractures (Yang et al., 
2012). During oestrogen deficiency, increased levels of homocysteine may lead 
to increased matrix metalloproteinases, proteins that degrade the bone matrix, 
decreased bone blood flow and increased activity of the osteoclasts, with 
decreased osteoblast activity (Herrmann et al., 2005b; Vacek et al., 2013). 
Further, it can damage hydroxyproline, mitochondria and collagen. Higher 
concentrations of homocysteine downregulate lysyl-oxidase, which induces 
crosslinks of collagen, a key component of the bone matrix (Liu et al., 1997; 
Thaler et al., 2011). Nevertheless, the results of this study did not include 
homocysteine measurements; however, homocysteine may also be formed via 
methionine metabolism and may be involved in the bone breakdown in the OVX 
sheep. These findings suggest that the circulating levels of methionine play a role 
in changes in bone metabolism, which may lead to dysregulated bone 
remodelling and may be detrimental to bone quality through modifications of 
bone collagen proteins.  
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In this study, tryptophan levels were increased in the OVX group. 
Tryptophan and its metabolites impact bone formation, stimulating the 
proliferation and differentiation of bone marrow-derived mesenchymal stem cells 
(Michalowska et al., 2015). The possible mechanism of altered tryptophan in 
bone loss may be enhanced osteoclastogenesis. Studies indicated that 
tryptophan may play a role in osteoclastogenesis via the kynurenine pathway 
of tryptophan catabolism, as interferon y (IFN-y) is formed via the kynurenine 
pathway (El Refaey et al., 2015). IFN-y is a cytokine that is produced in the 
bone microenvironment by cells, and it promotes osteoclast activity. During 
menopause, oestrogen deficiency upregulates the pro-inflammatory cytokines, 
as IFN-y increases the bone loss in postmenopausal women (Pfeilschifter et al., 
2002; Weitzmann and Pacifici, 2006). The results in this study provide evidence 
that OVX and glucocorticoid treatment perturbed tryptophan levels in both OVX 
and OVXG sheep, and further studies in animal models are needed to 
determine whether tryptophan metabolites could be utilised as novel 
biomarkers for bone loss in postmenopausal women.  
Plasma concentrations of hydroxylysine were increased in the OVXG 
group when compared with the OVX control group. Hydroxylysine is a urinary 
marker of bone resorption derived from collagen crosslinks (Guerrero et al., 
1996). In bone tissue, bone collagen proteins comprise about 90% of the organic 
matrix of the bone. Bone collagen supports properties of bone such as tissue 
mass, micro- and macro-architecture and material properties, which all contribute 
to bone strength (Viguet-Carrin et al., 2006). Bone collagen is rich in proline, 
hydroxyproline and glycine. Proline and lysine residues are hydroxylated to 
hydroxyproline and hydroxylysine, respectively, which contribute to the formation 
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of collagen crosslinks and to bone matrix quality (Yamauchi and Shiiba, 2008; Hu 
et al., 2011; Boskey, 2013). Circulating levels of hydroxylysine as biomarker have 
been reported in human osteoporotic bone matrix (Bailey et al., 1993). Although 
the hydroxylysine urinary marker was not measured here, an increase in CTx-1 
level was seen in the OVX sheep. Thus, the plasma levels of hydroxylysine in 
OVX sheep may reflect the increased bone remodelling as a response to 
oestrogen deficiency. 
The strengths of this study are the application of untargeted metabolite 
profiling using HILIC–MS analysis of plasma samples from OVX sheep to 
explore the dynamics of disease progression in the metabolite profile, and 
subsequent identification of plasma biomarkers of postmenopausal 
osteoporosis. The limitations of this study include the small sample size of 
treated groups, specifically the ewes that were treated with glucocorticoids, and 
due to the large variability of the data further validation will be required. In 
addition, blood samples were collected once a month, as the study design 
considered both a short- and long-term response to treatments. Larger sample 
size, and multiple sampling time points from the early stage of oestrogen 
deficiency and glucocorticoid treatment, should be considered in future studies 
to identify biomarkers that are unique to the early onset of osteoporosis in 
postmenopausal women. 
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5.5 Conclusions 
 
In this chapter it was proposed to employ a HILIC–MS-based 
metabolomics approach in OVX sheep to improve our understanding of bone loss 
in women. The present study is the first to elucidate the relation between the 
metabolome and bone loss in OVX sheep. Circulating metabolites were altered 
with OVX during the five months of intervention. The results indicated that 
metabolite profiles were affected in the OVX and OVX-plus-glucocorticoid groups 
over two months. In addition, the association between potential metabolites 
including methionine, phenylalanine, tryptophan, valine and hydroxylysine 
showed a correlation with bone loss by using BMD and bone turnover markers. 
In summary, the findings of this study showed that the biosynthesis of 
phenylalanine, tyrosine and tryptophan, and the metabolism of cysteine, 
methionine, valine, leucine and isoleucine, are potentially the main perturbed 
metabolic pathways regulating bone loss in OVX sheep. These findings suggest 
new directions to examine the mechanisms of bone loss in OVX sheep, and 
indicate that these specific metabolites may have value as prognostic biomarkers 
for osteoporosis in humans.  
  
 144 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 145 
   
Chapter 6 
 
 
 
 
 
 
 
 
 
MS-based lipidomics approach 
reveals changes in lipid profiles 
of ovariectomised sheep 
 
 
 
This chapter describes the impact of short-term and long-term ovariectomy (OVX) 
and glucocorticoid hormonal interventions in sheep by lipid profiling using ultra-
performance liquid chromatography−mass spectrometry (UHPLC-MS). This 
study aimed to determine the dynamic changes of circulating lipids in the OVX 
sheep. This chapter also assessed the relationship between clinical bone 
parameters and lipid profiles in order to determine whether those significant 
features are linked to bone metabolism and bone loss.  
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Abstract 
In this chapter, it was hypothesised that lipidomics would identify novel 
lipids in the plasma lipidome of ovariectomised sheep that may better explain the 
association between bone loss and menopause. The purposes of this study were 
to determine the effect of ovariectomy (OVX) and glucocorticoid treatment on the 
plasma lipid profile in sheep in two different approaches, a short-term (two 
months) and long-term (five months) approach, and assess correlations between 
bone clinical parameters and lipid profiles. Ultra-performance liquid 
chromatography−mass spectrometry untargeted lipidomics analysis of blood 
plasma was applied to follow the progression of disease in four hormonal 
intervention models related to postmenopausal osteoporosis: an OVX group, a 
group of OVX plus five doses of glucocorticoids, a group of OVX with only two 
doses of glucocorticoids, and a control group. Plasma samples were collected at 
baseline and once per month over five months. Bone biomarkers, serum of C-
terminal telopeptide of type 1 collagen and osteocalcin were measured using 
immunoenzymatic assays. Bone mineral density was assessed by dual-energy 
x-ray absorptiometry. Dynamic variations were observed in the lipid profiles of the 
two evaluated approaches, the short-term and the long-term approaches. Lower 
relative intensities of the lipid profiles of ewes after ovariectomy and 
glucocorticoid treatments were detected. The short-term approach showed the 
change in relative intensities of five lipids, while the long-term approach revealed 
changes in 14 lipids over time, including cardiolipin, ceramide 1-phosphates, 
phosphatidylinositol, phosphatidic acid, lysophosphatidylethanolamines, 
phosphatidylserines and phosphatidylglycerol. Cardiolipin was negatively 
associated with the lumbar spine bone mineral density at two months, while 
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ceramide 1-phosphates was positively associated at five months. Differences 
observed in lipid profiles of sheep after oestrogen deficiency and glucocorticoid 
interventions suggest that the identified lipids can be potential clinical targets for 
developing new biomarkers for osteoporosis prognosis. Lipidomics analysis 
represents a novel technique that would be helpful in the future to detect 
perturbed lipids in postmenopausal women.  
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6.1 Introduction  
 
Osteoporosis cases are most common in the elderly population, but 
postmenopausal women are the most affected as oestrogen withdrawal induces 
bone loss. During menopause, there are several changes such as decreased 
oestrogen levels, and postmenopausal women are also at increased risk of 
cardiovascular events. Serum lipids may be the link between cardiovascular 
disease and osteoporosis in postmenopausal women (Cui et al., 2005).   
Lipids play an important role in skeletal metabolism and bone health. 
Triglycerides (TGs), total cholesterol (TCHO), low-density lipoprotein cholesterol 
(LDL-C) or high-density lipoprotein cholesterol (HDL-C) are the common clinical 
parameters to measure lipid metabolism (Tian and Yu, 2015). A role of the 
cholesterol biosynthetic pathway in differentiation of mesenchymal stem cells in 
bone marrow has been reported, where products of this pathways reduce BMD 
and lipid oxidation inhibits osteoblast cells (Parhami et al., 2002). Furthermore, 
the association between TGs and lipoproteins in bone loss has been studied; 
however, the information published is controversial. Adami et al. (2004) reported 
that lipid profiles are associated with BMD, where a positive relationship between 
BMD and low-density lipoprotein and total triglycerides, and a negative 
association between BMD and high-density lipoprotein, were found. 
Postmenopausal women with hypercholesterolemia, high LDL-C or HDL-C had a 
lower lumbar spine and femoral BMD than those women with a normal lipid profile 
(Orozco, 2004). Chen et al. (2018) reported higher levels of HDL and TCHO in 
postmenopausal osteoporosis. However, several studies have reported that there 
was no relationship between lipids and BMD (Tankó et al., 2003; Samelson et al., 
2004; Solomon et al., 2005). Despite this, osteoporosis is a progressive and 
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complex disease that is associated with changes particularly in lipid metabolism, 
where those changes promote lipid oxidation and adipogenesis rather than 
osteogenesis in the bone marrow (Chen et al., 2018). However, the exact 
molecular mechanisms for lowering the BMD in postmenopausal women remain 
unclear. A better understanding of the biological mechanisms underlying 
postmenopausal bone loss is required.  
Despite menopause being associated with a variety of pathologies such 
as cardiovascular abnormalities, diabetes and bone loss in women, early 
detection of osteoporosis is difficult (Tankó et al., 2003). While bone imaging 
scans are generally accepted as non-invasive methods, they cannot predict 
bone loss. Currently, the diagnosis of osteoporosis is carried out using dual-
energy x-ray absorptiometry (DXA), the gold standard technique for measuring 
the BMD in postmenopausal women as well as measuring bone turnover 
biomarkers (Kanis, 2002; Naylor and Eastell, 2012). While DXA is highly reliable, 
changes in BMD can only be detected by this method over a period of years. 
Thus, the development of a fast and simple prognostic method is desired, 
where the detection of early biomarkers for osteoporosis can be used to diagnose 
or predict the risk of bone loss in postmenopausal women.  
In this sense, metabolomics is an emerging tool for studying many 
diseases including cancer, diabetes, Alzheimer’s, osteoarthritis disease and 
others (Adams et al., 2013; Trushina and Mielke, 2014; Trivedi et al., 2017). 
Metabolomics allows the measurement and characterisation of small molecules 
such as organic and amino acids, saccharides, lipids and other biomarkers in 
a biological system (Newgard, 2017). Lipidomics is a subset of metabolomics, 
which studies the full characterisation of lipid molecular species (Lagarde et al., 
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2003). Lipid metabolism alterations in bone, specifically in the cellular balances 
between adipocytogenesis and osteoblastogenesis at the bone marrow, are 
controlled by many factors, including lipids. During menopause, lipid 
accumulation alters bone marrow cells and could be a determinant of increased 
bone remodelling that could affect bone mass, and this is associated with obesity 
and osteoporosis in postmenopausal women (Reid, 2010; Hardouin et al., 2014). 
In this sense, lipids and their derivatives, such as sphingosine-1-phosphate, 
lysophosphatidic acid and some fatty acid amides, are known to regulate many 
cellular process and any change can lead to bone pathologies such as 
osteoporosis (During et al., 2015). Further and detailed studies might be needed 
to uncover the underlying lipid profiles for postmenopausal osteoporosis.  
In the present study, it was hypothesised that OVX alone or combining 
OVX with glucocorticoids would change the plasma lipid profiles in ewes and alter 
the bone remodelling process to lead to bone loss. The aim was to determine the 
effect of OVX and glucocorticoid treatment on the plasma lipid profile in ewes 
using UPLC–MS untargeted lipidomics analysis. Furthermore, a second aim was 
to assess correlations between bone clinical parameters and the lipid profile in 
OVX sheep.  
 
6.2 Materials and methods 
 
6.2.1 Animals used and experimental design  
 
The animal model characterisation, presented in Chapter 3 of this thesis, 
was performed as described in Section 3.2.1. Briefly, this study consisted of 28 
Merino ewes that were group pen-housed in a barn. Sheep were allocated into 
four groups at random intervention treatments, an OVX alone group (n = 12) or 
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combined with a glucocorticoid treatment, one group received five monthly doses 
(OVXG n = 3) or two monthly doses followed by no treatment (OVXG2 n = 3), 
and a control group (n = 10) for five months. Blood samples were collected 
monthly and plasma samples were stored at –80 °C prior to lipid extraction. 
Femoral and lumbar spine bone samples were collected from culled animals at 
months two or five. 
 
6.2.2 Lipidome extraction from OVX sheep plasma samples  
 
Lipid extraction was performed as described in Section 5.2.5.2 of this 
thesis. Briefly, plasma samples were collected from the OVX sheep and stored 
at –80 °C. Then, the samples were thawed at 4 °C, and 100 µL of plasma was 
collected and transferred into a microcentrifuge tube and 800 µL of cold 
chloroform:methanol (1:1 v/v) was added. Thereafter, the resulting solutions were 
homogenised for 1 min and incubated for 30 min at –20 °C. Then, 400 µL of water 
was added to each sample, which were then vortexed for 30 s. 200 µL of the 
bottom layer was transferred to a new microcentrifuge tube to evaporate to 
dryness under a stream of nitrogen. Finally, samples were reconstituted in 100 
µL of Folch solvent mixture (chloroform:methanol 2:1 v/v) containing 16:0 d31-
18:1-phosphatidylethanolamine internal standard at 10 µg/mL concentration. All 
the samples were vortexed for 1 min, centrifuged for 10 min at 11,000 rpm at 4 
°C and 100 µL was transferred to a vial containing an insert and stored at 4 °C 
for immediate analysis by UPLC–MS. The lipid quality control (QC) samples were 
prepared with 20 µL of each sample. The pooled lipid QC samples were aliquoted 
into multiple quality control vials and stored at –80 °C for future analysis.  
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6.2.3 Lipid analysis 
 
The order of the LC-MS chromatographic runs of individual samples, QC 
samples and blanks was performed as describe in Section 5.2.5.3 of this thesis. 
Lipid analysis was performed on a Thermo UPLC–MS system (Thermo 
Fisher Scientific, Waltham, MA, USA) that consisted of an Accela 1250 
quaternary pump, a Thermo-PAL autosampler fitted with a 15,000 psi injection 
valve (CTC Analytics AG., Zwingen, Switzerland), a 2 μL injection loop and an Q-
Exactive Orbitrap mass spectrometer 
Chromatographic separation of lipid samples was conducted using a CSH-
C18 column (100 × 2.1 mm; 1.7 μm particle size, Waters, Milford, MA, USA). The 
gradient elution began at a flow rate of 600 μL/min. The analysis was performed 
using three solvents: solvent A was a mixture of 0.1% formic acid in ACN–
isopropanol (50:50 v/v), solvent B was a mixture of 0.1% formic acid in ACN–
water (60:40 v/v) with 10 mM ammonium formate, and solvent C was a mixture 
of 0.1% formic acid in isopropanol–ACN (90:10 v/v) with 10 mM ammonium 
formate. The mobile phase was a mixture of solvent B and solvent C. The 
gradient elution programme was conducted as follows: starting with 85% solvent 
B (0–1 min), decreased from 70–18% (2–11 min) and held at 1% (11.50–14 min), 
returned to 85% (22–27 min), while solvent A was held at 100% (14.1–22 min) 
and allowed to equilibrate for 5 min prior to the next sample injection. Data were 
collected in profile data acquisition mode over a mass range of m/z 200–2000 at 
a mass resolution setting of 70,000 with a maximum trap fill time of 100 ms using 
the Xcalibur v2.1 software (Thermo Scientific, Hemel Hemstead, UK) provided by 
the manufacturer. The parameter settings for MS2 analysis were a mass 
resolution of 35,000 with a maximum trap fill time of 250 ms. Lipid positive ion 
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mode parameters were as follows: spray voltage, 3.2 kV; capillary temperature, 
275 °C; capillary voltage, −0.2 V; tube lens, 120 V. Negative ion mode parameters 
were as follows: spray voltage, −3.2 kV; capillary temperature, 275 °C; capillary 
voltage, −0.1 V; tube lens, −100 V.  
Data preprocessing for the lipidomics analysis was performed as 
described in Section 5.2.5.3 of this thesis. Table 6.1 summarised the extraction 
parameters applied for this untargeted lipidomics analysis.  
Table 6.1: XCMS main parameters applied for untargeted LC-MS-based 
lipidomics spectral processing. 
 
*signal to noise threshold 
 
For lipid annotations, the mass spectra were searched within the plasma 
samples of OVX sheep using the software tool LipidSearch™. Briefly, the 
software settings allowed one to search through Q-Exactive MS2 fragmentation 
spectra with a parent mass tolerance of 5 ppm and a product mass tolerance of 
10 ppm to match fragmentation spectra against the LipidSearch™ library. The 
software was programmed to search for the parent ions M+H, M+NH4 and M+Na 
in positive ionisation mode, and M–H, M–H+HCOO and M–H+CH3COO in 
negative ionisation mode. A similar search on the parent mass alone was done 
using LipidBlast and lipids were identified with the matching precursor ion mass 
uncertainty 0.008 Da for positive mode and 0.01 Da for negative mode.   
  
Parameters Related to Settings
ppm m/z 10
peakwidth Retention time 5,20
Prefilter intensity 3, 20000
Snthresh* intensity 20
noise intensity 10000
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6.2.4 Bone biomarkers analysis 
 
The bone biomarker analysis of C-terminal telopeptide of type 1 collagen 
and osteocalcin was performed as described in Section 3.2.4 of this thesis.  
6.2.5 Bone mineral density 
 
Lumbar spine and femoral BMD assessments have been described in 
Section 3.1.5 of this thesis.  
 
6.2.6 Statistical analysis 
 
The statistical analyses were performed as described in Section 5.2.6 of 
this thesis.  
 
6.3 Results 
 
The present study is the first to report the effects of OVX alone or 
combined with glucocorticoids on the plasma lipidome with follow-up 
measurements in OVX sheep. The lipid profiles of 28 ewes (10 samples from the 
control group, 12 samples from the OVX group, 3 samples from the OVXG group 
and 3 from the OVXG2) over five months of the study were characterised and 
compared. This untargeted plasma lipid profiling aimed to measure the circulating 
lipids of OVX sheep and OVX sheep that received either five or two monthly 
doses of glucocorticoids (OVXG and OVXG2, respectively). Detailed lipidomics 
analysis of these groups of treated sheep revealed differences. In this chapter, 
the relationship between lipids and clinical bone parameters was also assessed.  
In Figure 6.1, the total ion current chromatograms produced by UPLC–MS 
of a quality control sample of OVX sheep are shown in positive mode (A) and 
negative mode (B), demonstrating that most of the lipids eluted from the column 
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in the region between 3–10 minutes where phospholipids elute. It can be 
observed that several lipid classes were detected in both positive and negative 
ionisation modes in the OVX sheep. Several compounds were detected within 
different lipid classes such as lysophosphatidylcholines (LPCs), 
lysophosphatidylethanolamines (LPEs), between 1–4 minutes, 
phosphatidylinositol (PI), phosphatidylcholines (PCs), 
phosphatidylethanolamines (PEs), phosphatidylserines (PSs), 
phosphatidylglycerols (PGs), sphingomyelins (SMs), ceramides (Cer). 
Specifically, cholesterol esters (ChEs), diacylglycerols (DGs) and triacylglycerols 
(TGs) were detected only in positive ionisation mode and between 11–13 
minutes.  
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Figure 6.1: UPLC–MS total ion chromatograms of plasma lipid profiling in 
positive (A) and negative (B) modes for lipid identification of a quality control 
sample of OVX sheep. LPC (lysophosphatidylcholine), LPE 
(lysophosphatidylethanolamine), PI (phosphatidylinositol), PC 
(phosphatidylcholine), PG (phosphatidylglycerol), PE 
(phosphatidylethanolamine), PS (phosphatidylserine), SM (sphingomyelin), Cer 
(ceramide), DG (diacylglycerol), TG (triacylglycerol). 
 
The samples were analysed in both positive and negative ion modes. A 
total of 2612 features (positive ionisation) were detected and after filtration and 
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removal of background noise and unstable compounds, the remaining 165 lipid 
features were fitted within the linear mixed model. Similarly, 4456 features 
(negative ionisation) were detected and after filtration and removal of background 
noise and unstable compounds, the remaining 391 lipid features were fitted within 
the linear mixed model.   
 
6.3.1 Effect of OVX on the plasma lipidome of sheep: short-term approach 
 
6.3.1.2 PCA: short-term approach 
 
It was difficult to directly observe changes in the lipid profiles among the 
three groups (see Appendix C, Figure C.1). Thus, all time points for each group 
were analysed individually to obtain global information regarding the lipid 
changes. 
PCA was performed to visualise grouping trends and outliers in the data. 
Principal component 1 (PC1) versus principal component 2 (PC2) scores plots 
of the plasma samples are shown in Figure 6.2. No noticeable differences can 
be observed in the PCA over the period of time. The distribution of all the serum 
samples from the control group at baseline, month one and month two are shown 
in Figure 6.2A, with the majority of samples located near the centre of the plot, 
over that period of time. At baseline, the resulting scatter plot showed that PC1 
and PC2 explained 64.5% of the variance, while two outliers from month two can 
be observed. For the OVX group (Figure 6.2B), PC1 and PC2 explained 69.9% 
of the total variance. Plasma samples from OVX changed over the time points, 
and at month two were generally separated from the OVX samples from baseline 
(month zero), with only minor overlap between these two sampling times. Again, 
two outliers from baseline were observed. The OVXG group is shown in Figure 
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6.2C, with PC1 and PC2 explaining 65.1% of the variance. Consistent with the 
OVX group, the OVXG samples similarly changed over time (although again there 
was some minor overlap between baseline and month two), suggesting that the 
lipid profiles changed in the ewes in a dose-dependent manner as a result of the 
interventions when samples from all time points are analysed together.  
 
 
Figure 6.2: Inter-animal variation in the plasma of sheep over two months of the 
study period. PCA scatter plots derived from UPLC–MS spectra dataset based 
on normalised and autoscaled data. Each data point represents the lipid profile 
of a single ewe. PCA scoring plot showing the variation of control group (A) (● 
baseline (month zero); ● month one; ● month two) R2 = 70.9% and Q2 = 43.7%; 
(B) R2 = 77.7% and Q2 = 64.5%; and (C) R2 = 73.7% and Q2 = 46.4%. 
 
6.3.2.2 Linear mixed model: short-term approach 
 
To identify individual lipidomics changes, all detected features obtained 
from both positive and negative ionisation were analysed using a linear mixed 
model, and only those features that yielded significant results from the interaction 
of treatment and time were further analysed. Forty-eight features were significant 
from the linear mixed model; however, only five of these were subsequently 
identified: one phosphatidylglycerol, two cardiolipins and two phosphatidylinositol 
lipids. In this chapter, only those five identified lipids are described and all the 
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remaining unidentified features are shown in a complementary section of this 
chapter (see Appendix C, Table C.1). 
In general, in this study, the lipid profiles of all the identified lipids at month 
one and month two (Table 6.2) for the OVX group decreased in relative intensity. 
The same trend was noticed in the OVXG group at month one, with the exception 
of cardiolipin (CL) (76:7). At month two, the relative intensities of PG, CL (76:7) 
and PI (35:5) decreased, with the exception of CL (72:5) and PI (14:0).  
 
Table 6.2: Effect of OVX and glucocorticoids on the lipidome of sheep in the 
short-term approach. Relative intensities were measured in plasma samples of 
control group (n = 10), OVX group (n = 12) and OVXG (n = 6). Using linear 
mixed models, the relative intensities of the lipid profiles were found to 
significantly change over two months. 
Data presented are predicted means, standard error of the difference (SED) and p-values. Trt (Treatment). Int 
(Interaction treatment and time) Trt (Treatment). Int (Interaction treatment and time). PG = phosphatidylglycerol, CL 
= cardiolipin, PI = phosphatidylinositol. 
 
To identify the magnitude of the individual changes of the identified lipids, 
the FCs and mean values in the OVX group with respect to the control group, 
and the OVXG group with respect to the OVX group, of the selected lipids at 
each time point were calculated (Table 6.3). In general, fold changes of the 
selected lipids changed in relative intensity of the treated groups when 
Mean
RT (Relative intensity, E+05) p -value
m/z (sec) Feature Trt 0 1 2 SEM Trt Time Int
735.521 183.607 PG 33:0 Control 1.819 1.910 2.114 0.209 0.002 0.076 0.004
OVX 2.672 2.145 2.059 0.191
OVXG 2.080 2.064 1.825 0.270
752.511 183.615 CL 76:7 Control 3.483 3.419 3.583 0.187 0.005 0.004 0.013
OVX 4.575 3.800 3.592 0.171
OVXG 3.787 3.843 2.984 0.242
726.496 183.625 CL 72:5 Control 0.456 0.449 0.460 0.024 0.005 0.011 0.016
OVX 0.602 0.485 0.467 0.022
OVXG 0.464 0.484 0.447 0.031
785.429 183.632 PI 31:5 Control 0.509 0.497 0.536 0.038 0.011 0.011 0.028
OVX 0.724 0.574 0.523 0.035
OVXG 0.565 0.569 0.453 0.049
557.236 210.017 PI 14:0 Control 0.175 0.170 0.198 0.017 0.035 0.104 0.038
OVX 0.256 0.209 0.186 0.016
OVXG 0.198 0.214 0.152 0.023
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compared with their control groups; however, those changes were not 
statistically significant. In the OVX group at month one, the relative intensity of 
PI species and CL (76:7) were increased by >1.1-fold when compared with the 
control group. However, at month two, the relative intensity of all the lipids 
decreased by <1-fold. In the OVXG group, the relative intensity of all lipids 
decreased by <1-fold when compared with the OVX group at month one and 
month two. Together, these results suggest that perturbed plasma lipid species 
might reflect the change of lipid profiles of sheep after OVX and glucocorticoid 
interventions.  
 
Table 6.3: FC of the lipid abundance between the OVX and control groups and 
between the OVXG and the OVX groups at month one and month two. 
 
FC was calculated by dividing the value of the relative intensities of lipids in OVX group by control group, OVXG group by 
OVX group. FC with a value >1 indicated a relatively higher intensity present in treated animals, whereas a value <1 
indicated a relatively lower intensity compared with their respective control animals. PG =phosphatidylglycerol, CL = 
cardiolipin, PI = phosphatidylinositol. 
 
To assess the relationship between bone turnover markers, BMD and 
the lipids in OVX sheep, Pearson correlations were calculated. The correlation 
coefficient values between the lipids and bone clinical parameter markers are 
shown in Table 6.4. This study showed no statistically significant association 
between the relative intensity of identified lipids and the clinical bone parameters 
in OVX sheep, with the exception of one CL (72:5), which was negatively 
correlated with lumbar spine BMD. An inverse relationship was observed with PG 
and all clinical bone parameters. Likewise, an inverse relationship between the 
OVX vs OVXG vs 
 Control OVX 
FC FC FC FC
Lipid class Pathways 1 month 2 months 1 month 2 months
PG 33:0 Glycerophospholipid 1.082 0.905 1.011 1.006
CL 76:7 Glycerophospholipid 1.111 1.002 1.011 0.831
CL 72:5 Glycerophospholipid 1.082 1.016 0.997 0.958
PI 31:5 Phosphatidylinositol phosphate 1.154 0.976 0.991 0.866
PI 14:0 Phosphatidylinositol phosphate 1.230 0.936 1.021 0.817
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identified lipids and the CTx-1 marker was observed, with the exception of CL 
(72:5), while an inverse relationship was observed between CL (72:5) and 
femoral BMD. PI species showed no relationship with serum OC biomarker. 
Weak positive associations with PI species and femoral and lumbar spine BMD 
were also observed. 
 
Table 6.4: Correlation coefficients between lipids selected by univariate 
analysis in the short-term approach. Pearson correlation between bone 
formation marker (OC), bone resorption marker (CTx-1), femoral BMD and 
lumbar spine BMD and selected lipids at month two.  
 
Bold numbers indicate statistically significant correlation (p-value < 0.05) PG = phosphatidylglycerol, CL = cardiolipin, 
PI = phosphatidylinositol. 
 
6.3.2 Effect of OVX on the plasma lipidome of sheep: long-term approach 
 
6.3.2.1 PCA: long-term approach 
 
PCA analysis was also performed on the dataset for the long-term 
approach. The PCA did not reveal a clear separation among groups. Lipid profiles 
acquired with UPLC–MS were not able to distinguish between controls or treated 
groups, when analysing all treatments per individual time point (see Appendix C, 
Figure C.2). Thus, each group and all its time points were analysed individually 
to obtain global information regarding possible lipid changes. 
PCA plots of the lipid profiles obtained from the analysis of OVX sheep 
over five months are shown in Figure 6.3. Examining the resulting PCA score 
plots, samples in the control and treated groups were mostly located near the 
centre of the plot, suggesting there were modest differences in the treated ewes. 
OC CTx-1 Femoral BMD Lumbar spine BMD
n  = 28 n  = 28 n  = 11 n  = 11
Pearson Pearson Pearson Pearson
Lipid class correlation p -value correlation p -value correlation p -value correlation p -value
PG 33:0 -0.262 0.178 -0.251 0.198 -0.159 0.641 -0.019 0.955
CL 76:7 0.177 0.369 -0.358 0.061 0.272 0.419 0.191 0.575
CL 72:5 0.317 0.1 0.24 0.219 -0.366 0.269 -0.866 0.001
PI 31:5 0.002 0.992 -0.125 0.526 0.149 0.662 0.182 0.592
PI 14:0 -0.001 0.997 -0.349 0.069 0.221 0.514 0.225 0.505
 162 
   
Moreover, while there were no sample separations between treatment groups 
with time, a small disease progression can be noticed in the OVX sheep (Figure 
6.3B); PC1 and PC2 explained 71.6% of the variance) when compared with the 
control group (Figure 6.3A); PC1 and PC2 explained 64.8%). Two outliers can be 
observed in the OVX group from baseline, and two from month two in the control 
group. Glucocorticoid-treated sheep (Figure 6.3C); PC1 and PC2 explained 
67.8%) showed a different plasma lipid profile in comparison with the OVXG2 
group and OVX group. Further, all samples from OVXG2 were clustered in the 
middle of the score plot, with the exception of two samples from month one 
(Figure 6.3D); PC1 and PC2 explained 65.1%). 
 
 
Figure 6.3: Inter-animal variation in the plasma of sheep over five months of the 
study period. PCA scatter plots derived from UPLC–MS spectra dataset based 
on normalised and autoscaled data. Each data point represents the lipid profile 
of a single ewe. PCA scoring plot showing the variation of control group (A) (● 
baseline (month  zero); ● month one; ● month two; ● month three; ● month four; 
and ● month five) R2 = 71.5% and Q2 = 49.5%; OVX group (B) R2 = 75.9% and 
Q2 = 66.5%; OVXG group (C) R2 = 67.8% and Q2 = 55.2%; and OVXG2 group 
(D) R2 = 73.4% and Q2 = 35.4%. 
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6.3.2.2 Linear mixed model: long-term approach 
 
One-hundred-and-twenty-six features were significant from the interaction 
between treatment and time; however, only 14 of these features were 
subsequently identified. The lipids identified by the linear mixed model presented 
a significant interaction between treatment and time (Table 6.5). At month one, 
the OVX group showed decreased relative intensities of all lipids, with the 
exception of CerP (39:1). Similarly, in the OVXG groups, all the relative intensities 
of the selected lipids decreased, with the exception of PG (42:0). In the OVXG2 
group, however, all the selected lipids increased relative intensities, with the 
exception of CL (84:15). By contrast, at month three, the OVX and OVXG groups 
showed increased relative intensities of all the lipids. In the OVXG2 group, 
increased relative intensities of three CL species (76:7, 72:5, 76:8), two PI 
species (31:5, 14:0), PA (21:2), lysoPE and PS were observed. At month five, 
increased relative intensities of all the lipids in the OVX and OVXG2 groups were 
observed, while in the OVXG group, all the peak intensities of lipids were 
decreased, with the exception of PA (25:3) and lysoPE.  
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Table 6.5: Effect of OVX and glucocorticoids on the lipidome of sheep in the 
long-term analysis. Relative intensities were measured in plasma samples of 
control group (n = 5), OVX group (n = 6), OVXG (n = 3) and OVXG2 (n = 3). 
Using a linear mixed model, the relative intensities of the lipid profiles were 
found to significantly change over time. 
  
Data presented are predicted means, standard error of the difference (SED) and p-values.  
Trt (Treatment). Int (Interaction treatment and time). CL = cardiolipin, CerP = ceramide 1-phosphates, . PI = 
phosphatidylinositol, PA = phosphatidic acid, lysoPE = lysophosphatidylethanolamines, PS = phosphatidylserines, PG = 
phosphatidylglycerol. 
  
Mean p -value
(Relative intensity, E+5)
mz RT Lipid Trt 0 1 2 3 4 5 SEM Trt Time Int
725.492 183.614 CL 72:6 Control 1.004 0.982 1.162 0.995 1.062 1.078 0.062 0.018 0.082 0.023
OVX 1.433 1.176 1.053 1.156 1.041 1.136 0.056
OVXG 1.109 1.052 1.011 1.139 1.102 1.019 0.080
OVXG2 1.093 1.120 1.061 1.040 0.990 1.059 0.080
752.511 183.615 CL 76:7 Control 3.506 3.338 3.894 3.496 3.628 3.730 0.252 0.088 0.023 0.016
OVX 4.655 3.849 3.465 4.215 3.164 4.122 0.230
OVXG 3.932 3.656 2.849 3.978 3.647 3.085 0.326
OVXG2 3.642 4.030 3.119 3.252 3.430 3.613 0.326
726.496 183.625 CL 72:5 Control 0.445 0.420 0.492 0.450 0.450 0.494 0.030 0.030 0.026 0.018
OVX 0.633 0.500 0.446 0.533 0.426 0.506 0.027
OVXG 0.491 0.442 0.436 0.461 0.450 0.446 0.039
OVXG2 0.436 0.527 0.459 0.465 0.435 0.467 0.039
751.518 183.651 CL 76:8 Control 0.655 0.636 0.767 0.676 0.671 0.751 0.055 0.011 0.060 0.042
OVX 0.971 0.779 0.704 0.855 0.682 0.842 0.050
OVXG 0.800 0.686 0.693 0.784 0.731 0.704 0.071
OVXG2 0.673 0.873 0.600 0.702 0.631 0.728 0.071
800.511 524.119 CL 84:15Control 0.656 0.638 0.754 0.637 0.694 0.676 0.031 0.027 0.060 0.005
OVX 0.825 0.734 0.637 0.742 0.676 0.722 0.028
OVXG 0.734 0.673 0.593 0.646 0.670 0.636 0.040
OVXG2 0.726 0.694 0.745 0.707 0.620 0.660 0.040
686.546 524.192 CerP 39:1Control 1.006 0.938 1.131 0.982 0.989 1.045 0.061 0.042 0.071 0.014
OVX 1.301 1.135 1.026 1.187 1.005 1.138 0.055
OVXG 1.121 1.103 0.952 1.177 1.080 0.916 0.078
OVXG2 1.043 1.193 1.164 1.017 0.900 1.034 0.078
660.543 564.314 CerP 37:0Control 30.813 29.823 34.655 30.705 30.661 31.521 1.417 0.019 0.029 0.045
OVX 37.761 34.926 32.182 35.569 30.496 34.523 1.294
OVXG 36.159 32.864 29.254 31.352 31.646 31.601 1.830
OVXG2 33.828 34.127 33.006 28.673 31.193 31.655 1.830
785.429 183.632 PI 31:5 Control 0.486 0.456 0.573 0.469 0.531 0.544 0.051 0.022 0.022 0.016
OVX 0.800 0.596 0.498 0.667 0.475 0.594 0.047
OVXG 0.607 0.508 0.425 0.623 0.526 0.455 0.066
OVXG2 0.522 0.630 0.482 0.513 0.466 0.535 0.066
557.236 210.017 PI 14:0 Control 0.165 0.153 0.239 0.166 0.195 0.205 0.025 0.120 0.153 0.019
OVX 0.281 0.219 0.174 0.252 0.158 0.233 0.023
OVXG 0.214 0.194 0.132 0.258 0.190 0.187 0.032
OVXG2 0.182 0.233 0.172 0.177 0.158 0.193 0.032
543.316 209.543 PA 25:3 Control 0.614 0.581 0.801 0.618 0.675 0.701 0.057 0.117 0.103 0.018
OVX 0.927 0.712 0.646 0.820 0.622 0.741 0.052
OVXG 0.715 0.656 0.574 0.746 0.678 0.697 0.074
OVXG2 0.727 0.778 0.715 0.655 0.561 0.690 0.074
558.243 249.978 PS 20:4 Control 0.696 0.607 0.809 0.716 0.680 0.824 0.077 0.073 0.036 0.038
OVX 1.119 0.823 0.687 0.943 0.691 0.767 0.071
OVXG 0.820 0.743 0.573 0.856 0.845 0.672 0.100
OVXG2 0.733 0.834 0.685 0.739 0.678 0.735 0.100
464.323 214.017 lysoPE 18:0Control 0.770 0.594 0.883 0.700 0.743 0.790 0.076 0.014 0.004 0.043
OVX 1.158 0.858 0.735 0.986 0.691 0.943 0.069
OVXG 0.872 0.663 0.646 0.807 0.716 0.865 0.098
OVXG2 0.748 0.883 0.752 0.769 0.642 0.806 0.098
558.243 249.978 PS 20:4 Control 0.696 0.607 0.809 0.716 0.680 0.824 0.077 0.073 0.036 0.038
OVX 1.119 0.823 0.687 0.943 0.691 0.767 0.071
OVXG 0.820 0.743 0.573 0.856 0.845 0.672 0.100
OVXG2 0.733 0.834 0.685 0.739 0.678 0.735 0.100
861.656 251.742 PG 42:0 Control 1.524 1.299 1.807 1.616 1.555 1.857 0.167 0.138 0.185 0.026
OVX 2.458 1.802 1.516 1.974 1.560 1.656 0.153
OVXG 1.590 1.603 1.416 1.776 1.968 1.618 0.216
OVXG2 1.611 1.656 1.643 1.642 1.565 1.609 0.216
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To identify the individual changes of the identified lipids, the FCs and mean 
values of these lipids were calculated for the OVX group with respect to the 
control group, the OVXG group with respect to the OVX group, and the OVXG2 
group with respect to the OVX group (Table 6.6).  
The OVX group showed a significant FC of five lipids at month one, three 
at month two and eleven at month three (significant lipids presented with bolded 
FC values, p-value < 0.05, Table 6.5). All the lipids at month one, month three 
and month five (with the exception PA (21:2), PS and PG) were increased in 
relative intensities by >1-fold when compared with the control group. A 
significant increase of FC values was noticed at month one in CL (84:15), CerP 
species and PG; at month two in CL (84:15), PI (14:0) and PA (25:3); and at 
month three in CL (76:7, 72:5, 76:8, 84:15), CerP species, PI species, PA 
(25:3), lysoPE and PS. In contrast, only <1-fold increases of all lipids were 
observed at month two.  
Combination treatments in the OVXG group induced an increase in 
relative intensities of lipids by >1-fold at month four when compared with the 
OVX group. A significant increase of FC values was noticed at month three in 
CL (84:15) and CerP (37:0); and month five in CerP (39:1). Conversely, 
cessation of glucocorticoids in the OVXG2 group resulted in the observation of 
FC values higher than 1 in all lipids in month one; month two with the exception 
of CL (76:8); and month five with the exception of PA (25:3), lysoPE and PG. 
CL (84:15) was significantly increased at month two when compared with the 
OVXG group. These results suggest that OVX or the combination of OVX and 
glucocorticoid treatments affected the lipid profiles of sheep by inducing 
changes in lipid metabolism.  
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Table 6.6: FC of the lipid abundance between the OVX and control groups, 
between the OVXG and the OVX groups and between the OVXG2 and the 
OVXG groups from month one to month five. 
 
FC was calculated by dividing the value the relative intensities of lipids in OVX group by control group, OVXG group by 
OVX group and OVXG2 by OVXG. FC with a value >1 indicated a relatively higher intensity present in treated animals, 
whereas a value <1 indicated a relatively lower intensity compared with their respective control animals. All FC values, 
which are in bold, are significant at p-value < 0.05 calculated using post-hoc Fisher's Least Significant Difference (LSD) 
test for pair-wise multiple comparison of the group means. CL = cardiolipin, Cer-P = ceramide 1-phosphates, PI = 
phosphatidylinositol, PA = phosphatidic acid, lysoPE = lysophosphatidylethanolamines, PS = phosphatidylserines, PG = 
phosphatidylglycerol. 
OVX vs 
Control
FC FC FC FC FC
Lipid class Pathways 1 month 2 months 3 months 4 months 5 months
CL 72:6 Glycerophospholipid 1.198 0.906 1.161 0.980 1.053
CL 76:7 Glycerophospholipid 1.153 0.890 1.206 0.872 1.105
CL 72:5 Glycerophospholipid 1.190 0.907 1.185 0.947 1.025
CL 76:8 Glycerophospholipid 1.225 0.918 1.264 1.017 1.121
CL 84:15 Glycerophospholipid 1.150 0.845 1.165 0.975 1.069
CerP 39:1 Glycosphingolipid 1.210 0.907 1.208 1.017 1.089
CerP 37:0 Glycosphingolipid 1.171 0.929 1.158 0.995 1.095
PI 31:5 Phosphatidylinositol phosphate 1.307 0.869 1.423 0.896 1.092
PI 14:0 Phosphatidylinositol phosphate 1.432 0.727 1.525 0.809 1.137
PA 25:3 Glycerophospholipid, phosphatidylinositol phosphate 1.225 0.806 1.326 0.922 1.057
PA 21:2 Glycerophospholipid, phosphatidylinositol phosphate 1.396 0.789 1.313 0.937 0.934
lysoPE 18:0 Glycerophospholipid 1.444 0.833 1.410 0.930 1.193
PS 20:4 Glycerophospholipid 1.355 0.849 1.318 1.017 0.931
PG 42:0 Glycerophospholipid 1.386 0.839 1.222 1.003 0.892
OVXG vs
 OVX
FC FC FC FC FC
Lipid class Pathways 1 month 2 months 3 months 4 months 5 months
CL 72:6 Glycerophospholipid 0.894 0.960 0.986 1.059 0.897
CL 76:7 Glycerophospholipid 0.950 0.822 0.944 1.153 0.748
CL 72:5 Glycerophospholipid 0.883 0.978 0.865 1.057 0.881
CL 76:8 Glycerophospholipid 0.881 0.985 0.916 1.071 0.837
CL 84:15 Glycerophospholipid 0.917 0.931 0.870 0.991 0.881
CerP 39:1 Glycosphingolipid 0.972 0.928 0.991 1.075 0.805
CerP 37:0 Glycosphingolipid 0.941 0.909 0.881 1.038 0.915
PI 31:5 Phosphatidylinositol phosphate 0.852 0.852 0.934 1.106 0.766
PI 14:0 Phosphatidylinositol phosphate 0.889 0.757 1.023 1.200 0.804
PA 25:3 Glycerophospholipid, phosphatidylinositol phosphate 0.921 0.888 0.910 1.090 0.941
PA 21:2 Glycerophospholipid, phosphatidylinositol phosphate 0.864 0.935 0.900 1.236 0.900
lysoPE 18:0 Glycerophospholipid 0.773 0.878 0.818 1.036 0.918
PS 20:4 Glycerophospholipid 0.903 0.835 0.908 1.222 0.876
PG 42:0 Glycerophospholipid 0.890 0.934 0.900 1.262 0.977
OVXG2 vs 
OVXG
FC FC FC FC FC
Lipid class Pathways 1 month 2 months 3 months 4 months 5 months
CL 72:6 Glycerophospholipid 1.065 1.049 0.913 0.898 1.040
CL 76:7 Glycerophospholipid 1.102 1.095 0.817 0.940 1.171
CL 72:5 Glycerophospholipid 1.192 1.053 1.009 0.967 1.048
CL 76:8 Glycerophospholipid 1.273 0.866 0.896 0.863 1.033
CL 84:15 Glycerophospholipid 1.031 1.255 1.095 0.925 1.038
CerP 39:1 Glycosphingolipid 1.081 1.223 0.864 0.833 1.129
CerP 37:0 Glycosphingolipid 1.038 1.128 0.915 0.986 1.002
PI 31:5 Phosphatidylinositol phosphate 1.240 1.135 0.824 0.887 1.175
PI 14:0 Phosphatidylinositol phosphate 1.196 1.304 0.687 0.834 1.027
PA 25:3 Glycerophospholipid, phosphatidylinositol phosphate 1.186 1.246 0.878 0.828 0.990
PA 21:2 Glycerophospholipid, phosphatidylinositol phosphate 1.134 1.129 0.863 0.794 1.041
lysoPE 18:0 Glycerophospholipid 1.332 1.165 0.953 0.896 0.931
PS 20:4 Glycerophospholipid 1.123 1.196 0.863 0.802 1.094
PG 42:0 Glycerophospholipid 1.033 1.160 0.925 0.795 0.995
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The correlation coefficient values between the lipids and bone clinical 
parameters at month five are shown in Table 6.7. After five months of oestrogen 
deficiency and glucocorticoid treatments, the relative intensities of all the 
plasma lipids were more frequently negatively correlated with serum OC and 
CTx-1. However, more positive correlations were observed with femoral BMD and 
lumbar spine. The correlations between bone turnover biomarkers, serum OC 
and CTx-1, and for all the identified lipids in sheep at month five, were not 
significant, with exception of CerP (39:1), which was positively correlated with 
lumbar spine BMD.  
 
Table 6.7: Correlation coefficients between lipids selected by univariate 
analysis in the long-term analysis. Pearson correlation between bone formation 
marker (OC), bone resorption marker (CTx-1), femoral BMD and lumbar spine 
BMD and selected lipids at month five.  
  
Bold numbers indicate statistically significant correlation (p-value < 0.05). CL = cardiolipin, Cer-P = ceramide 1-
phosphates, PI = phosphatidylinositol, PA = phosphatidic acid, lysoPE = lysophosphatidylethanolamines, PS = 
phosphatidylserines, PG = phosphatidylglycerol. 
 
  
OC CTx-1 Femoral BMD Lumbar spine BMD
n  =17 n  = 17 n  = 17 n  = 17
Pearson Pearson Pearson Pearson
Lipid class correlation p -value correlation p -value correlation p -value correlation p -value
CL 72:6 -0.215 0.407 0.107 0.683 0.392 0.12 0.458 0.064
CL 76:7 -0.057 0.827 0.038 0.884 0.381 0.132 0.442 0.076
CL 72:5 -0.195 0.454 -0.076 0.771 0.452 0.068 0.397 0.115
CL 76:8 -0.086 0.744 0.062 0.813 0.09 0.731 0.253 0.327
CL 84:15 -0.199 0.445 -0.45 0.864 0.4 0.112 0.383 0.129
CerP 39:1 0.045 0.863 -0.016 0.953 0.353 0.165 0.509 0.037
CerP 37:0 -0.12 0.647 0.13 0.619 0.117 0.656 0.014 0.985
PI 31:5 -0.056 0.832 -0.074 0.779 0.285 0.268 0.362 0.154
PI 14:0 -0.132 0.612 -0.062 0.814 -0.03 0.909 0.119 0.65
PA 25:3 -0.19 0.465 -0.114 0.662 0.002 0.993 0.014 0.957
PA 21:2 -0.381 0.131 -0.24 0.354 0.333 0.192 0.376 0.137
lysoPE 18:0 -0.019 0.943 0.063 0.809 -0.186 0.476 -0.085 0.747
PS 20:4 -0.382 0.13 -0.289 0.261 0.34 0.181 0.342 0.179
PG 42:0 -0.284 0.269 -0.176 0.498 0.27 0.294 0.27 0.295
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6.4 Discussion  
  
In this study, an untargeted lipidomics approach was applied for plasma 
samples using UPLC–MS analysis to further analyse the impact of oestrogen 
deficiency on the lipidome of OVX sheep. The results showed a dynamic change 
in the plasma lipid profiles of OVX sheep in response to the treatments, and the 
lipid species altered were from varying lipid classes including 
lysophosphatidylethanolamines (lysoPEs), phosphatidylinositols (PIs), 
phosphatidylcholines (PCs), phosphatidylethanolamines (PEs), 
phosphatidylserines (PSs), phosphatidylglycerols (PGs), and ceramides (Cer). In 
addition, from this study, a second purpose was to assess the correlations with 
bone clinical parameters. None of the associations were significant in either the 
short-term or the long-term approach, with the exception of CL (72:5) in the 
short-term approach. These results revealed differences in the lipidome in both 
short-term and long-term approaches, which affect circulating plasma lipids, 
but there were no associations with bone remodelling in OVX sheep. 
It was of interest to evaluate the dynamic changes of the lipidome of OVX 
sheep not only after treatments were initiated but also up to five months after 
those interventions. In the short-term approach, OVX increased CL (76:7) and PI 
species at month one. In contrast, in the glucocorticoid-treated animals, a 
decrease in levels of all identified lipids was observed at month one, and the 
same effect was observed at month two. In general, this study had a small sample 
size for a lipidomics analysis; however, the short-term approach provided a better 
probability to improve the characterisation of the lipidome in OVX sheep due to it 
having more animals in each treatment group (control group n = 10; OVX n = 12; 
and OVXG n = 6).  
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In the long-term approach, lipid profiles changed after OVX or 
glucocorticoid treatments. Relative intensities of lipids were increased at 
months one and three, and remained relatively stable until the end of the study 
in the OVX group. In the OVXG treatment, the relative intensities of the all lipids 
decreased in the OVXG group after five months. In contrast, in the OVXG2, a 
dynamic lipid compositional change could be observed from month one. These 
relative intensities decreased steadily until the end of this study, with the 
exception of CL (72:6), CerP (39:1) and PI (31:5) at month five; however, these 
lipids showed an opposite trend compared to the one observed in the OVXG 
group over time. These results suggested that suppression of glucocorticoids 
altered changes in the lipidome of those animals in the OVXG2. 
The OVX sheep model was selected because it mimics postmenopausal 
bone loss and it is recommended by the WHO as a large species for evaluating 
skeletal osteoporosis therapies (Bonjour et al., 1999). Lipids are involved in 
several cellular functions and physiological conditions associated with energy 
storage, structure, apoptosis and signalling, and these have an effect on skeletal 
metabolism and bone health (Gross and Han, 2011). In this study, lipid profiles 
were affected, where various relative intensities of lipids changed in the early 
stage of oestrogen withdrawal in the OVX sheep. Although lipid clinical markers 
such as TGs, TCHO, LDL-C or HDL-C were not measured, these findings 
coincide with previous results, where it was reported that perturbed levels of lipid 
metabolism are associated with osteoporosis (Manelli and Giustina, 2000; 
Mazziotti et al., 2006; van Staa, 2006; Buizert Petra et al., 2009). The mechanism 
underlying this altered lipid metabolism seems to be related to the main effect of 
oestrogen withdrawal and glucocorticoids treatment. The effects of oestrogen 
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loss on bone metabolism are well known, where the main effect is to induce an 
imbalance between bone formation and resorption phases due to apoptosis of 
osteoblasts and increase in osteoclastogenesis (Khosla et al., 2012). Further, it 
is known that excessive use of glucocorticoids can disturb lipid metabolism, 
induce adipogenesis and suppress osteoblastogenesis in the bone marrow 
(Henneicke et al., 2014). Overall, glucocorticoids increase bone fragility with 
increased bone loss and decreased mechanical strength. Glucocorticoids affect 
bone remodelling, and induce an increased osteoclast bone resorption and a 
reduced osteoblast formation; they also perturb calcium metabolism by inhibiting 
intestinal calcium absorption, which leads to a calcium deficit and an altered 
mineral metabolism (Fitzpatrick, 2002; Weinstein, 2010; Cooper et al., 2016). 
Future studies are needed to further investigate the link between lipids and bone 
loss, especially at the lipidome level.  
This study detected some perturbed phospholipids in the OVX sheep. 
Phospholipids play a critical role in the bone marrow as fatty acid reservoirs, and 
are a major component of all cell and lipoprotein membranes. The six major 
phospholipid subclasses are PC, PS, PE, PI, PG and PA (Gimenez et al., 2011; 
Frega et al., 2012). In this study, levels of phospholipids decreased after OVX 
and increased at month three until the end of the study period. Although this is 
the first study that presents lipid profiles from OVX sheep, previous studies have 
reported lipidome changes in OVX rats. Zhu et al. (2010) reported decreased 
eicosapentaenoic acid, ergocalciferol and cholecalciferol, and increased 
arachidonic acid, in OVX rats. Conversely, an earlier study reported increased 
levels of fatty acids (arachidonic acid and octadecadienoic acid) and cholesterol 
after OVX compared with those levels before surgery in OVX rats (Ma et al., 
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2013a; Zhang et al., 2014a). However, in this study, arachidonic acid was not 
detected; PCs and PIs are substrates for this fatty acid (Hayakawa et al., 1993). 
This implies that altered phospholipids might be involved in osteoclastogenesis 
promoting loss of BMD, which affects bone remodelling as a result of oestrogen 
depletion. 
Sphingolipids are a major component of cell membranes and play a role 
in cell signalling. Ceramides are precursors to many other sphingolipids. In blood 
plasma, they are associated with lipoproteins (Zheng et al., 2006; Gault et al., 
2010). The major subclass identified in this study was two species of ceramide 
phosphate. Our findings were similar to a previous study that reported that levels 
of ceramide, ceramide-1-phosphate, sphingomyelin, 1-O-alkenyl-
lysophosphatidylethanolamine and lysophosphatidylethanolamine were elevated 
in the OVX rats compared to those in the sham-operated rats (Vinayavekhin et 
al., 2016). Ceramide has been implicated in increasing the cellular oxidative state, 
and this has been linked to stress or death signals. Ceramide levels have been 
reported to affect osteoblast apoptosis (Tepper et al., 1995; Hill and Tumber, 
2010). Thus, perturbed ceramide levels may play a key role in bone loss in 
postmenopausal women.  
Cardiolipins (CL) are phospholipids that are embedded in the inner 
mitochondrial membrane and are a key factor for energy production. Current 
evidence highlights that mitochondrial dysfunction by reactive oxygen species 
leads to the oxidation of mitochondrial cardiolipins, and this has been linked to 
atherosclerosis (Lane et al., 2015; Schlame and Greenberg, 2017). Although our 
results are unable to establish a direct role of CL in osteoporosis, this might be 
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related via bone marrow cells, where oestrogen withdrawal regulates the complex 
cell differentiation of osteoblasts and adipocytes (Elbaz et al., 2009). 
In addition, in this study, the correlations of detected plasma lipids with 
traditional bone clinical parameters were measured. Bone clinical parameters 
are used to measure or monitor bone remodelling in postmenopausal 
osteoporosis. These findings showed weak associations between the lipid 
profiles and bone loss in OVX sheep. An earlier study reported that higher 
concentrations of phosphatidylcholine (docosahexaenoic acid) and arachidonic 
acid were positively associated with loss of femoral BMD in postmenopausal 
women (K et al., 2012). These long-chain fatty acids serve as precursors in the 
production of cytokines involved in bone remodelling, indicating the main role of 
this lipid in bone health (Coetzee et al., 2007). Phospholipid species identified 
from the lipidomics analysis could be potentially used for developing biomarkers 
for postmenopausal osteoporosis. However, validation of these results need to 
further investigated using other biological matrixes as osteoporotic bone tissues 
to analyse the changes of the bone microenvironment in postmenopausal 
conditions. 
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6.5 Conclusions  
 
OVX and glucocorticoid treatments altered plasma lipid profiles in sheep 
over the five months of the study. Differences observed in the relative intensities 
of the lipid classes CL, PI, PA and PS after OVX relate to disorders in 
glycerophospholipid and phosphatidylinositol pathways. The measurement of the 
changes in circulating lipids has potential implications for identification of further 
risk factors associated with oestrogen withdrawal in women, and may contribute 
to loss of BMD. Understanding the intrinsic mechanisms of the CL, PI, P and PS 
classes in bone remodelling, as well as their potential connection to bone loss, is 
needed to provide evidence to not just predict bone loss but also to design novel 
drugs for the treatment of osteoporosis. 
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Chapter 7 
 
 
 
 
 
 
 
Association of plasma lipids and 
polar metabolites with low bone 
mineral density in Singaporean–
Chinese postmenopausal women 
 
 
This chapter compares the plasma lipid and metabolite profiles of Singaporean–
Chinese (SC) postmenopausal women with normal and low bone mineral density 
(BMD) using an untargeted LC–MS metabolomics approach. This chapter also 
evaluates the relationship between bone mineral density measurements, bone 
turnover markers and plasma lipid and metabolite profiles in order to determine 
whether those significant features are linked to bone loss. 
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Abstract 
The diagnosis of osteoporosis is mainly based on clinical examination and 
bone mineral density assessments. The present pilot study compares the lipid 
and metabolite profiles in blood plasma of 95 Singaporean–Chinese (SC) 
postmenopausal women with normal and low bone mineral density (BMD) using 
an untargeted LC–MS metabolomics approach. The primary finding of this study 
was to report the associations between lipids and femoral neck BMD in SC 
postmenopausal women. Twelve lipids were identified by the orthogonal partial 
least-squares (OPLS) model to be associated with low mineral density. There 
was a significant decrease in plasma concentrations of eight glycerophospholipid, 
glycerolipid and sphingolipid species in postmenopausal women with low BMD, 
but increased plasma concentrations of four glycerophospholipid species 
(phosphatidylserine, phosphatidylinositol, phosphatidylethanolamine and 
phosphatidic acid species). Further, this study found no significant differences in 
plasma amino acid metabolites. However, trends for lower ranges of 4-
aminobutyric acid, turanose, proline, aminopropionitrile, threonine, methionine 
and a peptide in women with low BMD were noted. This pilot study showed 
associations between lipid metabolism and femoral neck BMD in SC women. 
Further studies should be conducted on larger populations for evaluating the 
bone health effect of these compounds and their usefulness to be clinical 
biomarkers for osteoporosis prediction in women.  
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7.1 Introduction 
 
Postmenopausal women have a greater risk of bone loss and developing 
osteoporosis. Osteoporosis affects above 200 million people worldwide, and 
about nine million osteoporotic fractures—of which 1.6 million are at the hip—are 
registered per year (Aaseth et al., 2012). Hip fractures from Asian populations 
account for around 30% of the worldwide total; in Singapore, hip fracture rates 
have been increasing by 1.2% annually in Chinese women (Cooper et al., 2011).  
In women, low oestrogen level is a risk factor for osteoporosis. Oestrogen 
withdrawal promotes the activation of bone remodelling at the basic multicellular 
units (BMUs). Bone formation decreases because there is a reduction of 
osteoblastic cell lifespan, and bone resorption increases as a result of an 
increased differentiation and lifespan of osteoclasts (Weitzmann and Pacifici, 
2006). The impact of oestrogen loss in bone metabolism, including several 
biochemical and physiological alterations, is characterised by a high level of 
oxidative stress, inflammation and altered metabolism in the bone 
microenvironment (Manolagas, 2010; Redlich and Smolen, 2012).  Previous 
studies demonstrated that oxidative stress, caused by mitochondrial alterations, 
induces reactive oxygen species (ROS)  generation, and leads to osteoblast cell 
death by increasing the oxidised bone microenvironment (Mody et al., 2001; 
Maggio et al., 2003). In addition, oestrogen withdrawal upregulates bone 
microenvironment pro-inflammatory cytokines like interleukin-1 (IL-1), 
interleukin-6 (IL-6), TNF-α, granulocyte macrophage colony-stimulating factor, M-
CSF and prostaglandin-E2 (PGE2), which regulate osteoclast differentiation and 
function and therefore bone loss (Jilka et al., 1992; Riggs, 2000). Osteoporosis 
may be present well before diagnosis; despite the current serum biochemical 
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analysis and radiological examination methods for screening of osteoporosis and 
fracture risk in postmenopausal women (Kanis, 2002), none of these methods 
are suitable for prediction of early bone loss in women. The elucidation of the 
cellular and biochemical events of bone metabolism after oestrogen withdrawal 
may lead to a better understanding of the molecular mechanism involved in 
osteoporosis and bone cell signalling pathways in women, and subsequently 
may allow identification of early predictors of bone loss that can be used as 
prognostic markers.  
Metabolomics offers the potential for analysing the biochemical changes 
in the pathology of diseases. Metabolomics studies are conducted by using 
several analytical platforms; however, NMR and MS are the most widely reported 
techniques (Patti et al., 2012). A small number of plasma metabolomics studies 
have reported the metabolite concentration shifts under postmenopausal 
conditions in OVX animals and humans (Liu et al., 2014; Ke et al., 2015; Liu et 
al., 2015; Iida et al., 2016), while numerous studies on the relationship between 
bone loss and oestrogen deficiency have been reported in both OVX animals 
and humans (Long et al., 2009; Xue et al., 2011; Liu et al., 2012; Ma et al., 2013a; 
You et al., 2014; Lee et al., 2016; Miyamoto et al., 2017).  
Because of the limited information reported on the association between 
the plasma metabolome and BMD in SC women, research in this area is required 
to allow the identification of potential metabolites that can be used to understand 
the causal pathways involved in postmenopausal osteoporosis. It was 
hypothesised that novel metabolomic markers will improve the prediction of SC 
postmenopausal women at increased osteoporotic risk. Therefore, this study 
aimed to analyse the lipid and metabolite profiles of blood plasma from SC 
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postmenopausal women using an LC–MS untargeted metabolomics approach. 
Moreover, to maximise the identification of biomarkers associated with bone loss 
in postmenopausal women, we also performed statistical tests on a restricted 
subset of the SC women with either osteoporosis (T-score < −2.5) or normal BMD 
(T-score > −1). It was hypothesised that lipids and metabolites of women with 
osteoporosis differed from the whole population. Further, correlation analyses 
were conducted between metabolites and femoral neck BMD in postmenopausal 
women. 
 
7.2 Materials and methods  
 
7.2.1 Study population, inclusion and exclusion criteria  
 
All subjects were informed about the objective of the study and gave their 
informed consent for the participation in the present study. The study was 
approved by the Ethics Committee for Research Involving Human Subjects, 
Singapore (Approval No. 2014/01066). The study was done in accordance with 
the Declaration of Helsinki (2000) of the World Medical Association. 
Ninety-seven SC postmenopausal women aged between 55 and 70 years 
were included in the study. The key inclusion criterion was women who were at 
least five years postmenopausal (based on a history of cessation of 
menstruation). Exclusion criteria included prior diagnosis with osteoporosis, 
diabetes mellitus or any condition that affects bone and liver function, and to not 
be taking any medication that will affect the study. 
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7.2.2 Blood collection 
 
Blood samples were taken only once between 8 and 10 a.m. Blood was 
collected in ethylenediamine tetraacetic acid (EDTA) tubes (BD Vacutainer™ 
K3E 15%, Becton, Dickinson and Company, Plymouth, UK). Then, EDTA tubes 
were put on ice and centrifuged at 1500 g for 10 min. Plasma samples were 
transferred into separate 1 mL tubes for extractions for metabolomics analysis, 
CTx-1, parathyroid hormone (PTH) and 25-hydroxyvitamin D3 were stored frozen 
at −80 °C and thawed on the day of the analysis.  
7.2.3 Analysis of blood parameters 
 
Blood samples were taken to measure plasma markers of CTx-1 as well 
as PTH and 25-hydroxyvitamin D3. CTx-1 and PTH concentrations were analysed 
by electrochemiluminescence immunoassay using the Roche COBAS® e411 
system (Roche Diagnostics, Indianapolis, IN, USA). 25-hydroxyvitamin D3 
concentration was analysed using isotope-dilution liquid chromatography–
tandem mass spectrometry (IDLC–MS–MS) (Maunsell et al., 2005) by 
Canterbury Health Laboratories, Christchurch, New Zealand. The CTx-1 blood 
marker of two participants was outside of the range, and data acquired were thus 
excluded from further analysis. Data from 95 participants was available. 
 
7.2.4 Bone mineral density  
 
BMD was measured using dual x-ray absorptiometry (DXA). DXA scans 
of hip (femoral neck) were carried out using a Hologic QDR-Discovery A 
densitometer (Hologic Discovery QDR 4500A densitometer, Hologic Inc., 
Bedford, MA, USA). BMD was determined and women were classified into 
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normal or low BMD according to the WHO classification. WHO provides an 
operational definition of osteoporosis based on T-score, where the T-score is 
the number of the standard deviations below the mean peak BMD for young 
adults. Women with a BMD 2.5 standard deviations below are classified as 
osteoporotic. In this study, participants in the entire cohort were classified into 
two groups according to bone status: (1) low BMD = women with a T-score < 
−1, and (2) normal BMD = women with a T-score > −1.0. Further, a selected 
subset of participants were also classified into two groups: (1) osteoporosis = 
women with a T-score < −2.5, and (2) normal BMD: women with T-score > −0.1 
(World Health Organization, 1994). 
 
7.2.5 Metabolomics analysis  
 
7.2.5.1 Sample preparation 
 
The sample preparation method has been described in Chapter 5, Section 
5.2.5.2. 
 
7.2.5.2 Metabolite and lipid analyses  
 
Metabolite analysis has been described in Chapter 5, Section 5.2.5.3. 
Lipid analyses has been described in Chapter 6, Section 6.2.3. Table 7.1 
summarised the extraction parameters applied for the untargeted metabolomics 
analysis.  
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Table 7.1: XCMS main parameters applied for the metabolomics analysis of the 
LC-MS spectral processing. 
*signal to noise threshold 
 
7.2.6 Statistical analyses 
 
7.2.6.1 Univariate analysis 
 
The characteristics of the study population were compared using a t-test. 
Normality of the data was tested using the Shapiro–Wilk normality test, where 
age, BMI, CTx-1, PTH, 25-hydroxyvitamin D3 and BMD parameters were 
expressed as mean and standard deviation (SD). Linear regression was applied 
to model the relationship between age-BMI adjusted mean concentrations. Thus, 
analysis of covariance was performed to adjust for possible confounders using 
age and BMI. In addition, the objective was to assess whether lipids and 
metabolites were associated with BMD. Age-adjusted correlation coefficients 
were calculated for each lipid and metabolite. Age- and BMI-adjusted mean 
concentrations of each lipid and metabolite were calculated in both groups. To 
assess whether those associations were independent, pairwise correlations were 
evaluated between identified lipids and metabolites. The p-values were 
calculated using Benjamini–Hochberg false discovery rate (FDR), where FDR p-
value < 0.05 was considered as statistically significant. The fold changes in lipids 
and metabolites between BMD groups were performed by parametric test using 
MetaboAnalyst 4.0 web server (Chong et al., 2018). Statistical data analysis was 
ppm m/z 5 10
peakwidth Retention time 5,20 20,50
Prefilter intensity 3, 10000 3, 2000
Snthresh* intensity 20 10
noise intensity 3000 500
Settings for metabolomics 
analysis
Parameters Related to Settings for 
lipidomics analysis
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performed using R (R 3.3.3, R Foundation for Statistical Computing, Vienna, 
Austria). 
 
7.2.6.2 Multivariate analysis  
 
Prior to multivariate analysis (MVA), different datasets were created: (1) an 
entire cohort containing all samples (n = 95), and (2) a subset (n = 30), in which 
only 15 women with osteoporosis and 15 women with normal BMD were included. 
Both the entire cohort and subset were used for modelling the correlations 
between BMD and metabolites in SC postmenopausal women. For MVA, each 
variable was mean centered and univariate scaled over all the samples and 
imported into SIMCA-P+ v14.1 software (Umetrics, Umea, Sweden). SIMCA was 
used to construct an orthogonal partial least-squares (OPLS) regression model 
for analyzing BMD. The supervised method analyses the linear relationship 
between BMD and metabolite profiles. In OPLS, the R2X, R2Y, and Q2 (cum) 
parameters were used for the model evaluation, representing the explanation, 
fitness and prediction power, respectively. R2X is the percentage of all LC–MS 
response variables explained by the model. R2Y is the percentage of all sample 
variables explained by the model. Q2 is the percentage of all sample variables 
predicted by the model (Liland, 2011). Only one component was extracted to 
predict membership probability in each group. Then, from the coefficient score 
plot, a normal probability plot was created and 95% of features were excluded to 
fit a new model. The objective was to select the most relevant variables from the 
interaction between the metabolites and femoral neck BMD relative to bone 
status (step 1, OPLS methods) and to add these variables into a new model to 
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display the contribution of each metabolite to the modulation of osteoporosis (step 
2). 
 
7.3. Results 
 
This study analysed lipids and metabolites in blood plasma of SC 
postmenopausal women. Overall, after analysing lipids and metabolites, two 
datasets were created for further multivariate analysis. The correlations between 
those compounds and femoral neck BMD were investigated by using univariate 
and OPLS regression statistical analyses. The lipid profiles revealed differences 
in the plasma of women with normal BMD and lower BMD/osteoporosis. 
Metabolites exhibited no differences; however, a trend was observed in several 
metabolites such as a peptide, amino acids and amines. 
 
7.3.1. Characteristics of the postmenopausal women bone status 
 
Women with low BMD were older and had lower BMI when compared with 
women in the normal group. PTH concentrations were lower in the 
postmenopausal groups with low BMD/osteoporosis compared to normal-BMD 
groups (Table 7.2). Serum 25-hydroxyvitamin D3 concentrations were adequate 
(equal to or >50 nmol/L) for all the groups. Bone resorption marker (CTx-1) 
concentrations were significantly higher in the postmenopausal group with low 
BMD/osteoporosis compared to normal-BMD groups. 
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Table 7.2: Characteristics of the SC postmenopausal women according to bone 
status, entire cohort (n = 95) and subset (n = 30) analyses. 
 
Entire Cohort 
(n = 95) 
Subset 
(n = 30) 
Parameters 
Normal 
BMD  
(n = 23) 
Low BMD  
(n = 72) 
p-
value 
Normal 
BMD  
(n = 15) 
Osteoporosis  
(n = 15) 
p-
value 
Age (years) 
59.4  
(4.19) 
61.3 
 (4.19) 
0.06 
58   
(3.42) 
61  
(3.42) 
0.02  
BMI (kg/m2) 
23.8  
(2.61) 
22.5 
 (2.61) 
0.04  
23.8  
(2.25) 
20.7  
(2.25) 
<0.001  
PTH (pmol/L) 
4.7  
(1.35) 
4.5  
(1.32) 
0.29 
4.8  
(1.59) 
4.3  
(1.59) 
0.08 
CTx-1 (µg/L) 
0.44  
(0.21) 
0.55 
 (0.20) 
0.02 
0.41  
(0.26) 
0.64  
(0.26) 
0.04 
25-hydroxyvitamin D3 
(nmol/L) 
57.4  
(15.24) 
60.1 
(14.87) 
0.23 
56.5  
(16.84) 
54.8  
(16.84) 
0.81 
Femoral neck BMD 
(g/cm2) 
0.75  
(0.05) 
0.60  
(0.05) 
<0.001  
0.78  
(0.04) 
0.51  
(0.04) 
<0.001  
Data are presented as mean (SD). The resulting p-values obtained by ANOVA are given. A p-value < 0.05 was 
considered as statistically significant. 
 
7.3.1.1 Entire cohort 
 
Table 7.2 shows the population characteristics for the postmenopausal 
women. The mean ages for these groups were 59.4 and 61.3 years for the 
normal- and low-BMD groups, respectively. Women with low BMD had lower BMI 
than those with normal BMD (23.8 vs 22.5 kg/m2, p-value = 0.04). There were no 
significant differences between the groups for PTH and 25-hydroxyvitamin D3 
concentrations. Mean PTH values were 4.7 and 4.5 pmol/L (p-value = 0.29), and 
mean 25-hydroxyvitamin D3 concentrations were 57.4 and 60.1 nmol/L (p-value 
= 0.23) for the normal- and low-BMD groups, respectively. However, CTx-1 
concentrations and femoral neck BMD were significantly different. Mean CTx-1 
concentrations were 0.44 and 0.55 µg/L for the normal- versus low-BMD groups, 
respectively. Femoral neck BMD was 0.75 g/cm2 and 0.60 g/cm2 (p-value ≤ 
0.001) for the normal- and low-BMD groups, respectively. 
  
 187 
   
7.3.1.2 Subset 
 
Women with osteoporosis were older than those with normal BMD (58 vs 
61, p = 0.02), and had lower BMI (23.8 vs 20.7 kg/m2, p-value = 0.008). Similarly, 
there were no significant differences between the groups for PTH, CTx-1 and 25-
hydroxyvitamin D3 concentrations. Mean PTH values were 4.8 and 4.3 pmol/L (p-
value = 0.08) and mean 25-hydroxyvitamin D3 concentrations were 56.1 and 54.8 
nmol/L (p-value = 0.81) for the normal BMD and osteoporosis groups, 
respectively. Serum CTx-1 concentrations were 0.41 and 0.64 µg/L (p-value = 
0.04) and femoral neck BMD values were 0.78 g/cm2 and 0.51 g/cm2 (p-value < 
0.001) for the normal BMD and osteoporosis groups, respectively. 
 
7.3.2. Metabolomics approach 
 
7. 3.2.1 Lipids  
 
7.3.2.1.1 Entire cohort 
 
Overall, 7082 features (positive and negative ionisation) were detected by 
lipidomics, and after filtration and removal of noise and unstable compounds, the 
remaining 1662 lipid features were fitted within the OPLS model. The OPLS 
model 1 was fitted and the cumulative R2Y and Q2 values were 0.302 and 0.042, 
respectively (Table 7.3). However, the predictive ability for the model Q2 was low, 
which indicated that it was not a good model. Therefore, the OPLS model with 
1662 features was not able to explain the association of the explanatory variables 
and femoral neck BMD. 
Subsequently, a new model (model 2) was created by selecting those 
features based on the exclusion of uncorrelated lipid features on the normal 
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probability coefficient score plot (between 0.05% and 0.95%) from model 1, 
resulting in 98 lipids being selected. The new model yielded R2Y and Q2 values 
of 0.469 and 0.233, respectively (Table 7.3). The new OPLS model parameters 
for fitness and the predictive capability Q2 were better than in the previous model 
(step 1) and significant based on the cross-validated analysis of variance (CV-
ANOVA) (p-value ≤ 0.001). Figure 7.1A shows the OPLS predictive model for 
femoral neck BMD of the lipidomic plasma extracts from normal- and low-BMD 
postmenopausal women. A lineal clustering of the low-BMD postmenopausal 
women occurred on the left-hand side of the plot, while normal-BMD subjects 
were clustered on the top right-hand side. The results indicated that lipids change 
linearly with femoral neck BMD (R2Y = 0.469). Further, positive correlation values 
(upper portion of the plot) indicated increased serum lipid concentrations in 
normal BMD versus low BMD. 
 
Figure 7.1: Orthogonal partial least squares (OPLS) from the lipid profiles of SC 
postmenopausal women. OPLS scatter plot of SC postmenopausal women with 
normal (green circles) and low BMD and osteoporosis (red circles) values based 
on orthogonally filtered partial square (OPLS) regression model 2. Graph (A): 98 
features among 95 women, entire cohort. Graph (B): 149 features among 30 
women, subset. t[1]/u[1] correlation plot; t1 refers to scores of the first component 
in independent variables; u1 refers to scores of the first component in responses. 
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Table 7.3: Parameters of orthogonal partial least-squares regression models 
based on the data from lipids separation for the entire cohort and the selected 
subset of SC postmenopausal women. 
Dataset Step Component R2X R2Y Q2 
Entire cohort (n = 95) 1 1P and O1 0.395 0.302 0.042 
Entire cohort (n = 95) 2 1P and O2 0.678 0.469 0.233 
Subset (n = 30) 1 1P and O1 0.434 0.601 0.209 
Subset (n = 30) 2 1P and O1 0.540 0.773 0.540 
P predictive. O orthogonal in X. Component: number of significant components calculated by cross validation. 
R2X value is the predictive and orthogonal variation in model samples (X) explained by the model. R2Y value 
is the amount of variation in X which is correlated to Y (response matrix). Q2 value describes the predictive 
ability of the model. 
 
Negative associations were found between femoral neck BMD and the lipids 
of postmenopausal women. Based on univariate analysis, the top 50 features 
were significant by t-tests. However, only five features were known lipids and 
these were associated with femoral neck BMD (Table 7.4; Appendix D, Table 
D.1, Figure D.1). The five known lipids include three phosphatidylserines (PSs), 
one diacylglycerol (DG) and one plasmenylphosphatidylethanolamine 
(plasmenyl-PE). The PS species detected comprised 36:1, 33:6 and 29:6, where 
a decreasing common trend was observed in the low-BMD group. A correlation 
matrix revealed negative correlations among the five lipids and femoral neck 
BMD, PS 36:1 (r = −0.027), PS 33:6 (r = −0.070), PS 29:6 (r = −0.086), DG 42:4 
(r = −0.075), and plasmenyl-PE 38:4 (r = −0.01). 
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Table 7.4: Means and 95% confidence interval of lipids associated to the entire 
cohort of SC postmenopausal women (n = 95) with normal and low femoral neck 
BMD in univariate and multivariate approaches. 
Lipid 
Normal 
BMDa 
(n = 23) 
Low BMDa 
(n = 72) 
p-
value 
Log2 
(FC) 
Correlationb 
PS 31:6; [M + H]+ 
0.893 
(0.427–
1.871) 
0.867 
(0.675–
1.114) 
0.939 −0.455 −0.027 
PS 33:6; [M + H]+ 
0.857 
(0.408–
1.800) 
0.876 
(0.681–
1.127) 
0.955 −0.373 −0.070 
PS 29:6; [M + H]+ 
0.906 
(0.428–
1.918) 
0.921 
(0.714–
1.188) 
0.967 −0.296 −0.086 
DG 42:4; [M + NH4]+ 
0.850 
(0.395–
1.828) 
0.947 
(0.725–
1.219) 
0.804 −0.176 −0.075 
Plasmenyl-PE 38:4; [M + 
H]+ 
0.745 
(0.353–
1.571) 
0.841 
(0.653–
1.083) 
0.760 −0.174 −0.01 
Lipids are expressed as mean and 95% confidence interval (CI). ANOVA was used to compare lipid mean 
concentrations. a Covariates: age and BMI; b Age-adjusted correlation coefficient. Statistical p-value calculated using 
Benjamini–Hochberg false discovery rate (FDR). A p-value < 0.05 was considered as statistically significant. Fold 
of change (FC) expressed as the relation between the lipid mean of the normal BMD group to the lipid mean of the 
low BMD group. + Adducts in positive ionisation. – Adducts in negative ionisation. PS (phosphatidylserine), DG 
(diacylglycerol), plasmenyl-PE (plasmenylphosphatidylethanolamines). 
 
7.3.2.1.2 Subset  
 
Similarly, an additional OPLS regression model was fitted to the subset of 
samples (n = 30) with the 1662 features to analyse the relationship of femoral 
neck BMD and lipids. 
This OPLS model showed the relationship between the lipids and femoral 
neck BMD and this was described by high values of R2Y and Q2, 0.601 and 
0.209, respectively (Table 7.3). After excluding 95% of the lipids, a new OPLS 
model (step 2) was fitted with 149 lipids. The scatter plot for this statistical 
analysis showed a straight line indicating a relationship between the predictive 
values and the observed responses (Figure 7.1B). This new model showed 
higher values of R2Y and Q2, 0.773 and 0.54, respectively, and was significant 
based on the CV-ANOVA (p-value ≤ 0.001), and also showed a strong linear 
correlation of R2Y = 0.772. Lipids that were highly associated with the normal 
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and osteoporosis groups through both approaches are listed in Table 7.5. Twelve 
known lipids were significant and included one phosphatidic acid (PA), two 
ceramide-1-phosphates (CerPs), four phosphatidylserine (PS) species, three 
diacylglycerol (DG) species, one phosphatidylethanolamine (PE), and one 
phosphatidylinositol (PI) (Table 7.5, Appendix D, Table D.2, Figure D.2). A 
correlation matrix revealed negative correlations among eight lipids and femoral 
neck BMD, while a positive correlation was observed with PS (20:4), PI, CerP 
(24:0) and PE (Table 7.5). 
 
Table 7.5: Means and 95% confidence intervals of lipids associated to the subset 
of selected SC postmenopausal women (n = 30) with normal BMD and 
osteoporosis in univariate and multivariate approaches. 
Lipid 
Normal BMDa 
(n = 15) 
Osteoporosisa 
(n = 15) 
p-value Log2 (FC) Correlationb 
PA 34:4; [M − H]− 
0.531 
(0.321–0.878) 
1.617 
(0.822–3.182) 
0.005 0.412 −0.403 
CerP 38:1; [M + H]+ 
1.871 
(1.196–2.927) 
0.605 
(0.3319–1.105) 
0.002 −0.637 −0.384 
PS 20:4; [M − H]− 
0.547 
(0.330–0.906) 
1.585 
(0.804–3.124) 
0.008 0.395 0.274 
DG 40:0; [M + NH4]+ 
1.545 
(0.907–2.630) 
0.425 
(0.207–0.870) 
0.002 0.729 −0.270 
PS 33:6; [M + H]+ 
1.435 
(0.908–2.267) 
0.504 
(0.277–0.933) 
0.004 −0.560 −0.363 
PS 31:6; [M + H]+ 
1.423 
(0.886–2.286) 
0.506 
(0.267–0.958) 
0.006 −0.656 −0.377 
PS 32:6; [M + H]+ 
1.414  
(0.885–2.259) 
0.515 
(0.274–0.967) 
0.007 −0.573 −0.359 
PI 14:0; [M − H]− 
0.608 
(0.357–1.036) 
1.572 
(0.767–3.220) 
0.022 0.327 0.165 
DG 42:4; [M + NH4]+ 
1.510 
(0.976–2.336) 
0.574 
(0.319–1.033) 
0.005 −0.327 −0.374 
CerP 24:0; [M − H]− 
1.254 
(0.728–2.160) 
0.418 
(0.201–0.869) 
0.010 −0.265 0.008 
DG 47:5; [M + NH4]+ 
1.670 
(0.920–3.032) 
0.854 
(0.382–1.905) 
0.135 −0.351 −0.014 
PE 42:1; [M − H]− 
0.592 
(0.346–1.013) 
1.246 
(0.605–2.568) 
0.069 0.585 0.034 
Lipids are expressed as mean and 95% confidence interval (CI). ANOVA was used to compare lipid mean 
concentrations. a Covariates: age and BMI; b Age-adjusted correlation coefficient; Statistical p-value 
calculated using Benjamini–Hochberg false discovery rate (FDR). p-value < 0.05 was considered as 
statistically significant. Fold of change (FC) expressed as the relation between the lipid mean of the normal 
BMD group to the lipid mean of the osteoporosis group. + Adducts in positive ionisation. – Adducts in negative 
ionisation. PS (phosphatidylserine), PA (phosphatidic acid), DG (diacylglycerol), PE 
(phosphatidylethanolamine), CerP (ceramide-1-phosphate), PE (phosphatidylethanolamine), and PI 
(phosphatidylinositol). 
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7.3.2.2 Metabolites  
 
7.3.2.2.1 Entire cohort 
 
Five hundred and seventy-four features (positive ionisation) were detected 
by metabolomics. After filtration and removal of unwanted background and 
unstable compounds, the remaining 127 metabolites were fitted in an OPLS 
regression model. However, cumulative R2Y and Q2 values were 0.223 and 
−0.371, respectively (Table 7.6), and the predictive ability for the model Q2 was 
very low, which indicated that it was not a suitable model. 
Features scoring between 0.05% and 0.95% on the normal probability 
coefficient score plot were taken out to fit a new model (step 2), which had only 
12 features. Values of cumulative R2Y and Q2 values for this OPLS model were 
0.205 and 0.035, respectively (Figure 7.2A). Both step 1 and step 2 for metabolites 
showed little prediction for the two OPLS regression models. Therefore, the OPLS 
model with 127 features was not able to explain the association of the explanatory 
variables and femoral neck BMD. However, this analysis provided evidence for the 
association between four metabolites and femoral neck BMD (Table 7.7, Appendix 
D, Table D.3, Figure D.3), 4-aminobutyric acid (r = −0.013), threonine (r = −0.172), 
a tripeptide formed by asparagine–glycine–cystine (Asn–Gly–Cys) (r = −0.059), 
and turanose (r = −0.039). 
Table 7.6: Parameters of orthogonal partial least squares regression models 
based on the data from metabolites separation for the entire cohort and the 
selected subset of SC postmenopausal women. 
Dataset Step Component R2X R2Y Q2 
Entire cohort (n = 95) 1 1P and O1 0.483 0.223 −0.371 
Entire cohort (n = 95) 2 1P and O1 0.512 0.205 0.035 
Subset (n = 30) 1 1P and O1 0.437 0.749 −0.399 
Subset (n = 30) 2 1P and O1 0.514 0.526 0.247 
P predictive. O orthogonal in X. Component: number of significant components calculated by cross-validation. R2X 
value is the predictive and orthogonal variation in model samples (X) explained by the model. R2Y value is the 
amount of variation in X which is correlated to Y (response matrix). Q2 value describes the predictive ability of the 
model. 
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Figure 7.2: Orthogonal partial least squares (OPLS) from the metabolite profiles 
of SC postmenopausal women. OPLS scatter plot showing relationship between 
metabolites and femoral neck BMD in SC postmenopausal women with normal 
(green circles) and low BMD and osteoporosis (red circles) values based on 
orthogonally filtered partial square (OPLS) regression model 2 with 12 
metabolites among 95 women, entire cohort (A) and 30 women, subset (B). 
t[1]/u[1] correlation plot; t1 refers to scores of the first component in independent 
variables; u1 refers to scores of the first component in responses. 
 
Table 7.7: Means and 95% confidence intervals of metabolites associated to the 
entire cohort of SC postmenopausal women (n = 95) with normal and low femoral 
neck BMD in univariate and multivariate approaches. 
Metabolite Normal BMDa 
(n = 23) 
Low BMDa 
(n = 72) 
p-value Log2 (FC) Correlationb 
4-Aminobutyric acid 1.400 
(0.909–2.155) 
0.874 
(0.679–1.125) 
0.062 −0.185 −0.013 
Threonine 1.315 
(0.806–2.011) 
0.843 
(0.658–1.081) 
0.073 −0.159 −0.172 
Asn–Gly–Cys 0.794 
(0.512–1.230) 
1.014 
(0.512–1.230) 
0.337 0.058 0.059 
Turanose 1.319 
(0.858–2.028) 
0.845 
(0.657–1.087) 
0.076 −0.174 −0.039 
Metabolites are expressed as mean and 95% confidence interval (CI). ANOVA was used to compare metabolites 
mean concentrations. a Covariates: age and BMI; b Age-adjusted correlation coefficient. Statistical p-value 
calculated using Benjamini–Hochberg false discovery rate (FDR). p-value < 0.05 was considered as statistically 
significant. FC expressed as the relation between the metabolite mean of the normal BMD group to the metabolite 
mean of the low BMD group. 
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7.3.2.2.2 Subset  
 
In addition, the OPLS regression (step 1) was fitted to the subset of samples 
(n = 30) with the 127 metabolites to analyse the relationship of femoral neck BMD 
and metabolites, but this model did not show prediction (Q2 = −0.399) (Figure 
7.2B). After filtering using coefficient selection (as described above), the OPLS 
model 2 showed a higher cross-validation value, Q2 = 0.247, when compared 
with the model from step 1 (Table 7.6, Appendix D, Table D.4, Figure D.4). The 
correlation matrix revealed negative correlations among metabolites and femoral 
neck BMD, proline (r = −0.295), aminopropionitrile (r = −0.315), threonine (r = 
−0.170), and Asn−Gly−Cys (r = −0.038); while positive correlation was observed 
with methionine (r = −0.494) (Table 7.8). 
 
Table 7.8: Means and 95% confidence intervals of metabolites associated to a 
subset of selected SC postmenopausal women (n = 30) with normal BMD and 
osteoporosis in univariate and multivariate approaches. 
Metabolite 
Normal BMDa 
(n = 15) 
Osteoporosisa 
(n = 15) 
p-value Log2 (FC) Correlationb 
Proline 
1.581 
(0.928–2.692) 
0.786 
(0.384–1.609) 
0.084 −0.234 −0.295 
Aminopropionitrile 
0.729 
(0.418–1.272) 
1.848 
(0.875–3.905) 
0.03 −0.270 −0.315 
Threonine 
1.561 
(0.911–2.674) 
0.765 
(0.371–1.579) 
0.081 −0.219 −0.170 
Methionine 
1.534  
(0.894–2.632) 
0.758 
(0.366–1.567) 
0.085 0.141 0.494 
Asn-Gly-Cys 
1.428 
(0.782–2.607) 
0.593 
(0.264–1.334) 
0.056 0.142 −0.038 
Metabolites are expressed as mean and 95% confidence interval (CI). ANOVA was used to compare metabolites mean 
concentrations. a Covariates: age and BMI; b Age-adjusted correlation. Statistical p-value calculated using Benjamini–
Hochberg false discovery rate (FDR). A p-value < 0.05 was considered as statistically significant. FC expressed as the 
relation between the metabolite mean of the normal BMD group to the metabolite mean of the osteoporosis group. 
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7.4. Discussion 
 
The potential of metabolomics was explored for the discovery of molecules 
associated with BMD loss in SC postmenopausal women. It is well established 
that bone loss is linked to age and low levels of oestrogen in women in both 
Caucasian and Asian populations. After menopause, there are several molecular 
changes affecting bone metabolism, where those alterations result in an 
increased bone resorption and a declined BMD (Manolagas and Parfitt, 2010; 
Nakashima et al., 2011). Thus, the identification of novel potential biomarkers 
may be useful for understanding the connections of the lipids and metabolites 
associated with osteoporosis and their capacity to predict bone loss in SC 
postmenopausal women.  
In order to optimise the prediction of biomarkers for bone loss, a second 
dataset (subset) was created to analyse the relationship between the plasma 
metabolome of SC women with severe osteoporosis (T-score < −2.5) and normal 
BMD (T-score > −1). Therefore, in this study, the results from univariate and 
multivariate analyses were presented using two different datasets: the entire work 
set and a subset of samples. This statistical filtering using OPLS regression 
modelling facilitated the removal of uncorrelated lipid features and allowed 
several lipids to be detected as predictors of postmenopausal osteoporosis in 
women. 
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7.4.1 Lipids 
 
In this study, changes of the lipid profiles, and the relationship of those 
lipids with femoral neck BMD, were compared in SC postmenopausal women. 
Glycerophospholipid species PS (20:4/29:6/31:6/32:6/33:6), PE (42:1), PA (34:4) 
and PI (14:0) were found to be different between normal and low femoral BMD 
groups.  
Lipid metabolism disorders have been linked to pathological conditions 
including obesity, metabolic syndrome, cardiovascular diseases and bone loss, 
where cells and signalling pathways may be affected (Cui et al., 2005). 
Adipocytes and osteoblasts are derived from the mesenchymal stem cells (MSC) 
and the balance of osteoblast versus adipocyte requires interactions between 
extracellular signalling stimuli. Changes in one any of those factors enhances 
bone fat deposition and promote bone loss (Almeida and O’Brien, 2013). 
Oestrogen plays a key role in the cell fate of MSCs to differentiate into either 
osteoblasts or adipocytes; oestrogen also regulates inflammation (Zhao et al.; 
Muruganandan et al., 2009). Further, peroxisome proliferator-activated receptor 
(PPARy) transcription factor is essential for adipogenesis. Thus, altered lipid 
metabolism causes oxidative stress and increased expression of PPARy, which 
reduces osteoblast numbers in the skeleton, and oestrogen contributes to the 
regulation of this PPARy signalling pathway (Dieudonne et al., 2000; Almeida et 
al., 2009).  
Oestrogen deficiency induces bone loss and changes in lipid profiles, BMD 
and cytokines; however, little information exists on the application of plasma 
lipidomics for studying postmenopausal osteoporosis. In vivo and in vitro studies 
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have reported that lipid metabolism disorders promote bone loss by inhibiting 
osteoblast differentiation and promoting adipogenic differentiation through MSC 
stimuli. Phosphatidylinositol (PI) metabolism is essential for signalling by RANK, 
a local regulator of osteoclastogenesis and bone resorption (Takeshita et al., 
2002; Wada et al., 2006). This study showed elevated concentrations of PI 
species (14:0) in SC women with low BMD/osteoporosis compared with the 
normal-BMD group, suggesting that PI species may lead to chronic inflammatory 
processes and this might induce bone loss in postmenopausal osteoporosis. 
Circulating levels of several lipid classes also have been associated with 
physiological processes including the regulation of inflammation. In an in vitro 
study, lipid metabolism of PE, PS and lysoPC changed during MSC activation 
due to pro-inflammatory stimuli with TNF-α and IFN-γ  (Campos et al., 2016). This 
suggests that changes in lipid profiles promote production of cytokines and 
differentiation of osteoclasts and may be attributed to oestrogen withdrawal. 
Diacylglycerols (DGs) are cellular mediators released from membrane 
lipids that play a key role in the regulation of inflammation and disease (Kilpinen 
et al., 2013). The results in this study showed a decrease in the concentrations 
of glycerolipid species identified as DG (40:0/42:4) in the osteoporosis group 
compared to the normal BMD postmenopausal group. While it is not clear 
whether DG levels are associated with bone mass, there is evidence suggesting 
a relationship between circulating DG profiles and oestrogen loss. A previous 
study reported plasma DG (33:2) decreased with ageing (Jové et al., 2016). 
Additionally, an animal study reported that serum monoacylglycerol and 
triacylglycerol concentrations decreased in OVX rats as a model of oestrogen 
deficiency (Vinayavekhin et al., 2016), suggesting that lipid profiles and 
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oestrogen loss upregulate bone pro-inflammatory cytokines, which control 
osteoclast differentiation and promote bone loss. 
However, information on the association between plasma lipids and 
femoral neck BMD in postmenopausal women is limited. Previous studies in 
postmenopausal women have reported conflicting associations between 
triacylglycerol and hip BMD (Makovey et al.; Cui et al., 2005; Brownbill and Ilich, 
2006). The findings in this study showed a positive association between DG 
species and hip femoral neck BMD. This result indicates that lipid profile changes 
may be involved in MSCs’ functional, anti-inflammatory activities and cytokine 
production as a result of oestrogen withdrawal, which enhances MSC signalling 
and inhibits osteoblast differentiation (Pacifici et al., 1991; Zheng et al., 1997; 
Zhou et al., 2001). However, further studies are needed to clarify the links 
between plasma lipid concentrations and femoral neck bone loss in 
postmenopausal women.  
Sphingolipids also play a structural role in cellular membranes, and act as 
bioactive signalling molecules. Ceramide is one of the simple sphingolipids and 
is involved in the control of many cellular processes including proliferation, 
differentiation and apoptosis (Gómez-Muñoz, 2004; Arana et al., 2010). It has 
been shown that phosphorylated ceramide (CerP) stimulates cell survival and 
proliferation in bone marrow-derived macrophages through molecules such as 
NF-κB, RANK and its ligand RANKL (Gómez-Muñoz et al., 2004; Gangoiti et al., 
2008). However, in our study, two sphingolipid species, CerP (24:0/38:1), were 
significantly reduced in the low BMD postmenopausal group compared with the 
normal-BMD group. These results contradict a previous animal study of 
oestrogen loss, where CerP concentrations were upregulated in OVX rats 
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(Vinayavekhin et al., 2016). Further, in a human study, Lee et al. (2012) found 
that higher sphingosine-1-phosphate (S1P) concentrations were associated with 
low BMD in postmenopausal women. This suggests that the increased levels of 
CerP promote differentiation of bone marrow-derived macrophages with 
biological effects on bone metabolism, and could be attributed to oestrogen 
deficiency. 
Taken together, these findings suggest that altered lipid metabolism could 
be a regulator of osteoclast differentiation and bone loss in SC postmenopausal 
women. Further studies are required to investigate the potential role of these 
lipids as biomarkers for early diagnosis of bone loss in SC postmenopausal 
women.  
 
7.4.2 Metabolites 
 
This approach enabled the identification of amino acids, amines and other 
polar metabolites. Our study found no significant associations between polar 
metabolites and femoral neck BMD in SC postmenopausal groups based on 
OPLS analysis. However, proline, threonine and aminopropionitrile 
concentrations were found to be lower in SC postmenopausal women with low 
BMD and osteoporosis based on univariate analysis. 
Amino acids play a key role in bone health and are involved in bone 
remodelling. During osteoporosis, alterations in amino acids may affect bone 
mass, suggesting that lower levels of circulating amino acids are associated with 
low BMD. Previous metabolomics studies in postmenopausal women have 
reported that tryptophan, lysine, homoserine and 3-hydroxy-L-proline 
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concentrations decreased in the osteoporosis group compared with 
pre/postmenopausal women with normal BMD using GC–MS (Qi et al., 2016). 
Miyamoto et al. (2017) reported that serum concentrations of a dipeptide formed 
with glycine and glycine (Gly–Gly) and cysteine were lower and hydroxyproline 
concentrations were higher in low-BMD postmenopausal women using capillary 
electrophoresis/mass spectrometry (CE–MS). You et al. (2014) found higher 
glutamine concentrations and lower lactate and acetone concentrations 
associated with low BMD in Taiwanese women using NMR spectroscopy.  
Amino acids modulate bone marrow stem cell (BMSC) function, 
signalling, proliferation and differentiation. Arginine is the precursor for the 
synthesis of many molecules including urea, nitric oxide, proline and glutamate 
(Morris, 2006). Disorders in arginine metabolism are suggested to cause 
decalcification, disturbance in calcium absorption and osteomalcia. Growth 
hormone and insulin-like growth factor-I, both bone-forming growth factors, are 
stimulated by arginine, and a disorder in these factors causes an increase in 
inflammatory cytokines and osteoporosis (Chevalley et al., 1998). Proline and its 
metabolite hydroxyproline are the major amino acid components in collagen, and 
serum hydroxyproline can be used as a bone collagen degradation marker (Ma 
et al., 2013a; Wood et al., 2014). Homocysteine is a metabolite in methionine 
metabolism, and at high levels interferes with collagen crosslinking, suggesting 
that increased homocysteine levels can lead to increased fracture risk in ageing 
(van Meurs et al., 2004). Further, aminopropionitrile has been reported in in vitro 
studies as a collagen crosslinking inhibitor, and with homocysteine, caused a 
decreased bone strength (Turecek et al., 2008). The mechanistic implications of 
altered metabolites and their association with bone remodelling and the link to 
 201 
   
BMD are not clear, but both BMSC differentiation and collagen formation are 
critical factors that influence BMD, suggesting that perturbations of amino acids 
under postmenopausal osteoporosis may partly contribute to bone loss in elderly 
women. Information on the association between metabolites and SC 
postmenopausal women is scarce and needs to be corroborated with further 
work. As it was not possible to test for a possible relationship between 
metabolites and femoral neck BMD due to the small study groups and the high 
variability among participants, these findings need to be kept in perspective. 
The limitations of our study include the small number of participants and 
higher variability among them such as genetic, age, environment, diet and 
lifestyle factors, and body composition. This was addressed when two different 
datasets were analysed, the entire cohort and subset, and the subset study 
showed that two compounds for the polar metabolites and three for the lipids 
were similar to those already detected in the entire cohort. Supporting these 
findings is the fact that the same compounds were associated with BMD in both 
dataset analyses for the pathology of osteoporosis. Overall, future studies on 
larger populations are needed to confirm these findings and enable more reliable 
results for assessing the association between the metabolome and femoral neck 
BMD for prognosis of osteoporosis in SC postmenopausal women.  
  
 202 
   
7.5. Conclusions  
 
This pilot study suggested that plasma lipids and metabolites differed 
between women of normal versus low BMD, and these are involved in several 
metabolic pathways such as sphingolipid metabolism, phospholipid metabolism 
and fatty acid β-oxidation. Moreover, this study demonstrated that lipidomic and 
metabolic profiling are promising tools for finding novel biomarkers for bone loss 
in SC women. Further, prospective studies on larger populations are needed to 
corroborate these findings and elucidate their key roles in osteoporosis 
development and progression in SC postmenopausal women. Thus, 
understanding the cellular responses to molecular changes of bone metabolism, 
and how these are associated with bone loss in postmenopausal women, may 
offer the potential of discovering new biomarkers for prognosis of bone loss in 
elderly women.  
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Chapter 8 
 
 
 
 
 
 
 
Thesis discussion 
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Osteoporosis is a bone disorder characterised by low mass and micro-
architectural deterioration of bone tissue, which lead to bone fragility and an 
increase in fracture risk. Many studies have investigated the role of biomarkers 
of bone turnover, which are currently blood-based biomarkers, in 
postmenopausal osteoporosis. Further studies are needed to consolidate their 
use for prediction of bone loss.  
From the research conducted (Chapter 2) on various animal models used 
in published studies for the study of postmenopausal osteoporosis, it is clear that 
the OVX sheep model is useful to understand the mechanisms that contribute to 
bone loss. However, there has been controversy about the optimal period of time 
for achieving bone loss in this model. More recent studies have proposed 
metabolomics to identify novel biomarkers for an earlier diagnosis of a particular 
disease, and to develop new treatments or nutritional strategies for the treatment 
of bone loss. Most of the metabolomics analyses of osteoporosis, which are 
based on serum or plasma, have been conducted in OVX rats. However, profiling 
of all the detectable metabolites present in blood needs to be conducted on 
animal models that have similar anatomy, cell biology and physiological changes 
to those seen in humans in order to translate the findings to clinical practice in 
humans (Turner, 2001). 
The purpose of this thesis’s research was to optimise a sheep model for 
postmenopausal osteoporosis, and identify novel biomarkers to improve our 
understanding of postmenopausal bone loss. Additionally, the research included 
a study cohort of SC postmenopausal women, where the aim was to describe the 
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association between the plasma metabolome and lipidome according to BMD 
status, as well as to identify novel blood biomarkers for osteoporosis.  
In this sheep model, ovariectomy in combination with monthly injections of 
glucocorticoids successfully resulted in decreased BMD and increased bone 
remodelling over five months. Metabolomics analyses showed differences 
between the plasma metabolome and lipidome of OVX and OVX combined with 
glucocorticoid treatments in ewes. Additionally, the findings from the OVX sheep 
revealed lipids and metabolites associated with BMD and bone biomarkers, 
including alterations in multiple amino acids, metabolites, fatty acid β-oxidation 
and lipid metabolism, as well as altered metabolic pathways that could provide 
new insights into postmenopausal osteoporosis.  
This PhD thesis reports the improvement and characterisation of a large 
animal model of postmenopausal osteoporosis, the OVX sheep. The results of 
this PhD thesis contribute to the published knowledge of using OVX sheep in 
combination with glucocorticoids to generate a faster onset of bone loss. Today, 
there is growing interest to test new therapies against bone loss, and the use of 
animal models has the advantage of allowing more-invasive methods than those 
used in humans to assess bone loss in order to predict what occurs in humans. 
In this sense, the OVX sheep model can be used to generate bone samples for 
compositional assessment, as well as provide serial blood samples for 
measurement of known bone markers to monitor responses to osteoporosis 
therapies for identification of new biomarkers. 
This PhD thesis also reports the metabolic changes in the OVX sheep 
model in response to oestrogen deficiency, providing novel information about the 
specific alterations in lipids and metabolites associated with bone loss in 
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postmenopausal osteoporosis. These findings are in agreement with the results 
from the human study, where perturbations of methionine and ceramide 1-
phosphates were also observed in SC postmenopausal women with low BMD. 
The results from the metabolomics analyses support the proposed application of 
LC–MS-based metabolomics as a diagnostic approach to identify lipids and 
metabolites associated with bone loss in postmenopausal women. Future studies 
are required to explain how the metabolites and lipids are involved in the 
development of postmenopausal osteoporosis.  
 
8.1 Thesis discussion 
 
8.1.1 Effect of OVX combined with glucocorticoids on bone remodelling and BMD 
 
This study investigated which measurement outcomes are the most 
suitable to optimise and characterise a sheep model for postmenopausal 
osteoporosis using OVX alone or OVX combined with glucocorticoids. 
According to the results obtained in Chapter 3, the OVX ewes that received five 
months of glucocorticoid treatment showed a lower BMD as well as variation of 
the bone turnover markers OC and CTx-1, when compared with the OVX group. 
Strong negative correlations were found between lumbar spine and OC at two 
months, and femoral BMD and CTx-1 at five months.  
The findings in Chapter 3 are similar to previous studies reported in 
postmenopausal women, where changes of biomarkers of bone turnover during 
menopause are correlated with bone loss (Garnero et al., 1996). It is 
established that combining OVX and glucocorticoids accelerates bone loss in a 
short time, by inducing bone resorption and suppressing bone formation 
(Mazziotti et al., 2006). Glucocorticoids promote osteoclastogenesis, and thus 
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after glucocorticoid exposure there is an increase in bone resorption. Inhibition of 
osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes 
have been reported as effects of glucocorticoid exposure (Canalis, 2003; 
Mazziotti et al., 2006; Manolagas, 2009). Glucocorticoids also inhibit osteoblast 
synthesis of type 1 collagen, a major component of bone tissue. The synthesis of 
collagen is the scaffold for mineralisation, so suppression of collagen synthesis 
results in reduced bone mass and therefore increased bone loss and higher risk 
of fracture (Seeman and Delmas, 2006).  
In this study, increased concentrations of bone biomarkers were observed 
during the first two months in OVX sheep but decreased thereafter, and were 
regulated by oestrogen deficiency and glucocorticoids. Previous studies have 
been conducted using an OVX sheep model for osteoporosis, but there has been 
controversy about the optimal period of time for inducing bone loss in OVX ewes 
(Chavassieux et al., 2001; Lill et al., 2002c; Sigrist et al., 2007; Ding et al., 2010). 
Here, the OVX combined with glucocorticoids provides a better model for 
postmenopausal osteoporosis due to the results showing higher bone turnover 
rate and reduced BMD, suggesting the generation of bone loss in a short time 
(five months). Validation of these findings in an additional study with a larger 
sample size per treatment group is required to confirm whether the OVX sheep 
model could provide information of prediction of bone loss, and diagnosis and 
test of new dietary interventions or drug treatments for postmenopausal 
osteoporosis.  
In addition, there are variations within skeletal sites which need to be 
assessed to understand the details of bone loss in osteoporosis. In Chapter 4, 
the aims were: 1) to investigate the direct changes after OVX and glucocorticoid 
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treatment on left tibias of ewes; 2) to evaluate correlations between proximal and 
distal metaphyseal bone parameters of the left tibias; and 3) to determine the 
bone mechanical properties using the three-point bending test. The bone 
samples were taken from the ewe model described in Chapter 3. There were no 
differences in the longitudinal measurements of the distal tibial metaphysis in the 
OVX model; however, the findings showed that vBMD of the distal tibial 
metaphysis decreased over time. The effects of OVX plus glucocorticoids on the 
proximal tibial metaphysis showed decreased vBMD, bone area and BMC, 
trabecular vBMD, trabecular area, and trabecular BMC; periosteal and endosteal 
circumference and cortical thickness also decreased at five months. When 
metaphyseal sites were examined, bone parameters in both distal and proximal 
sites correlated well.  
There were no differences in maximum load, stiffness and energy among 
the four groups determined from the three-point bending test in the mid-diaphysis 
of the tibia after sacrifice. However, mechanical properties of bone such as 
maximum load, stiffness, and energy to failure decreased over time. Combining 
OVX with glucocorticoids decreased trabecular and cortical strength parameters 
in the tibia of ewes over five months. When glucocorticoid treatment was 
discontinued after two months, a recovery process was noticed in the ewes that 
received only two doses, where bone mechanical properties increased at five 
months.  
Bone provides mechanical and protective functions against fracture, and 
these functions are compromised as a result of long-term oestrogen depletion 
plus glucocorticoid treatment. The major predictors of bone strength are material 
composition and architecture, where bone mass, geometric distribution and 
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mechanical properties are functions of bone strength. Previous studies in ewes 
treated with prednisolone have shown reductions in trabecular bone volume and 
trabecular thickness (Lill et al., 2002c; Arens et al., 2007). Bone consists of a 
mineral phase formed by crystals of hydroxyapatite and an organic part, mainly 
formed by type 1 collagen (Seeman and Delmas, 2006). Modifications in bone 
mineral tissue affect both mechanical and protective functions. This might be 
explained because glucocorticoids affect the metabolism and function of 
osteocytes, where the elastic modulus surrounding osteocyte lacunae is altered, 
and as a result there is a reduction of mineralization in the bone matrix (Lane, 
2006). Future studies are required to investigate whether the same amount of 
bone loss occurs in other anatomical areas of OVX sheep.  
 
8.1.2 Application of MS-based metabolomics approach in OVX sheep as a model 
of osteoporosis 
 
To gain insight into the mechanisms behind bone loss in the OVX sheep 
model, plasma metabolites were evaluated using HILIC–MS-based 
metabolomics analysis (Chapter 5) and related to bone turnover markers and 
BDM. The relative intensities of 5-methoxytryptophan, valine, methionine, 
tryptophan, glutaric acid, 2-pyrrolidone-5-carboxylic acid, indole-3-
carboxaldehyde, 5-hydroxylysine and malic acid showed dynamic changes over 
time. In the short-term approach (two months), a negative correlation between 
methionine and OC was observed. Glutaric acid was negatively associated with 
femoral and lumbar spine BMD. In the long-term approach (five months), 5-
methoxytryptophan was negatively associated with CTx-1 marker and femoral 
BMD. Methionine was also negatively associated with femoral BMD.  
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Postmenopausal osteoporosis is accompanied by oxidative stress and 
inflammation, which can affect the bone microenvironment, specifically the bone 
marrow, and alter the bone remodelling process. Previous metabolomics 
analyses have shown altered metabolite profiles after OVX in rats. Branched-
chain amino acids (valine, leucine and isoleucine), homocysteine, 
hydroxyproline, ketone bodies, asparagine, glutamine, tryptophan, lysine, proline, 
serine and threonine circulating levels varied in OVX rats (Ma et al., 2011; Ma et 
al., 2013b; Assadi-Porter et al., 2015). Amino acids play a role in bone health and 
modulate bone marrow stem cells’ functions, signalling and proliferation. Thus, 
altered amino acid metabolism due to oestrogen withdrawal may lead to 
disturbances in bone remodelling, not only suppressing bone formation cells but 
also increasing the production of pro-inflammatory cytokines and ROS generation 
in the bone marrow.  
In addition, a UPLC–MS metabolomics analysis was used to measure the 
plasma lipid profile of the OVX sheep in two different approaches (Chapter 6). 
Correlations between bone clinical parameters and the lipid profile were 
assessed in OVX sheep. The relative intensities of 14 lipids changed over five 
months, including cardiolipin (CL), ceramide-1-phosphates (CerPs), 
phosphatidylinositol, phosphatidic acid, lysophosphatidylethanolamines, 
phosphatidylserines and phosphatidylglycerol. Pearson correlations analysis 
showed that cardiolipin was negatively associated with the lumbar spine at two 
months, and ceramide-1-phosphate was associated positively with lumbar spine 
at five months. Lipids play an important role in skeletal metabolism and bone 
health, and plasma lipids may be the link between oestrogen deficiency and bone 
loss in postmenopausal women (Rosen and Bouxsein, 2006). Previous studies 
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have reported lipidome changes in OVX rats (Zhu et al., 2010; Ma et al., 2013b; 
Zhang et al., 2014a), where the main findings suggested that perturbed 
phospholipid metabolism might be involved in a pro-inflammatory process, which 
affects bone formation and bone remodelling as a result of oestrogen depletion. 
Perturbations in specific metabolic pathways such as glycolysis, the TCA cycle, 
glutamine metabolism and fatty acid metabolism due to oestrogen deficiency 
have been reported as metabolic pathways that might impact on bone 
remodelling (Lee et al., 2017). Further studies are required to optimise the sheep 
as an experimental model and validate the results presented in Chapters 5 and 
6 to obtain a more controlled study of bone loss in response to oestrogen 
deficiency and glucocorticoids.  
The main limitation of this study was that the OVX sheep model was based 
on a small sample size, with four treatment groups. This experimental design was 
underpowered when determining the statistical significance for the longitudinal 
assessment of the distal metaphysis of the tibia. However, bone remodelling, 
lumbar spine and femoral BMD, and plasma lipidome and metabolome could be 
assessed over five months. The minimum number necessary of animals per 
group can be estimated from the results of Chapter 3 and Chapter 4, whether it 
is accepted 5% of alpha error (meaning p < 0.05) and 20% of beta error (meaning 
80% of statistical power) (Kadam and Bhalerao, 2010). Thus, the required sample 
size per group (n) to see a difference is 27 animals per group for OC, 31 for CTx-
1 markers and 8 animals for distal tibia. However, for biomarker discovery 
studies, estimating the sample size per group for high dimensional can be 
calculated using the average power and the significance levels using false 
discovery rate (Xia et al., 2015). The sample size was estimated with the results 
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from Chapter 5 and Chapter 6, and 200 samples per group will be needed to 
guide a next study design. Therefore, the number of animals per group required 
to achieve a reasonable statistical power and detect clearer differences among 
treated groups would vary depending of the variable measured. However, the 
findings from the OVX sheep model provided specific information in the context 
of clinical study for postmenopausal osteoporosis. The strengths of this study are: 
1) the improvement of an OVX sheep model, where significant bone loss was 
generated over five months; 2) the assessment of bone metabolism and mass 
during and after the cessation of glucocorticoids combined with OVX in sheep; 
and 3) this study is the first to report plasma lipids and metabolites in OVX sheep, 
and their associations with bone loss. 
 
8.1.3 Association of plasma lipids and metabolites with low BMD in SC 
postmenopausal women  
 
This study aimed to analyse the plasma lipid and metabolite profiles from SC 
postmenopausal women using an LC–MS metabolomics analysis. Further, 
correlation analyses were established between plasma metabolites and femoral 
neck BMD in postmenopausal women. Plasma concentrations of 
glycerophospholipid, glycerolipid and sphingolipid species in postmenopausal 
women with low BMD were decreased, while plasma concentrations of 
glycerophospholipid species phosphatidylserine, phosphatidylinositol, 
phosphatidylethanolamine and phosphatidic acid were increased. Trends for 
lower levels of 4-aminobutyric acid, turanose, proline, aminopropionitrile, 
threonine, methionine and the peptide asparagine–glycine–cystine in women with 
low BMD were found. Osteoporosis is associated with increased marrow fat 
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content and lower BMD (Yeung et al., 2005). Therefore, accumulation of plasma 
lipids might be associated with increased marrow fat and decreased BDM. 
However, histomorphometric analyses would be required to evaluate whether the 
accumulation of bone marrow affects BDM (Verma et al., 2002; Zhou et al., 2008; 
Sheu and Cauley, 2011). Further, information on the association between 
metabolites and SC postmenopausal women remains limited and needs to be 
corroborated with future work.  
The limitations of this study include the small number of participants and 
higher variability among them such as environment, diet, lifestyle and body 
composition. However, this was addressed when two different datasets were 
analysed, and both the entire cohort and subset findings were consistent, as the 
subset study showed similar compounds to those already detected in the entire 
cohort.  
In addition, the metabolomics analyses were performed separately on the 
plasma of OVX sheep and the SC postmenopausal women. In the OVX sheep, 
metabolite and lipid alterations associated with bone loss included methionine, 
glutaric acid, tryptophan, 5-methoxytryptophan, CL and CerP (Chapters 5 and 
6), and these correlated with OC, CTx-1, femoral BMD and lumbar spine BMD. 
In the SC women, proline, threonine, methionine, 4-aminobutyric acid, 
aminopropionitrile, phosphatidic acid, diacylglycerol, CerP and 
phosphatidylinositol correlated well with low femoral neck BMD (Chapter 7). From 
these findings, it was found that only methionine and CerP were the common 
compounds altered in both the OVX sheep and SC women studies (Table 8.1). 
Methionine level increased in OVX sheep vs control group at month two and 
month five but decreased in the SC women with osteoporosis compared with 
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those in the normal BMD group. The observations from the OVX sheep agreed 
with previous studies that have reported higher levels of homocysteine, a 
metabolite of methionine, altered bone turnover markers and lower BMD 
(Herrmann et al., 2005a; Ozdem et al., 2007; Gerdhem et al., 2009). CerP 
showed lower relative abundance in OVX sheep and SC women with bone loss 
when compared with healthy groups. Those compounds, which are known to be 
involved in bone remodelling, could be considered to be of clinical relevance in 
postmenopausal bone loss. Further work is needed to validate these 
metabolomics findings, and clarify the functional mechanisms of methionine, 
CerP in relation to bone mineral density in postmenopausal osteoporosis.  
The small sample size of the studies described in this thesis might have 
limited the statistical power and the results should be interpreted with caution. 
Despite the limited sample size, the present metabolomics analysis indicates 
that the OVX sheep is an ideal model for prediction of human bone loss, 
demonstrating alterations in both species in the plasma lipid and metabolite 
profiles, as well as the association between those compounds and bone mineral 
density.  
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Table 8.1: List of the altered metabolites in OVX sheep and in SC women with 
low BMD. 
 
↑ indicates an up-regulated increase in metabolite level, whereas ↓ indicates a down-regulated in metabolite level.√ 
indicates potential biomarker. 
 
8.2 Thesis conclusions 
 
Validation of the OVX sheep model was achieved and showed to be 
suitable as a model for postmenopausal osteoporosis by combining OVX and 
glucocorticoids over five months. These treatments resulted in a reduction of 
bone formation and increased bone resorption. These results suggest that, after 
considering the differences of sample sizes in the experimental groups, 
glucocorticoid treatment affected the bone remodelling process more than 
oestrogen deficiency over five months.  
This research applied LC–MS-based metabolomics to investigate the 
differences in lipids between OVX alone and OVX with glucocorticoid treatments 
in sheep. OVX alone and OVX with glucocorticoid treatments altered plasma lipid 
Metabolite Altered in OVX sheep Altered in SC women 
with low BMD
Potential biomarker
Methionine ↑ ↓ √
Glutaric acid ↓
Tryptophan ↓
5-Methoxytryptophan ↓
Proline ↓
Threonine ↓
4-Aminobutyric acid ↓
Asn–Gly–Cys ↓
Aminopropionitrile ↑
Phosphatidic acid ↑
Ceramide-1-phosphate ↓ ↓ √
Phosphatidylserine ↓
Diacylglycerol ↓
Phosphatidylinositol ↑
Cardiolipin ↓
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profiles in sheep over five months, which could indicate oxidative stress and 
inflammation in the bone marrow.  
Variation in the relative intensities of CL, PI, PA and PS species after OVX 
may relate to dysfunctional glycerophospholipid and phosphatidylinositol 
pathways, and may increase marrow fat accumulation as well as bone loss in 
postmenopausal osteoporosis. Understanding the roles of the CL, PI, PA and PS 
species in bone remodelling, as well as their potential connection to bone loss, is 
needed to provide evidence to not just predict bone loss but also to design novel 
drugs for the treatment of osteoporosis.   
This OVX sheep model provides opportunities to enhance our 
understanding of bone diseases, to test new drugs, and to develop dietary 
interventions for the prevention of bone loss in postmenopausal women. 
In the human study, the findings suggest that plasma lipids and amino 
acids differed between women of normal versus low BMD. There was a decrease 
in plasma relative intensities of eight glycerophospholipid, glycerolipid and 
sphingolipid species in postmenopausal women with low BMD, but increased 
plasma relative intensities of four glycerophospholipid species 
(phosphatidylserine, phosphatidylinositol, phosphatidylethanolamine and 
phosphatidic acid). Further, this study found no significant differences in plasma 
amino acid metabolites.  
The findings from the lipid profiles identified lipids that are involved in 
sphingolipid metabolism, phospholipid metabolism and fatty acid β-oxidation. 
Lipid metabolism and fatty acid metabolism pathways, especially those with a key 
role in energy metabolism, were found to be associated with bone loss in SC 
women. This group of potential biomarkers are correlated with clinical bone 
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parameters and could be used for early detection, clinical diagnosis and 
monitoring of postmenopausal osteoporosis induced by oestrogen deficiency. As 
with the currently known bone markers, some of the metabolic changes revealed 
in this research may be predictive of future fracture, but to prove this relationship, 
longer-term studies are required.  
Further validations of methionine and CerP over a larger population may 
aid in the development of a rapid and reliable method for the early diagnosis of 
bone loss, and the monitoring and improvement of treatments in 
postmenopausal women.  
 
8.3 Future directions 
 
During the progression of this study, several areas of future research were 
identified. The results of this study contribute to the identification of predictive 
biomarkers of bone metabolic diseases such as osteoporosis. However, for the 
experimental design of ewe models for postmenopausal osteoporosis, three 
treatment groups would be best suited: group 1, OVX and low calcium and 
vitamin D diet; group 2, OVX combined with glucocorticoids and low calcium and 
vitamin D diet; and group 3, control group normal calcium and vitamin D diet. This 
would help to evaluate that the effects of different interventions are not only based 
on hormonal interventions, but also allow assessment of different diets and how 
these would affect the metabolome and lipidome in the OVX sheep model. 
Alternatively, using OVX with or without glucocorticoids on grass-fed animals in 
an outdoor flock might alleviate the time-induced bone loss observed in the 
current study and attributed to the indoor housing and resultant reduction in 
physical activity. Further studies, including molecular and histomorphometry 
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evaluations, are needed to further characterise the OVX sheep model. 
Additionally, assessments of clinical parameters, such as oestrogen, glucose, 
inflammatory cytokines, cholesterol and triglycerides, ideally would aid the 
identification of the intrinsic mechanisms that regulate the expression of 
osteoblast and osteoclast phenotypes during post-menopause. 
Furthermore, the current study design allowed for repeated blood 
sampling (monthly) of ewes, to evaluate the assumptions that oestrogen 
regulates bone remodelling and to understand disease progression over time. 
For this, the plasma lipid and metabolite profiles of treated and nontreated ewes 
were compared at baseline and once-monthly after initiated treatments over five 
months. However, changes in bone metabolism status occur quickly. To ensure 
that those changes can be monitored, the ideal approach should be to collect 
blood samples every two weeks where possible to investigate the onset of the 
disease, as bone loss and increased fracture risk occur before symptoms are 
apparent. Such an approach necessitates the use of the sheep (or other large 
animal) model, as frequent collection of large volumes of blood from rodents 
cannot be done.  
Validation of the identified metabolites and lipids will allow more reliable 
assessment of bone loss in postmenopausal women. This validation can be done 
by analytical validation, where external standards can be used to corroborate 
whether the identified feature co-elutes at the correct retention time from the 
chromatographic column and that the fragment ions of the potential biomarker 
match those of the actual compound. This also offers an opportunity to 
subsequently quantify their concentrations by utilising the responses of the 
compound and the internal standards added to the samples. Further validation of 
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the metabolites and lipid alterations should be analysed on larger and 
independent populations to reduce the effect of higher variability among them.  
In this study, measurements of bone biomarkers and bone mass were the 
parameters used to evaluate the association of the plasma metabolome and 
lipidome with bone loss. Metabolites present in blood may reflect the changes in 
other tissues, but the analysis of other biological matrixes such as bone tissues 
in LC-MS based metabolomics and lipidomics studies would allow direct 
measurement of the molecular changes of the bone microenvironment in 
postmenopausal osteoporosis.  
Follow-up studies are also recommended to analyse changes in the 
metabolite and lipid profiles relative to BMD of pre and postmenopausal women 
and could be useful to predict early bone loss.  In addition, follow-up studies to 
predict bone mass changes as well as to investigate the effects of genetics, age, 
environment, diet, lifestyle and body composition on osteoporosis development 
are needed.  
In this context, dietary intake has been proven to affect bone loss in post-
menopause, and therefore, studies using dietary interventions could detect bone 
health markers as a response to nutritional intake. The validation of the novel 
biomarkers in a human nutritional intervention study, in which the metabolites 
could improve bone metabolic health, would be valuable to understand the effect 
of nutritional interventions on the bone mass of postmenopausal women.  
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Appendix B. Effect of OVX on the plasma metabolome of sheep 
 
PCA: short-term approach 
 
PCA was used to analyse the plasma metabolite profiles of all treatments 
groups per individual time point. No noticeable differences can be observed in 
the PCA over two months. At baseline, the resulting scatter plot of PC1 and PC2, 
which explains 28.1% of the variance, showed that over time samples were 
clustered in the middle of the plot. One outlier from the control group and one 
from the OVX group were observed. Moreover, at month one a smaller difference 
was noticed between the OVXG group and the OVX group as shown by 
separation (Figure B.1B), as well as between the OVX group and control group, 
where PC1 and PC2 explained 35.3% of the variance. Two outliers were 
observed in the OVX group and one in the control group. However, at month two 
(Figure B.1C), the largest difference can be noticed between the OVXG group 
compared with OVX group, where the resulting scatter plot of PC1 and PC2 
explained 30.1% of the variance. One outlier was observed in the control group. 
These results show that the samples have different metabolite profiles over time. 
The fact that bone metabolism is increased after oestrogen withdrawal suggests 
that rapid changes observed in the metabolome are in response to the surgical 
or hormonal interventions.  
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Figure B.1: Inter-animal variation in the plasma metabolome of sheep over two 
months of the study period. PCA scatter plots derived from HILIC-MS spectra 
dataset based on normalised and autoscaled data.  Each data point represents 
the metabolite profile of a single ewe. PCA scoring plot showing the variation of 
control group (●), OVX group (●) and OVXG (●) at baseline measurement (A) 
28.1% R2 = 54.2% and Q2 = -5.5%, month one (B) 35.3%, R2 = 53.8% and Q2= 
16%, month two (C) 30.1%, R2 = 30% and Q2 = 1.8% 
 
Linear mixed model: short-term approach 
 
In this study, multiple circulating compounds were identified (annotated 
and unknown). Among the 26 features that showed significance based on the 
interaction, treatment, 18 remaining unidentified (unknown) and are presented in 
Table B.1. Changes on the plasma metabolome of the OVX sheep were 
observed, and from the statistical analysis those appeared as key features but 
remained unidentified. 
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Table B.1: List of unknown features based on the interaction, treatment and 
time of the metabolite profiles of ewes in the short-term approach.  
 
  
Mean
RT (Relative intensity, E+05) p -value
m/z (sec) Feature Trt 0 1 2 SEM Trt Time Int
126.903 493.065 Unknown Control 4.201 7.376 6.306 1.265 <0.05 <0.05 <0.05
OVX 7.757 15.257 16.797 1.103
OVXG 4.776 20.796 17.399 1.560
166.087 593.293 Unknown Control 1.667 2.454 2.589 1.455 0.423 0.001 0.006
OVX 2.316 1.981 2.877 1.224
OVXG 2.249 2.825 2.517 1.432
132.102 594.714 Unknown Control 1.117 0.694 0.896 1.117 0.176 0.070 0.033
OVX 1.097 0.885 0.964 1.097
OVXG 0.930 1.205 1.027 0.930
70.066 653.194 Unknown Control 6.856 6.341 7.334 0.594 0.040 0.107 0.041
OVX 7.384 7.436 9.296 0.514
OVXG 8.961 7.311 6.748 0.727
263.996 622.424 Unknown Control 0.431 0.363 0.380 0.055 0.041 0.217 0.050
OVX 0.577 0.385 0.447 0.047
OVXG 0.439 0.591 0.556 0.067
147.044 623.194 Unknown Control 0.373 0.970 0.448 0.094 0.003 0.395 0.001
OVX 0.467 0.875 0.526 0.081
OVXG 0.473 1.364 1.411 0.115
359.148 624.229 Unknown Control 0.367 0.412 0.417 0.043 0.007 0.061 0.036
OVX 0.379 0.277 0.414 0.037
OVXG 0.383 0.543 0.566 0.052
114.029 656.025 Unknown Control 5.875 8.047 7.622 5.875 0.287 0.001 0.005
OVX 7.857 6.315 9.771 7.857
OVXG 6.536 8.550 9.324 6.536
98.006 656.046 Unknown Control 0.298 0.416 0.397 0.038 0.762 0.000 0.016
OVX 0.367 0.326 0.489 0.033
OVXG 0.289 0.445 0.461 0.046
116.049 657.474 Unknown Control 1.667 2.454 2.589 0.202 0.423 0.001 0.006
OVX 2.316 1.981 2.877 0.175
OVXG 2.249 2.825 2.517 0.248
142.065 657.288 Unknown Control 0.368 0.533 0.566 0.050 0.932 0.067 0.001
OVX 0.525 0.416 0.581 0.043
OVXG 0.487 0.610 0.445 0.061
146.081 670.701 Unknown Control 0.975 1.017 0.776 0.102 0.026 0.094 0.044
OVX 1.107 0.792 1.081 0.089
OVXG 1.365 1.198 1.033 0.125
254.733 730.747 Unknown Control 0.907 0.666 0.486 0.085 0.524 <0.05 0.021
OVX 0.718 0.650 0.462 0.074
OVXG 1.147 0.573 0.313 0.105
124.006 797.024 Unknown Control 19.820 26.279 14.276 2.220 0.001 < 0.05 0.021
OVX 15.716 19.419 10.694 1.923
OVXG 15.567 34.766 20.146 2.720
127.050 817.752 Unknown Control 2.762 3.433 3.510 0.237 0.973 0.002 0.036
OVX 3.297 2.709 3.841 0.205
OVXG 3.060 3.140 3.497 0.290
83.060 851.458 Unknown Control 0.099 0.179 0.133 0.022 0.086 0.067 0.009
OVX 0.188 0.151 0.140 0.019
OVXG 0.174 0.238 0.183 0.027
62.963 893.059 Unknown Control 0.939 0.926 1.014 0.077 0.338 0.009 0.002
OVX 1.168 0.698 0.880 0.066
OVXG 0.923 1.023 1.119 0.094
453.924 915.178 Unknown Control 0.174 0.186 0.189 0.021 0.345 0.172 0.008
OVX 0.241 0.138 0.191 0.019
OVXG 0.172 0.223 0.241 0.026
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Effect of OVX on the metabolite profile in OVX sheep: long-term approach 
 
PCA: long-term approach 
 
To further investigate the dynamic changes on the plasma metabolome of 
OVX sheep, the metabolite profiles of all treatments groups per individual time 
point were analysed. The results from the PCA did not reveal a clear separation 
among groups when analysing the metabolite profiles per individual time point. 
PCA of the metabolite profiles obtained from the analysis of OVX sheep over five 
months are shown in Figure B.2. The resulting scatter plots showed clearly that 
animals were clustered in the middle of the plot, suggesting there were only 
modest differences between the treated animals. A modest difference can be 
noticed in the OVX group when compared with the control group at month three 
(Figure B.2D). However, the glucocorticoid-treated ewes OVXG showed a larger 
difference at month two (Figure B.2C), PC1 and PC2 explained 38.1% of the 
variance) and month three (Figure B.2D), PC1 and PC2 explained 36.6% of the 
variance) in comparison with the OVXG2 group and OVX group.  
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Figure B.2: Inter-animal variation in the plasma metabolome of sheep over five 
months of the study period. PCA scatter plots derived from HILIC-MS spectra 
dataset based on normalised and autoscaled data. Each data point represents 
the metabolite profile of a single ewe. PCA scoring plot showing the variation of 
control group (●), OVX group (●), OVXG (●) and OVXG2 ( ●) at baseline 
measurement (A) 39.2% R2 = 49.3% and Q2 = -1.3%, month one (B) 49.6%, 
R2=49.6% and Q2 = 19.2%, month two (C) 28.1%, R2 = 48.5% and Q2 = -13.8%, 
month three (D) 44.7%, R2 = 35.6% and Q2 = 0.9%, month four (E) 31.4%, R2 = 
42.9% and Q2 = -0.08% and month (F) 34.1%, R2 = 43.3% and Q2 = -0.5% 
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Linear mixed model: long-term approach 
 
The metabolites selected by linear mixed model presented a significant 
interaction between treatment and time; however, 22 remaining unidentified 
(unknown) and are presented in Table B.2. Dynamic changes on the plasma 
metabolome of the OVX sheep were noticed, and from the statistical analysis 
those appeared as key compounds but remained unidentified. This study 
intended to cover most of the metabolome for the identification and generation of 
potential diagnostic markers for postmenopausal osteoporosis. Future studies 
are needed to validate these findings and identify the source adducts or fragment 
ions.   
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Table B.2: List of unknown features based on the interaction, treatment and time of the metabolite profiles of ewes in the long-
term approach.  
Mean
m/z RT (Relative intensity, E+05) p -value
(sec) Feature Trt 0 1 2 3 4 5 SEM Trt Time Int
126.903 493.065 Unknown Control 3.519 6.812 6.257 6.638 6.098 7.815 1.860 0.001 < 0.0001 < 0.0001
OVX 8.286 14.130 18.537 16.025 13.093 15.041 1.698
OVXG 4.471 17.867 17.498 16.371 15.006 18.236 2.401
OVXG2 5.080 23.725 17.300 8.747 11.033 7.994 2.401
148.039 506.035 Unknown Control 0.336 0.929 0.499 0.859 1.066 0.578 0.929 0.098 0.003 0.013
OVX 0.696 0.898 0.396 0.695 0.983 1.146 0.898
OVXG 0.288 1.058 1.354 0.763 0.962 1.671 1.058
OVXG2 0.658 1.671 1.467 1.164 1.609 0.596 1.671
267.072 588.664 Unknown Control 2.414 1.753 2.955 3.117 2.330 3.162 0.545 0.347 < 0.0001 0.049
OVX 4.447 1.661 2.869 2.522 2.973 3.537 0.497
OVXG 6.136 1.918 2.351 2.364 1.658 3.078 0.703
OVXG2 4.513 3.661 3.893 2.595 2.824 3.738 0.703
253.966 622.590 Unknown Control 1.814 2.013 1.894 2.260 2.011 2.302 0.413 0.439 0.182 0.001
OVX 2.622 1.546 2.236 2.042 1.803 2.637 0.377
OVXG 2.275 2.442 2.513 1.430 2.162 1.638 0.533
OVXG2 2.118 2.949 2.608 2.000 2.303 2.416 0.533
117.914 623.014 Unknown Control 0.321 0.338 0.310 0.396 0.314 0.414 0.035 0.107 0.296 0.002
OVX 0.351 0.277 0.390 0.351 0.320 0.427 0.032
OVXG 0.405 0.376 0.389 0.286 0.384 0.285 0.045
OVXG2 0.323 0.520 0.466 0.451 0.399 0.400 0.045
147.044 623.194 Unknown Control 0.912 0.993 0.829 1.134 0.892 1.054 0.136 0.113 0.477 0.001
OVX 1.083 0.565 1.131 0.944 0.979 1.180 0.124
OVXG 1.190 1.306 1.343 0.580 1.065 1.025 0.176
OVXG2 1.019 1.654 1.461 1.209 1.195 1.187 0.176
359.148 624.229 Unknown Control 0.349 0.426 0.412 0.487 0.302 0.420 0.054 0.139 0.081 0.003
OVX 0.386 0.178 0.448 0.364 0.402 0.435 0.049
OVXG 0.346 0.486 0.571 0.262 0.424 0.438 0.070
OVXG2 0.419 0.599 0.561 0.386 0.488 0.424 0.070
144.044 635.951 Unknown Control 0.290 0.475 0.433 0.420 0.315 0.252 0.096 0.494 < 0.0001 < 0.0001
OVX 0.487 0.269 0.461 0.409 0.399 0.384 0.088
OVXG 0.442 0.854 0.649 0.267 0.348 0.394 0.124
OVXG2 0.526 0.824 0.910 0.371 0.290 0.173 0.124
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142.065 657.288 Unknown Control 0.275 0.560 0.568 0.609 0.496 0.505 0.065 0.588 0.202 0.007
OVX 0.445 0.327 0.568 0.464 0.454 0.507 0.060
OVXG 0.403 0.575 0.467 0.403 0.477 0.473 0.084
OVXG2 0.571 0.645 0.423 0.478 0.567 0.590 0.084
453.924 915.178 Unknown Control 0.193 0.174 0.220 0.214 0.141 0.184 0.029 0.753 0.042 0.027
OVX 0.218 0.106 0.231 0.180 0.230 0.252 0.027
OVXG 0.138 0.171 0.293 0.168 0.196 0.276 0.038
OVXG2 0.206 0.274 0.189 0.180 0.195 0.206 0.038
146.081 670.701 Unknown Control 0.857 0.839 0.706 0.861 0.769 0.965 0.162 0.058 0.259 0.035
OVX 0.912 0.657 1.175 1.072 0.998 1.227 0.148
OVXG 1.344 1.044 1.004 0.559 0.814 1.007 0.209
OVXG2 1.385 1.352 1.061 0.964 0.937 0.997 0.209
116.070 686.643 Unknown Control 0.623 0.539 0.587 0.612 0.525 0.549 0.067 0.418 0.137 0.011
OVX 0.531 0.377 0.618 0.506 0.610 0.632 0.061
OVXG 0.551 0.733 0.661 0.375 0.498 0.639 0.086
OVXG2 0.601 0.733 0.835 0.597 0.644 0.506 0.086
OVXG2 1.385 1.352 1.061 0.964 0.937 0.997 0.209
180.065 717.126 Unknown Control 1.043 1.067 1.267 1.542 1.137 1.257 0.196 0.107 0.043 0.029
OVX 1.360 0.671 1.434 1.325 1.529 1.522 0.179
OVXG 0.881 1.151 1.681 0.856 1.432 1.609 0.253
OVXG2 0.951 2.074 1.839 1.605 1.615 1.368 0.253
248.739 730.524 Unknown Control 3.215 1.964 1.799 1.312 1.023 0.969 0.259 0.620 < 0.0001 0.017
OVX 1.903 1.939 1.542 1.211 1.068 1.269 0.237
OVXG 3.173 1.841 1.023 0.878 1.005 0.989 0.335
OVXG2 3.733 1.780 0.901 0.933 0.926 1.062 0.335
107.064 766.480 Unknown Control 2.070 1.783 1.840 1.476 1.721 1.650 0.162 0.599 0.331 0.048
OVX 1.796 1.478 2.028 1.705 1.795 1.747 0.148
OVXG 1.955 2.160 1.983 1.825 1.367 1.681 0.210
OVXG2 2.151 1.824 1.417 2.079 2.052 1.917 0.210
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493.064 788.802 Unknown Control 0.133 0.119 0.105 0.136 0.078 0.062 0.018 0.872 0.042 0.007
OVX 0.111 0.122 0.125 0.074 0.130 0.121 0.017
OVXG 0.075 0.163 0.118 0.100 0.104 0.124 0.024
OVXG2 0.156 0.155 0.114 0.080 0.122 0.095 0.024
766.043 793.674 Unknown Control 20.467 22.350 17.229 8.492 10.708 11.111 0.022 0.599 0.000 0.018
OVX 14.046 17.517 11.231 7.508 14.332 12.465 0.020
OVXG 14.019 37.016 19.419 12.799 24.222 17.607 0.029
OVXG2 17.116 32.516 20.873 13.142 18.187 10.143 0.029
124.006 797.024 Unknown Control 0.609 0.752 0.749 0.859 0.593 0.849 2.476 0.009 < 0.0001 0.007
OVX 0.627 0.483 0.821 0.700 0.797 0.894 2.260
OVXG 0.537 0.558 0.721 0.480 0.695 0.723 3.196
OVXG2 0.735 0.704 0.707 0.860 0.847 0.911 3.196
109.039 817.678 Unknown Control 0.609 0.752 0.749 0.859 0.593 0.849 0.064 0.027 < 0.0001 0.037
OVX 0.627 0.483 0.821 0.700 0.797 0.894 0.058
OVXG 0.537 0.558 0.721 0.480 0.695 0.723 0.083
OVXG2 0.735 0.704 0.707 0.860 0.847 0.911 0.083
168.982 835.422 Unknown Control 0.786 0.876 0.659 0.622 0.680 0.656 0.113 0.304 0.871 0.010
OVX 0.477 0.722 0.703 0.687 0.725 0.718 0.103
OVXG 0.641 1.043 0.654 0.592 0.478 0.594 0.146
OVXG2 0.887 0.293 0.976 1.127 0.673 0.892 0.146
453.924 915.178 Unknown Control 0.193 0.174 0.220 0.214 0.141 0.184 0.029 0.753 0.042 0.027
OVX 0.218 0.106 0.231 0.180 0.230 0.252 0.027
OVXG 0.138 0.171 0.293 0.168 0.196 0.276 0.038
OVXG2 0.206 0.274 0.189 0.180 0.195 0.206 0.038
203.081 658.384 Unknown Control 1.071 1.595 1.513 1.245 1.223 1.358 0.162 0.143 0.106 0.028
OVX 1.146 0.754 1.463 1.270 1.340 1.190 0.148
OVXG 1.098 1.609 1.548 1.030 1.245 1.059 0.209
OVXG2 1.635 1.675 1.508 1.211 1.720 1.634 0.209
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Appendix C. Effect of OVX on the plasma lipidome of sheep 
 
PCA: short-term approach 
The plasma lipid profiles of all treatments groups per individual time point 
were analysed using PCA. No noticeable differences can be observed in the PCA 
over two months. At baseline, the resulting scatter plot showed that samples were 
clustered in the middle of the plot (Figure C.1A, PC1 and PC2, explained 72.8% 
of the variance). Two outliers were observed from the OVX group. At month one, 
a smaller difference between OVX and control was observed (Figure C.1B, PC1 
and PC2, explained 68.6% of the variance), where two outliers from the OVXG 
group were noticed. However, at two months the scatter plots did not reveal 
differences among the treatment groups (Figure C.1C, PC1 and PC2, explained 
64.7% of the variance). 
 
Figure C.1: Inter-animal variation in the plasma lipidome of sheep over two 
months of the study period. PCA scatter plots derived from UHPLC-MS spectra 
dataset based on normalised and autoscaled data. Each data point represents 
the lipid profile of a single ewe. PCA scoring plot showing the variation of control 
group (●), OVX group (●) and OVXG (●) at baseline measurement (A) 71.8% R2 
= 72.6% and Q2 = 64.9%, month one (B) 68.6%, R2 = 74.9% and Q2 = 60.4%, 
month two (C) 64.7%, R2 = 72.7% and Q2 = 49.9% 
Linear mixed model: short-term approach 
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In this study, multiple circulating compounds were identified (annotated 
and unknown). Among the 48 features that showed significance based on the 
interaction, treatment and time, 43 remaining unidentified (unknown) and are 
presented in Table C.1.  
Table C.1: List of unknown features based on the interaction, treatment and 
time of the lipid profile of ewes in the short-term approach.  
 
 
 
 
Mean
RT (Relative intensity, E+05) p -value
m/z (sec) Feature Trt 0 1 2 SEM Trt Time Int
301.166 101.547 Unknown Control 1.189 1.197 1.332 0.098 0.004 0.051 0.009
OVX 1.880 1.398 1.318 0.098
OVXG 1.281 1.398 1.171 0.098
347.172 101.676 Unknown Control 4.116 4.115 4.537 0.339 0.003 0.029 0.011
OVX 6.508 4.889 4.500 0.339
OVXG 4.512 4.788 3.962 0.339
599.360 104.805 Unknown Control 0.987 1.010 1.107 0.093 0.019 0.026 0.012
OVX 1.590 1.107 1.039 0.093
OVXG 1.059 1.063 0.933 0.093
473.284 183.588 Unknown Control 1.460 1.457 1.526 0.078 0.003 0.003 0.003
OVX 2.058 1.641 1.500 0.078
OVXG 1.589 1.662 1.376 0.078
413.246 183.599 Unknown Control 0.776 0.821 0.885 0.059 0.005 0.034 0.002
OVX 1.231 0.924 0.851 0.059
OVXG 0.867 0.942 0.781 0.059
666.537 183.605 Unknown Control 8.502 8.294 9.521 0.518 0.047 0.047 0.005
OVX 11.736 9.582 8.475 0.518
OVXG 9.360 9.573 8.838 0.518
736.525 183.608 Unknown Control 1.443 1.491 1.554 0.073 0.045 0.008 0.001
OVX 1.980 1.560 1.427 0.073
OVXG 1.554 1.568 1.472 0.073
803.510 183.612 Unknown Control 0.923 1.013 1.070 0.058 0.034 0.185 0.007
OVX 1.303 1.077 1.031 0.058
OVXG 1.086 1.136 0.922 0.058
477.344 209.901 Unknown Control 5.891 5.862 6.370 0.337 0.012 0.016 0.006
OVX 8.218 6.603 5.973 0.337
OVXG 6.358 6.419 5.864 0.337
404.309 221.664 Unknown Control 71.500 70.778 76.639 4.135 0.052 0.059 0.041
OVX 93.896 79.302 72.789 4.135
OVXG 78.722 80.643 69.454 4.135
441.277 221.673 Unknown Control 4.829 4.901 5.111 0.222 0.019 0.036 0.018
OVX 6.228 5.280 5.031 0.222
OVXG 5.255 5.433 4.645 0.222
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407.293 241.746 Unknown Control 0.481 0.466 0.515 0.031 0.041 0.066 0.031
OVX 0.650 0.528 0.481 0.031
OVXG 0.490 0.515 0.465 0.031
569.114 251.228 Unknown Control 1.808 1.754 1.934 0.138 0.012 0.025 0.037
OVX 2.570 2.038 1.852 0.138
OVXG 1.898 1.962 1.465 0.138
721.928 252.497 Unknown Control 1.020 1.000 1.148 0.058 0.015 0.456 0.048
OVX 1.328 1.162 1.124 0.058
OVXG 1.081 1.163 1.015 0.058
448.442 252.565 Unknown Control 1.519 1.472 1.593 0.084 0.017 0.043 0.050
OVX 1.995 1.687 1.557 0.084
OVXG 1.637 1.686 1.477 0.084
454.385 252.671 Unknown Control 3.065 3.038 3.275 0.151 0.006 0.085 0.037
OVX 3.996 3.444 3.283 0.151
OVXG 3.357 3.471 2.994 0.151
446.353 252.783 Unknown Control 2.742 2.714 2.909 0.130 0.020 0.073 0.032
OVX 3.491 2.992 2.884 0.130
OVXG 2.990 3.116 2.647 0.130
444.356 252.784 Unknown Control 4.597 4.566 4.882 0.215 0.010 0.054 0.041
OVX 5.890 5.115 4.817 0.215
OVXG 5.010 5.044 4.430 0.215
431.337 263.058 Unknown Control 2.063 1.971 2.169 0.122 0.067 0.018 0.034
OVX 2.731 2.175 2.032 0.122
OVXG 2.190 2.168 2.003 0.122
564.345 273.277 Unknown Control 2.795 2.810 2.957 0.134 0.003 0.027 0.028
OVX 3.736 3.160 3.004 0.134
OVXG 3.135 3.119 2.770 0.134
698.436 287.913 Unknown Control 0.906 0.908 0.942 0.059 0.014 0.028 0.037
OVX 1.218 0.965 0.944 0.059
OVXG 0.926 0.973 0.719 0.059
459.370 308.910 Unknown Control 1.804 1.779 2.007 0.099 0.042 0.071 0.013
OVX 2.382 2.038 1.827 0.099
OVXG 1.986 1.961 1.797 0.099
460.373 308.921 Unknown Control 0.457 0.450 0.482 0.026 0.023 0.013 0.014
OVX 0.618 0.511 0.449 0.026
OVXG 0.489 0.496 0.444 0.026
487.400 358.665 Unknown Control 1.202 1.112 1.226 0.064 0.420 0.013 0.031
OVX 1.454 1.227 1.068 0.064
OVXG 1.216 1.255 1.108 0.064
474.403 388.188 Unknown Control 4.694 4.661 4.864 0.186 0.014 0.052 0.041
OVX 5.788 5.122 4.825 0.186
OVXG 4.984 5.205 4.620 0.186
473.400 388.236 Unknown Control 14.156 13.953 14.552 0.537 0.009 0.018 0.024
OVX 17.569 15.330 14.441 0.537
OVXG 15.136 15.622 13.944 0.537
520.409 388.282 Unknown Control 3.724 3.707 3.911 0.145 0.006 0.126 0.017
OVX 4.644 4.109 3.863 0.145
OVXG 3.788 4.069 3.752 0.145
748.720 403.700 Unknown Control 49.719 47.990 54.849 2.778 0.042 0.082 0.007
OVX 64.615 50.371 52.710 2.778
OVXG 48.697 54.006 44.549 2.778
777.762 448.533 Unknown Control 0.615 0.611 0.617 0.020 0.039 0.037 0.041
OVX 0.725 0.630 0.616 0.020
OVXG 0.653 0.680 0.646 0.020
738.371 480.261 Unknown Control 0.639 0.621 0.724 0.033 0.006 < 0.0001 0.028
OVX 0.807 0.665 0.746 0.033
OVXG 0.744 0.513 0.600 0.033
1270.904 480.311 Unknown Control 0.339 0.321 0.380 0.015 0.247 < 0.0001 0.003
OVX 0.361 0.328 0.363 0.015
OVXG 0.386 0.238 0.334 0.015
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Effect of OVX on the plasma lipidome of sheep: long-term approach 
 
PCA: long-term approach 
 
The resulting scatter plots did not show a clear separation among groups 
when analysing the lipid profiles per individual time point. PCA of the lipid profiles 
obtained from the analysis of OVX sheep over five months are shown in Figure 
C.2. A modest difference can be noticed in the OVXG sheep (Figure C.2D, PC1 
and PC2 explained 74.4% of the variance) when compared with OVXG2. At 
month five, the scatter plots showed a smaller separation between the OVX group 
(Figure C.2F, PC1 and PC2 explained 74.4% of the variance) when compared 
with the control 
603.476 480.371 Unknown Control 2.468 2.443 2.738 0.108 0.004 0.014 0.039
OVX 3.035 2.625 2.671 0.108
OVXG 2.746 2.172 2.278 0.108
675.667 517.916 Unknown Control 2.784 2.955 3.096 0.112 0.175 0.359 0.038
OVX 3.336 3.100 2.922 0.112
OVXG 3.166 2.970 2.774 0.112
759.761 598.998 Unknown Control 3.191 3.316 3.486 0.103 0.250 0.602 0.038
OVX 3.698 3.428 3.326 0.103
OVXG 3.450 3.490 3.263 0.103
656.636 643.039 Unknown Control 5.546 5.868 6.061 0.179 0.019 0.508 0.028
OVX 6.714 6.163 6.007 0.179
OVXG 6.199 6.190 5.858 0.179
661.688 748.059 Unknown Control 62.976 57.301 61.303 2.377 0.653 < 0.0001 0.030
OVX 70.931 57.483 53.215 2.377
OVXG 68.696 54.673 52.120 2.377
689.719 755.548 Unknown Control 66.210 62.860 69.761 2.104 0.513 0.003 0.008
OVX 73.157 65.679 60.308 2.104
OVXG 69.649 61.873 60.682 2.104
1365.857 394.415 Unknown Control 0.321 0.339 0.379 0.023 0.730 0.366 0.035
OVX 0.400 0.348 0.340 0.023
OVXG 0.404 0.374 0.309 0.023
1385.971 394.562 Unknown Control 0.809 0.799 0.810 0.042 0.038 0.019 0.041
OVX 1.029 0.838 0.821 0.042
OVXG 0.831 0.889 0.725 0.042
1344.933 394.803 Unknown Control 76.625 76.536 76.360 3.471 0.023 0.017 0.039
OVX 96.270 80.389 78.735 3.471
OVXG 79.118 84.237 71.146 3.471
1342.926 394.862 Unknown Control 177.912 177.928 177.483 8.168 0.028 0.017 0.037
OVX 223.999 186.159 183.731 8.168
OVXG 184.501 195.778 165.176 8.168
1343.930 394.862 Unknown Control 163.231 163.704 163.149 7.689 0.032 0.022 0.038
OVX 205.803 171.151 168.513 7.689
OVXG 169.094 181.029 151.400 7.689
1346.938 394.919 Unknown Control 6.363 6.354 6.304 0.311 0.051 0.022 0.043
OVX 8.006 6.577 6.558 0.311
OVXG 6.637 7.112 5.934 0.311
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Figure C.2: Inter-animal variation in the plasma lipidome of sheep over five 
months of the study period. PCA scatter plots derived from UHPLC-MS spectra 
dataset based on normalised and autoscaled data.  Each data point represents 
the lipid profile of a single ewe. PCA scoring plot showing the variation of control 
group (●), OVX group (●), OVXG (●) and OVXG2 ( ●) at baseline measurement 
(A) 76.9% R2 = 76.8% and Q2 = 52.9%, month one (B) 73.4%, R2 = 49.6% and 
Q2= 19.2%, month two (C) 70.1%, R2 = 82.5% and Q2 = 51.1%, month three (D) 
74.4%, R2 = 74.5% and Q2 = 61.2%, month four (E) 59.3%, R2 = 59.3% and Q2 
= 35.5% and month (F) 69.9%, R2 = 69.9% and Q2 = 56.1% 
 
Linear mixed model: long-term approach 
 
The metabolites selected by linear mixed model presented a significant 
interaction between treatment and time; however, 112 remaining unidentified 
(unknown) and are presented in Table C.2.  
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Table C.2: List of unknown features based on the interaction, treatment and time of the lipid profile of ewes in the long-term 
approach.  
 
Mean
m/z RT (Relative intensity, E+05) p -value
(sec) Feature Trt 0 1 2 3 4 5 SEM Trt Time Int
393.054 48.306 Unknown Control 1.756 1.872 2.302 1.802 1.885 1.979 0.164 0.014 0.003 0.001
OVX 2.872 2.177 1.889 2.414 1.720 2.162 0.134
OVXG 2.213 1.876 1.790 2.278 1.877 1.704 0.190
OVXG2 1.948 2.252 1.860 1.889 1.695 1.877 0.190
347.172 101.676 Unknown Control 3.991 3.622 4.878 4.204 4.407 4.935 0.563 0.056 0.036 0.005
OVX 7.297 5.074 3.907 5.904 4.123 4.507 0.460
OVXG 4.750 4.416 3.567 5.302 5.044 3.961 0.650
OVXG2 4.273 5.160 4.358 4.425 4.088 4.263 0.650
640.149 125.909 Unknown Control 0.547 0.457 0.616 0.517 0.576 0.643 0.065 0.037 0.035 0.015
OVX 0.936 0.635 0.507 0.736 0.550 0.608 0.059
OVXG 0.611 0.547 0.468 0.637 0.653 0.549 0.084
OVXG2 0.518 0.660 0.473 0.560 0.524 0.555 0.084
763.204 171.958 Unknown Control 4.998 4.693 5.872 5.547 5.489 5.934 0.474 0.089 0.043 0.022
OVX 7.428 5.896 4.947 6.286 4.774 5.529 0.387
OVXG 5.656 4.848 4.860 5.547 5.344 4.823 0.547
OVXG2 5.085 5.504 4.724 5.358 4.739 5.672 0.547
701.428 178.166 Unknown Control 14.861 12.352 15.012 16.049 15.794 18.281 1.726 0.116 0.028 0.027
OVX 24.694 17.230 13.411 18.691 14.550 14.827 1.576
OVXG 15.732 14.849 13.938 15.000 17.049 14.168 2.228
OVXG2 14.272 16.479 12.537 15.371 14.067 15.769 2.228
692.403 178.192 Unknown Control 8.586 7.088 8.716 8.880 8.974 10.562 1.121 0.111 0.037 0.039
OVX 14.053 9.888 7.848 10.795 8.224 8.884 0.915
OVXG 8.899 8.402 7.918 8.696 9.699 8.228 1.294
OVXG2 8.180 9.603 7.117 8.797 8.070 9.256 1.294
673.375 179.623 Unknown Control 0.327 0.311 0.422 0.317 0.379 0.397 0.038 0.160 0.236 0.017
OVX 0.523 0.389 0.324 0.440 0.321 0.382 0.034
OVXG 0.378 0.332 0.285 0.388 0.376 0.357 0.049
OVXG2 0.337 0.430 0.294 0.351 0.323 0.347 0.049
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473.284 183.588 Unknown Control 1.440 1.369 1.676 1.383 1.493 1.531 0.123 0.016 0.004 0.002
OVX 2.184 1.663 1.424 1.870 1.360 1.695 0.100
OVXG 1.681 1.498 1.341 1.734 1.481 1.398 0.142
OVXG2 1.498 1.825 1.410 1.499 1.377 1.503 0.142
413.246 183.599 Unknown Control 0.746 0.773 0.988 0.761 0.860 0.843 0.081 0.029 0.064 0.003
OVX 1.305 0.949 0.804 1.076 0.763 0.934 0.074
OVXG 0.938 0.823 0.762 0.997 0.853 0.771 0.104
OVXG2 0.797 1.061 0.799 0.841 0.742 0.813 0.104
666.537 183.605 Unknown Control 8.134 8.056 10.679 8.240 9.029 9.311 0.716 0.172 0.252 0.006
OVX 12.236 9.714 7.879 10.440 8.408 10.103 0.654
OVXG 9.866 8.826 8.444 10.276 9.086 8.665 0.925
OVXG2 8.854 10.321 9.232 8.883 8.275 8.254 0.925
667.534 183.607 Unknown Control 35.479 34.395 46.632 33.353 39.300 40.819 3.557 0.395 0.078 0.002
OVX 56.479 41.626 33.401 42.542 32.827 44.271 3.247
OVXG 42.030 38.136 32.569 43.633 39.281 37.385 4.593
OVXG2 37.903 41.656 39.905 38.475 36.104 36.383 4.593
736.525 183.608 Unknown Control 35.479 34.395 46.632 33.353 39.300 40.819 3.557 0.395 0.078 0.002
OVX 56.479 41.626 33.401 42.542 32.827 44.271 3.247
OVXG 42.030 38.136 32.569 43.633 39.281 37.385 4.593
OVXG2 37.903 41.656 39.905 38.475 36.104 36.383 4.593
669.540 183.610 Unknown Control 3.748 3.580 4.264 3.597 3.956 4.205 0.338 0.028 0.087 0.027
OVX 5.697 4.328 3.791 4.842 3.650 4.554 0.309
OVXG 3.971 3.660 3.366 4.499 4.088 3.716 0.437
OVXG2 3.898 4.607 4.063 4.007 3.514 3.951 0.437
734.524 183.610 Unknown Control 0.704 0.682 0.831 0.710 0.770 0.788 0.055 0.098 0.037 0.010
OVX 1.041 0.775 0.702 0.865 0.703 0.816 0.050
OVXG 0.815 0.741 0.617 0.847 0.736 0.726 0.070
OVXG2 0.749 0.813 0.780 0.770 0.675 0.669 0.070
365.246 183.610 Unknown Control 27.759 26.539 35.022 26.807 29.645 31.341 2.539 0.024 0.020 0.003
OVX 44.526 33.455 27.838 37.716 26.721 34.067 2.317
OVXG 33.418 29.464 26.622 33.894 30.060 27.096 3.277
OVXG2 29.646 34.525 28.494 29.565 26.595 29.400 3.277
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753.515 183.612 Unknown Control 1.432 1.393 1.619 1.442 1.519 1.465 0.091 0.081 0.108 0.041
OVX 1.869 1.609 1.399 1.772 1.391 1.686 0.083
OVXG 1.614 1.516 1.407 1.624 1.490 1.445 0.118
OVXG2 1.499 1.718 1.522 1.537 1.445 1.452 0.118
375.275 183.618 Unknown Control 11.981 11.215 15.739 11.584 12.565 13.464 1.284 0.060 0.044 0.005
OVX 19.985 14.227 11.919 16.357 11.761 14.101 1.172
OVXG 13.995 12.670 11.750 15.576 13.074 11.483 1.658
OVXG2 12.628 15.049 13.162 12.743 11.188 12.380 1.658
788.433 183.646 Unknown Control 0.218 0.183 0.251 0.174 0.211 0.230 0.024 0.017 0.014 0.020
OVX 0.344 0.243 0.200 0.283 0.204 0.243 0.022
OVXG 0.237 0.192 0.172 0.232 0.203 0.176 0.031
OVXG2 0.227 0.281 0.204 0.224 0.180 0.216 0.031
477.344 209.901 Unknown Control 5.852 5.355 7.060 5.774 6.087 6.476 0.555 0.070 0.051 0.007
OVX 8.855 6.760 5.533 7.417 5.817 6.503 0.453
OVXG 6.737 5.940 5.572 6.801 6.487 5.719 0.640
OVXG2 5.980 6.897 6.156 6.034 5.563 5.830 0.640
478.347 209.908 Unknown Control 1.519 1.404 1.866 1.457 1.579 1.726 0.166 0.090 0.075 0.038
OVX 2.337 1.765 1.444 1.934 1.504 1.721 0.136
OVXG 1.758 1.564 1.452 1.841 1.613 1.491 0.192
OVXG2 1.556 1.649 1.548 1.595 1.411 1.587 0.192
447.333 213.997 Unknown Control 5.621 4.959 6.991 5.509 6.143 6.124 0.572 0.087 0.095 0.019
OVX 8.429 6.462 5.457 7.502 5.229 6.936 0.522
OVXG 6.468 5.562 5.029 6.784 5.950 6.078 0.738
OVXG2 5.700 7.060 5.471 5.666 5.327 5.961 0.738
448.336 214.001 Unknown Control 5.621 4.959 6.991 5.509 6.143 6.124 0.572 0.087 0.095 0.019
OVX 8.429 6.462 5.457 7.502 5.229 6.936 0.522
OVXG 6.468 5.562 5.029 6.784 5.950 6.078 0.738
OVXG2 5.700 7.060 5.471 5.666 5.327 5.961 0.738
437.304 214.021 Unknown Control 5.194 4.331 6.289 4.982 5.801 5.727 0.551 0.078 0.078 0.034
OVX 7.771 5.819 4.945 6.905 4.876 6.639 0.503
OVXG 5.882 4.972 4.566 5.964 5.463 6.062 0.711
OVXG2 5.200 6.266 5.045 5.219 5.060 5.417 0.711
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792.586 221.633 Unknown Control 11.726 10.835 13.083 11.250 11.989 11.786 0.549 0.133 0.117 0.013
OVX 14.066 12.382 11.210 13.113 11.282 12.676 0.501
OVXG 12.910 11.560 11.093 12.563 11.522 11.566 0.709
OVXG2 11.649 13.083 11.742 11.380 11.487 11.085 0.709
779.580 221.664 Unknown Control 4.044 4.187 4.892 4.148 4.409 4.467 0.252 0.359 0.275 0.009
OVX 5.459 4.787 4.164 4.771 4.141 4.565 0.230
OVXG 4.926 4.133 3.965 4.759 4.337 4.250 0.326
OVXG2 4.189 4.695 4.710 4.474 4.236 4.329 0.326
404.309 221.664 Unknown Control 70.142 66.871 85.500 67.215 73.353 75.976 6.645 0.082 0.045 0.009
OVX 102.490 81.825 68.638 89.415 66.879 83.019 5.426
OVXG 83.255 71.617 66.458 85.745 74.676 68.075 7.673
OVXG2 74.189 89.668 72.449 71.868 64.760 73.878 7.673
502.223 221.667 Unknown Control 9.470 9.300 11.669 9.386 10.012 10.371 0.861 0.078 0.033 0.013
OVX 14.298 11.435 9.836 12.515 9.189 11.111 0.786
OVXG 11.870 10.107 9.765 12.097 10.313 9.028 1.111
OVXG2 10.255 12.728 9.836 9.912 8.579 10.528 1.111
403.306 221.672 Unknown Control 285.696 272.442 352.203 276.164 294.542 307.960 22.911 0.082 0.050 0.007
OVX 411.923 329.323 280.845 357.967 275.814 332.016 20.915
OVXG 331.762 292.404 276.130 343.566 300.957 269.735 29.578
OVXG2 301.835 362.476 298.482 291.658 265.403 288.697 29.578
441.277 221.673 Unknown Control 4.728 4.674 5.531 4.607 4.806 4.845 0.315 0.026 0.020 0.010
OVX 6.551 5.352 4.831 5.929 4.714 5.274 0.288
OVXG 5.467 4.911 4.470 5.455 5.059 4.377 0.407
OVXG2 5.043 5.955 4.820 4.775 4.404 4.819 0.407
407.293 241.746 Unknown Control 0.480 0.431 0.580 0.449 0.474 0.513 0.044 0.091 0.087 0.018
OVX 0.714 0.535 0.444 0.583 0.443 0.550 0.041
OVXG 0.526 0.473 0.428 0.504 0.507 0.494 0.057
OVXG2 0.455 0.557 0.501 0.457 0.440 0.474 0.057
1060.510 241.887 Unknown Control 4.530 4.651 5.596 5.613 5.080 6.393 0.510 0.190 0.547 0.015
OVX 7.245 5.790 4.969 5.788 4.989 4.883 0.466
OVXG 5.406 4.704 5.173 5.640 5.416 3.891 0.659
OVXG2 4.496 5.442 4.409 4.833 4.485 5.917 0.659
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819.409 249.809 Unknown Control 4.530 4.651 5.596 5.613 5.080 6.393 0.510 0.190 0.547 0.015
OVX 7.245 5.790 4.969 5.788 4.989 4.883 0.466
OVXG 5.406 4.704 5.173 5.640 5.416 3.891 0.659
OVXG2 4.496 5.442 4.409 4.833 4.485 5.917 0.659
818.406 249.822 Unknown Control 2.652 2.178 2.987 2.943 2.792 3.256 0.344 0.286 0.145 0.021
OVX 4.165 3.064 2.426 3.415 2.664 2.673 0.314
OVXG 3.010 2.546 1.953 3.143 3.665 2.016 0.445
OVXG2 2.572 3.108 2.711 2.460 2.353 2.973 0.445
639.245 250.058 Unknown Control 0.132 0.109 0.148 0.159 0.144 0.157 0.016 0.031 0.006 0.020
OVX 0.227 0.170 0.124 0.185 0.132 0.155 0.014
OVXG 0.155 0.150 0.114 0.186 0.169 0.127 0.020
OVXG2 0.140 0.143 0.127 0.139 0.121 0.138 0.020
578.141 250.419 Unknown Control 1.781 1.434 2.063 1.595 1.823 2.057 0.216 0.161 0.142 0.043
OVX 2.758 2.091 1.696 2.361 1.692 1.812 0.197
OVXG 2.045 1.826 1.459 2.212 2.115 1.588 0.279
OVXG2 1.754 2.057 1.710 1.822 1.759 1.847 0.279
506.243 251.023 Unknown Control 1.781 1.434 2.063 1.595 1.823 2.057 0.216 0.161 0.142 0.043
OVX 2.758 2.091 1.696 2.361 1.692 1.812 0.197
OVXG 2.045 1.826 1.459 2.212 2.115 1.588 0.279
OVXG2 1.754 2.057 1.710 1.822 1.759 1.847 0.279
479.224 251.122 Unknown Control 17.033 14.760 19.691 17.411 17.467 19.598 1.866 0.101 0.045 0.031
OVX 27.322 20.058 16.131 22.325 16.678 18.063 1.703
OVXG 19.596 17.549 14.503 20.296 20.627 16.288 2.409
OVXG2 17.439 19.629 16.472 17.361 16.194 17.616 2.409
569.114 251.228 Unknown Control 1.774 1.556 2.138 1.827 1.852 2.041 0.212 0.106 0.057 0.026
OVX 2.833 2.110 1.669 2.435 1.666 1.903 0.194
OVXG 2.117 1.829 1.421 2.130 2.182 1.640 0.274
OVXG2 1.679 2.094 1.509 1.808 1.685 1.843 0.274
853.625 251.513 Unknown Control 3.403 2.951 3.698 3.893 3.701 4.077 0.428 0.387 0.153 0.047
OVX 5.384 3.977 3.209 4.441 3.104 3.258 0.391
OVXG 3.900 3.432 3.418 3.918 4.427 3.233 0.552
OVXG2 3.189 4.105 3.160 3.345 3.153 3.582 0.552
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854.628 251.513 Unknown Control 1.683 1.380 1.975 1.708 1.726 1.997 0.198 0.121 0.144 0.032
OVX 2.685 2.007 1.668 2.272 1.634 1.888 0.181
OVXG 1.845 1.856 1.433 2.073 2.264 1.764 0.255
OVXG2 1.830 1.979 1.783 1.826 1.630 1.822 0.255
444.249 251.550 Unknown Control 42.201 35.656 50.628 42.839 43.262 49.151 5.071 0.130 0.078 0.026
OVX 70.318 49.896 39.270 55.000 41.536 44.827 4.629
OVXG 48.064 43.298 36.776 50.030 52.202 40.944 6.546
OVXG2 42.755 48.595 42.192 43.231 40.346 42.430 6.546
359.153 251.554 Unknown Control 5.252 4.408 6.367 5.381 5.485 6.088 0.644 0.104 0.062 0.020
OVX 8.923 6.264 4.838 6.994 5.197 5.637 0.588
OVXG 6.103 5.391 4.648 6.223 6.371 5.085 0.832
OVXG2 5.268 6.226 5.185 5.333 4.947 5.286 0.832
490.255 251.555 Unknown Control 6.731 5.764 7.983 6.707 6.988 7.696 0.799 0.103 0.046 0.025
OVX 11.278 8.014 6.244 8.874 6.575 7.244 0.730
OVXG 7.979 6.991 5.810 7.944 8.139 6.550 1.032
OVXG2 6.896 7.965 6.660 6.869 6.364 6.782 1.032
443.248 251.556 Unknown Control 113.328 97.091 136.148 115.358 116.801 131.616 13.340 0.132 0.083 0.027
OVX 187.088 133.448 105.980 148.464 111.951 120.497 12.178
OVXG 129.386 116.553 99.853 134.418 139.059 110.784 17.222
OVXG2 114.923 132.085 114.175 116.190 107.918 113.821 17.222
427.215 251.563 Unknown Control 4.977 4.228 5.944 5.059 5.182 5.794 0.618 0.147 0.082 0.034
OVX 8.285 5.834 4.526 6.482 4.909 5.333 0.565
OVXG 5.811 5.085 4.329 6.077 6.063 4.771 0.798
OVXG2 4.853 5.865 4.866 5.045 4.646 4.943 0.798
1148.365 252.397 Unknown Control 0.754 0.751 0.858 0.757 0.787 0.807 0.037 0.278 0.340 0.037
OVX 0.921 0.835 0.756 0.815 0.720 0.849 0.034
OVXG 0.767 0.763 0.792 0.819 0.769 0.779 0.048
OVXG2 0.750 0.837 0.812 0.788 0.741 0.713 0.048
1069.420 252.413 Unknown Control 0.705 0.723 0.864 0.717 0.761 0.785 0.045 0.179 0.188 0.028
OVX 0.912 0.847 0.719 0.819 0.715 0.836 0.041
OVXG 0.818 0.756 0.748 0.810 0.730 0.704 0.058
OVXG2 0.762 0.865 0.784 0.769 0.660 0.681 0.058
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1147.361 252.436 Unknown Control 1.534 1.503 1.695 1.458 1.635 1.499 0.068 0.114 0.032 0.024
OVX 1.835 1.690 1.495 1.634 1.486 1.656 0.062
OVXG 1.729 1.519 1.588 1.579 1.327 1.492 0.088
OVXG2 1.573 1.580 1.625 1.501 1.495 1.496 0.088
806.891 252.449 Unknown Control 1.193 1.158 1.352 1.168 1.259 1.211 0.068 0.033 0.085 0.034
OVX 1.573 1.379 1.223 1.373 1.196 1.350 0.062
OVXG 1.372 1.223 1.264 1.347 1.154 1.207 0.088
OVXG2 1.199 1.410 1.289 1.275 1.142 1.237 0.088
782.898 252.449 Unknown Control 1.471 1.476 1.782 1.427 1.596 1.602 0.108 0.051 0.097 0.012
OVX 2.142 1.733 1.510 1.812 1.471 1.741 0.099
OVXG 1.811 1.544 1.570 1.652 1.591 1.545 0.140
OVXG2 1.554 1.734 1.661 1.601 1.492 1.372 0.140
727.945 252.462 Unknown Control 2.686 2.666 3.226 2.731 2.963 2.960 0.186 0.045 0.102 0.010
OVX 3.807 3.125 2.714 3.365 2.713 3.225 0.170
OVXG 3.116 2.825 2.816 3.046 2.816 2.649 0.240
OVXG2 2.919 3.292 2.848 2.841 2.565 2.776 0.240
805.887 252.507 Unknown Control 3.027 2.890 3.453 3.021 3.202 3.011 0.161 0.172 0.043 0.046
OVX 3.790 3.384 3.067 3.489 2.980 3.050 0.147
OVXG 3.389 3.159 3.201 3.015 3.044 2.968 0.208
OVXG2 3.113 3.555 3.123 3.081 2.881 2.921 0.208
863.919 252.510 Unknown Control 0.599 0.595 0.777 0.636 0.667 0.694 0.047 0.043 0.068 0.008
OVX 0.880 0.711 0.679 0.798 0.583 0.758 0.043
OVXG 0.731 0.665 0.602 0.724 0.627 0.619 0.061
OVXG2 0.655 0.739 0.710 0.589 0.611 0.680 0.061
387.475 252.510 Unknown Control 0.599 0.595 0.777 0.636 0.667 0.694 0.047 0.043 0.068 0.008
OVX 0.880 0.711 0.679 0.798 0.583 0.758 0.043
OVXG 0.731 0.665 0.602 0.724 0.627 0.619 0.061
OVXG2 0.655 0.739 0.710 0.589 0.611 0.680 0.061
522.446 252.513 Unknown Control 1.206 1.146 1.416 1.152 1.263 1.317 0.093 0.015 0.072 0.017
OVX 1.742 1.402 1.210 1.513 1.177 1.411 0.085
OVXG 1.318 1.243 1.115 1.320 1.265 1.112 0.120
OVXG2 1.238 1.427 1.186 1.210 1.092 1.232 0.120
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356.458 252.520 Unknown Control 0.496 0.481 0.640 0.493 0.545 0.566 0.046 0.040 0.050 0.013
OVX 0.770 0.623 0.540 0.647 0.489 0.607 0.042
OVXG 0.646 0.537 0.500 0.587 0.531 0.516 0.060
OVXG2 0.545 0.670 0.515 0.528 0.458 0.500 0.060
386.471 252.521 Unknown Control 0.496 0.481 0.640 0.493 0.545 0.566 0.046 0.040 0.050 0.013
OVX 0.770 0.623 0.540 0.647 0.489 0.607 0.042
OVXG 0.646 0.537 0.500 0.587 0.531 0.516 0.060
OVXG2 0.545 0.670 0.515 0.528 0.458 0.500 0.060
354.460 252.537 Unknown Control 1.610 1.595 2.023 1.565 1.757 1.738 0.143 0.039 0.057 0.010
OVX 2.443 1.965 1.656 2.120 1.556 1.990 0.131
OVXG 1.993 1.698 1.677 1.900 1.755 1.560 0.185
OVXG2 1.733 2.095 1.670 1.703 1.468 1.699 0.185
464.414 252.564 Unknown Control 5.897 5.723 7.193 5.850 6.293 6.441 0.469 0.032 0.053 0.012
OVX 8.693 7.085 6.169 7.571 5.738 7.062 0.428
OVXG 6.971 6.284 5.950 7.026 6.361 5.734 0.606
OVXG2 6.398 7.528 6.027 6.142 5.621 6.181 0.606
448.442 252.565 Unknown Control 1.464 1.349 1.727 1.414 1.536 1.565 0.115 0.015 0.033 0.009
OVX 2.171 1.732 1.502 1.882 1.419 1.747 0.105
OVXG 1.726 1.527 1.480 1.701 1.541 1.409 0.149
OVXG2 1.548 1.845 1.474 1.501 1.399 1.518 0.149
454.459 252.610 Unknown Control 2.876 2.714 3.445 2.813 3.002 3.112 0.228 0.016 0.032 0.012
OVX 4.202 3.440 2.940 3.708 2.786 3.394 0.208
OVXG 3.358 2.973 2.795 3.241 3.007 2.675 0.295
OVXG2 3.029 3.588 2.855 2.912 2.592 2.986 0.295
624.738 252.610 Unknown Control 0.665 0.606 0.732 0.621 0.712 0.683 0.045 0.019 0.541 0.045
OVX 0.807 0.735 0.665 0.775 0.665 0.787 0.041
OVXG 0.733 0.676 0.678 0.643 0.653 0.611 0.058
OVXG2 0.638 0.827 0.600 0.611 0.569 0.622 0.058
365.492 252.612 Unknown Control 1.032 0.971 1.360 0.986 1.070 1.105 0.104 0.054 0.035 0.010
OVX 1.620 1.241 1.034 1.346 0.962 1.282 0.095
OVXG 1.265 1.074 1.020 1.175 1.073 0.963 0.135
OVXG2 1.109 1.350 1.108 1.065 0.943 1.027 0.135
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532.401 252.632 Unknown Control 2.747 2.632 3.239 2.713 2.908 2.957 0.224 0.065 0.061 0.023
OVX 3.911 3.226 2.685 3.503 2.643 3.247 0.204
OVXG 3.231 2.861 2.747 3.176 2.923 2.656 0.289
OVXG2 2.911 3.486 2.623 2.814 2.604 2.823 0.289
454.385 252.671 Unknown Control 2.973 2.868 3.552 2.962 3.148 3.230 0.217 0.013 0.055 0.018
OVX 4.280 3.563 3.197 3.811 2.951 3.580 0.198
OVXG 3.465 3.197 2.973 3.516 3.123 2.861 0.281
OVXG2 3.248 3.746 3.014 3.115 2.918 3.169 0.281
872.870 252.697 Unknown Control 0.700 0.702 0.862 0.712 0.723 0.771 0.056 0.038 0.309 0.017
OVX 0.990 0.835 0.749 0.866 0.706 0.892 0.051
OVXG 0.834 0.778 0.713 0.830 0.762 0.586 0.072
OVXG2 0.726 0.899 0.777 0.720 0.745 0.738 0.072
462.419 252.707 Unknown Control 0.700 0.702 0.862 0.712 0.723 0.771 0.056 0.038 0.309 0.017
OVX 0.990 0.835 0.749 0.866 0.706 0.892 0.051
OVXG 0.834 0.778 0.713 0.830 0.762 0.586 0.072
OVXG2 0.726 0.899 0.777 0.720 0.745 0.738 0.072
385.465 252.714 Unknown Control 0.695 0.667 0.846 0.669 0.738 0.741 0.055 0.008 0.047 0.010
OVX 1.024 0.832 0.732 0.902 0.700 0.841 0.050
OVXG 0.844 0.729 0.690 0.790 0.714 0.652 0.071
OVXG2 0.714 0.881 0.700 0.714 0.622 0.721 0.071
363.483 252.734 Unknown Control 1.215 1.171 1.564 1.204 1.307 1.336 0.120 0.040 0.061 0.009
OVX 1.935 1.515 1.231 1.586 1.191 1.548 0.109
OVXG 1.508 1.293 1.277 1.410 1.321 1.209 0.155
OVXG2 1.319 1.649 1.318 1.269 1.123 1.237 0.155
463.408 252.756 Unknown Control 1.390 1.334 1.682 1.348 1.476 1.514 0.114 0.022 0.095 0.033
OVX 2.005 1.700 1.424 1.798 1.370 1.693 0.104
OVXG 1.645 1.480 1.387 1.600 1.472 1.403 0.147
OVXG2 1.482 1.712 1.421 1.443 1.313 1.419 0.147
446.353 252.783 Unknown Control 2.671 2.564 3.119 2.658 2.841 2.880 0.178 0.019 0.050 0.010
OVX 3.685 3.084 2.824 3.343 2.625 3.135 0.163
OVXG 3.126 2.809 2.655 2.986 2.777 2.542 0.230
OVXG2 2.855 3.423 2.639 2.717 2.506 2.740 0.230
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421.309 262.580 Unknown Control 7.003 6.071 8.082 6.955 7.082 7.808 0.641 0.016 0.024 0.043
OVX 10.304 7.994 6.426 8.894 6.990 8.575 0.585
OVXG 8.587 6.368 6.535 8.004 6.763 6.997 0.827
OVXG2 6.508 7.708 6.977 6.549 6.279 6.775 0.827
431.337 263.058 Unknown Control 2.036 1.782 2.496 1.910 2.042 2.141 0.193 0.027 0.014 0.007
OVX 3.044 2.299 1.948 2.560 1.873 2.407 0.158
OVXG 2.308 2.053 1.914 2.279 2.063 1.912 0.223
OVXG2 2.072 2.283 2.092 2.013 1.819 1.992 0.223
1006.634 264.130 Unknown Control 0.476 0.393 0.517 0.522 0.479 0.471 0.034 0.400 0.006 0.026
OVX 0.627 0.482 0.417 0.500 0.423 0.438 0.031
OVXG 0.478 0.473 0.428 0.474 0.459 0.375 0.044
OVXG2 0.443 0.432 0.451 0.456 0.463 0.420 0.044
698.436 287.913 Unknown Control 0.868 0.820 1.058 0.981 0.988 0.981 0.091 0.172 0.099 0.008
OVX 1.361 1.022 0.869 1.111 0.854 0.932 0.083
OVXG 0.952 0.853 0.724 1.058 1.094 0.874 0.117
OVXG2 0.900 1.094 0.713 0.842 0.822 0.956 0.117
697.434 287.940 Unknown Control 2.086 1.947 2.519 2.287 2.314 2.477 0.185 0.128 0.198 0.012
OVX 3.165 2.538 2.104 2.679 2.122 2.285 0.169
OVXG 2.399 2.200 2.018 2.354 2.510 2.270 0.239
OVXG2 2.186 2.589 2.032 2.198 2.131 2.175 0.239
714.424 287.945 Unknown Control 0.357 0.305 0.397 0.388 0.388 0.396 0.030 0.171 0.080 0.023
OVX 0.519 0.386 0.338 0.422 0.355 0.371 0.027
OVXG 0.378 0.351 0.317 0.341 0.396 0.384 0.038
OVXG2 0.351 0.406 0.342 0.371 0.343 0.362 0.038
1343.662 305.375 Unknown Control 0.495 0.393 0.459 0.486 0.482 0.581 0.044 0.488 0.304 0.006
OVX 0.593 0.500 0.458 0.453 0.447 0.375 0.040
OVXG 0.460 0.386 0.447 0.512 0.490 0.334 0.057
OVXG2 0.416 0.452 0.390 0.436 0.363 0.572 0.057
1336.683 305.781 Unknown Control 1.690 1.413 1.752 1.516 1.695 2.078 0.188 0.632 0.245 0.005
OVX 2.299 1.802 1.537 1.726 1.542 1.386 0.172
OVXG 1.701 1.486 1.842 1.943 1.501 1.333 0.243
OVXG2 1.321 1.592 1.158 1.629 1.301 2.093 0.243
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459.370 308.910 Unknown Control 1.759 1.650 2.252 1.764 1.883 1.841 0.141 0.056 0.077 0.006
OVX 2.616 2.094 1.724 2.178 1.798 2.038 0.128
OVXG 2.092 1.840 1.748 2.080 1.891 1.726 0.181
OVXG2 1.880 2.082 1.845 1.867 1.746 1.771 0.181
460.373 308.921 Unknown Control 0.456 0.410 0.525 0.436 0.463 0.485 0.037 0.095 0.013 0.006
OVX 0.681 0.528 0.422 0.545 0.425 0.492 0.034
OVXG 0.521 0.456 0.437 0.527 0.486 0.429 0.048
OVXG2 0.457 0.537 0.450 0.483 0.431 0.451 0.048
726.468 329.701 Unknown Control 7.054 6.543 8.122 7.433 7.734 7.328 0.505 0.251 0.231 0.043
OVX 9.685 7.809 6.940 8.370 7.183 7.448 0.461
OVXG 7.887 7.212 6.730 7.754 8.158 7.554 0.652
OVXG2 7.143 8.108 6.947 7.096 7.284 7.441 0.652
1373.753 334.826 Unknown Control 0.488 0.423 0.490 0.645 0.585 0.633 0.053 0.387 0.101 0.004
OVX 0.635 0.499 0.439 0.489 0.505 0.395 0.049
OVXG 0.419 0.429 0.473 0.516 0.570 0.419 0.069
OVXG2 0.490 0.395 0.440 0.508 0.366 0.664 0.069
1229.752 334.836 Unknown Control 7.514 6.738 7.264 8.017 7.870 8.720 0.777 0.759 0.578 0.031
OVX 8.455 7.722 7.160 7.567 7.153 5.541 0.710
OVXG 6.339 6.427 6.614 8.470 8.669 6.257 1.004
OVXG2 7.237 6.706 6.040 7.389 5.390 9.446 1.004
1255.772 334.890 Unknown Control 5.663 5.506 6.155 6.702 5.892 7.362 0.599 0.691 0.532 0.026
OVX 6.819 6.041 5.686 5.963 6.286 4.774 0.546
OVXG 3.636 5.583 5.119 6.556 6.646 5.827 0.773
OVXG2 5.943 5.138 5.393 5.976 5.527 7.299 0.773
487.400 358.665 Unknown Control 1.204 1.040 1.401 1.025 1.108 1.248 0.105 0.806 0.048 0.027
OVX 1.599 1.259 0.965 1.327 1.007 1.211 0.096
OVXG 1.232 1.186 1.066 1.329 1.201 1.073 0.136
OVXG2 1.200 1.324 1.149 1.182 1.089 1.171 0.136
474.403 388.188 Unknown Control 4.607 4.457 5.283 4.518 4.729 4.757 0.266 0.020 0.045 0.014
OVX 6.110 5.247 4.717 5.546 4.581 5.205 0.243
OVXG 5.309 4.880 4.591 5.415 4.768 4.415 0.344
OVXG2 4.660 5.530 4.649 4.682 4.397 4.641 0.344
520.409 388.282 Unknown Control 3.679 3.500 4.147 3.660 3.779 3.808 0.215 0.025 0.176 0.039
OVX 4.856 4.186 3.725 4.432 3.609 4.123 0.197
OVXG 3.752 3.932 3.592 4.026 3.820 3.647 0.278
OVXG2 3.825 4.206 3.912 3.746 3.635 3.828 0.278
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748.720 403.700 Unknown Control 44.136 45.701 60.513 47.490 40.579 53.153 4.110 0.002 0.105 0.001
OVX 66.991 53.829 53.609 57.016 49.066 54.930 3.751
OVXG 39.241 50.416 34.798 56.008 49.049 27.226 5.305
OVXG2 58.153 57.596 54.300 50.387 43.122 53.193 5.305
581.526 416.170 Unknown Control 40.752 40.118 46.305 41.760 44.470 42.890 1.987 0.051 0.834 0.022
OVX 51.986 46.418 43.172 48.570 43.075 46.472 1.814
OVXG 46.470 44.453 44.407 45.663 45.193 43.492 2.565
OVXG2 41.342 49.486 46.761 43.607 43.804 42.491 2.565
582.529 416.221 Unknown Control 15.604 15.363 17.526 15.866 16.916 16.413 0.804 0.026 0.835 0.019
OVX 19.911 17.639 16.443 18.717 16.369 18.433 0.734
OVXG 17.744 17.047 16.827 17.751 17.421 16.414 1.038
OVXG2 15.593 19.627 17.459 16.406 16.212 16.373 1.038
301.166 435.228 Unknown Control 1.879 1.794 2.345 1.948 1.982 2.200 0.203 0.198 0.269 0.031
OVX 2.906 2.370 1.816 2.483 1.982 2.086 0.185
OVXG 2.282 2.164 1.697 2.337 2.409 1.869 0.262
OVXG2 1.957 2.419 2.081 2.062 1.985 1.914 0.262
611.564 465.028 Unknown Control 2.606 2.592 3.006 2.703 2.728 2.805 0.154 0.030 0.456 0.016
OVX 3.460 3.037 2.786 3.114 2.694 2.978 0.141
OVXG 2.972 2.811 2.664 2.967 2.787 2.613 0.199
OVXG2 2.373 3.282 2.819 2.690 2.617 2.802 0.199
609.559 465.031 Unknown Control 30.679 29.182 34.309 30.631 31.732 31.720 1.569 0.024 0.139 0.027
OVX 39.445 34.496 31.558 35.928 30.930 34.014 1.432
OVXG 34.329 32.352 31.072 33.681 31.733 30.213 2.025
OVXG2 31.233 36.671 32.192 31.048 30.005 31.663 2.025
610.561 465.035 Unknown Control 12.368 12.102 13.920 12.504 12.868 12.795 0.633 0.025 0.101 0.014
OVX 16.146 13.946 12.872 14.614 12.505 13.714 0.578
OVXG 14.097 13.098 12.549 13.855 12.834 11.950 0.818
OVXG2 12.546 15.075 13.007 12.507 12.489 12.813 0.818
1270.904 480.311 Unknown Control 0.328 0.312 0.398 0.383 0.379 0.397 0.022 0.082 < 0.0001 0.011
OVX 0.366 0.337 0.357 0.413 0.347 0.383 0.020
OVXG 0.352 0.257 0.274 0.381 0.309 0.319 0.029
OVXG2 0.420 0.220 0.394 0.361 0.358 0.353 0.029
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614.509 480.487 Unknown Control 0.465 0.443 0.544 0.446 0.490 0.504 0.033 0.038 0.058 0.012
OVX 0.653 0.539 0.454 0.570 0.474 0.545 0.030
OVXG 0.542 0.473 0.442 0.527 0.506 0.442 0.042
OVXG2 0.500 0.538 0.519 0.530 0.420 0.492 0.042
758.427 480.646 Unknown Control 0.576 0.553 0.677 0.601 0.642 0.599 0.031 0.235 0.241 0.045
OVX 0.703 0.646 0.596 0.657 0.574 0.675 0.029
OVXG 0.682 0.583 0.628 0.662 0.607 0.625 0.040
OVXG2 0.610 0.635 0.628 0.594 0.536 0.584 0.040
613.505 480.656 Unknown Control 1.277 1.227 1.517 1.275 1.343 1.378 0.089 0.076 0.101 0.015
OVX 1.743 1.461 1.258 1.542 1.268 1.423 0.081
OVXG 1.499 1.245 1.290 1.482 1.390 1.066 0.115
OVXG2 1.296 1.415 1.269 1.337 1.257 1.299 0.115
657.513 480.830 Unknown Control 0.497 0.485 0.577 0.451 0.523 0.523 0.036 0.062 0.323 0.034
OVX 0.681 0.578 0.494 0.595 0.484 0.574 0.033
OVXG 0.587 0.576 0.525 0.583 0.564 0.488 0.047
OVXG2 0.503 0.537 0.560 0.499 0.504 0.521 0.047
638.593 510.821 Unknown Control 3.148 3.034 3.365 3.134 3.250 3.180 0.138 0.076 0.046 0.045
OVX 3.997 3.462 3.230 3.288 3.167 3.459 0.126
OVXG 3.578 3.354 3.447 3.383 3.272 3.239 0.178
OVXG2 3.215 3.561 3.438 3.220 3.175 3.261 0.178
637.589 510.834 Unknown Control 7.098 7.065 8.125 7.222 7.448 7.486 0.376 0.018 0.114 0.021
OVX 9.506 8.074 7.591 8.493 7.341 8.132 0.343
OVXG 8.367 7.860 7.712 8.181 7.697 7.258 0.485
OVXG2 7.543 8.746 7.153 7.449 7.177 7.776 0.485
639.596 510.964 Unknown Control 7.098 7.065 8.125 7.222 7.448 7.486 0.376 0.018 0.114 0.021
OVX 9.506 8.074 7.591 8.493 7.341 8.132 0.343
OVXG 8.367 7.860 7.712 8.181 7.697 7.258 0.485
OVXG2 7.543 8.746 7.153 7.449 7.177 7.776 0.485
654.580 511.106 Unknown Control 2.297 2.224 2.495 2.260 2.323 2.400 0.116 0.010 0.097 0.032
OVX 2.914 2.490 2.373 2.634 2.251 2.505 0.106
OVXG 2.582 2.260 2.182 2.465 2.284 2.287 0.150
OVXG2 2.173 2.484 2.218 1.966 2.256 2.401 0.150
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685.542 524.206 Unknown Control 2.452 2.233 2.721 2.310 2.548 2.316 0.118 0.043 0.029 0.004
OVX 3.071 2.720 2.397 2.768 2.373 2.656 0.108
OVXG 2.814 2.631 2.467 2.684 2.537 2.440 0.153
OVXG2 2.520 2.856 2.653 2.444 2.420 2.385 0.153
714.598 541.327 Unknown Control 0.676 0.597 0.877 0.665 0.808 0.732 0.064 0.079 0.528 0.006
OVX 0.990 0.782 0.702 0.883 0.679 0.859 0.058
OVXG 0.808 0.709 0.750 0.833 0.776 0.786 0.083
OVXG2 0.714 0.911 0.689 0.618 0.657 0.720 0.083
527.446 564.287 Unknown Control 5.401 5.206 5.841 5.239 5.585 5.440 0.258 0.026 0.057 0.024
OVX 6.638 5.959 5.305 6.139 5.216 6.100 0.236
OVXG 6.147 5.677 5.234 5.877 5.404 5.582 0.333
OVXG2 5.591 5.779 5.633 4.668 5.341 5.396 0.333
759.761 598.998 Unknown Control 3.123 3.247 3.773 3.126 3.382 3.224 0.162 0.184 0.546 0.041
OVX 3.898 3.425 3.280 3.641 3.330 3.595 0.148
OVXG 3.574 3.383 3.223 3.296 3.179 3.204 0.209
OVXG2 3.327 3.597 3.304 3.233 3.238 3.077 0.209
832.494 602.039 Unknown Control 0.399 0.373 0.451 0.369 0.392 0.401 0.022 0.150 0.050 0.047
OVX 0.480 0.448 0.386 0.434 0.357 0.442 0.020
OVXG 0.444 0.406 0.424 0.417 0.414 0.376 0.028
OVXG2 0.401 0.413 0.401 0.413 0.371 0.382 0.028
656.636 643.039 Unknown Control 5.337 5.618 6.353 5.785 5.970 5.660 0.252 0.017 0.389 0.015
OVX 7.002 6.307 5.831 6.572 5.711 6.281 0.230
OVXG 6.421 5.975 5.774 5.482 5.733 5.702 0.325
OVXG2 5.978 6.405 5.943 5.806 5.854 5.767 0.325
1326.901 394.961 Unknown Control 3.676 3.793 3.951 3.506 3.821 3.974 0.237 0.016 0.022 0.046
OVX 5.093 4.272 3.827 4.550 3.734 4.229 0.217
OVXG 4.214 4.003 3.374 4.400 3.986 3.678 0.307
OVXG2 3.986 4.484 3.910 3.938 3.463 3.749 0.307
1385.971 394.562 Unknown Control 0.770 0.793 0.821 0.748 0.783 0.793 0.055 0.081 0.004 0.025
OVX 1.116 0.868 0.766 0.902 0.733 0.834 0.050
OVXG 0.884 0.844 0.703 0.938 0.768 0.749 0.071
OVXG2 0.778 0.933 0.747 0.789 0.771 0.800 0.071
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Appendix D. Chapter 7 Supplementary information 
 
Lipids  
Entire cohort 
 
Table D.1: Significant lipids associated to postmenopausal women with normal 
and low femoral neck BMD in univariate and multivariate approaches.  
 
Box plot analysis was performed to analise the overall levels of those 5 plasma 
lipids between groups (Figure D.1).  
 
Figure D.1: Boxplots showing normalised peak intensities from original LC-MS 
data of lipids between postmenopausal women with low and normal BMD. PS 
(phosphatidylserine), DG (diacylglycerol), plasmeyl-PE 
(plasmenylphosphatidylethanolamines). 
  
m/z RT 
(sec) 
Compound 
710.396 167.767 PS 31:6; [M+H]+ 
738.427 167.765 PS 33:6; [M+H]+ 
682.365 167.371 PS 29:6; [M+H]+ 
718.634 218.244 DG 42:4; [M+NH4]+ 
752.567 397.265 plasmenyl-PE 38:4; [M+H]+ 
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Subset 
Table D.2: Significant lipids associated to a subset of selected postmenopausal 
women with normal (n =15) and low femoral neck BMD (n =15) in univariate and 
multivariate approaches.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
m/z RT 
(sec) 
Compound 
667.424 207.010 PA 34:4; [M-H]- 
674.546 344.08 CerP 38:1; [M+H]+ 
558.245 248.659 PS 20:4; [M-H]- 
698.663 248.467 DG 40:0; [M+NH4]+ 
738.427 167.765 PS 33:6; [M+H]+ 
710.396 167.767 PS 31:6; [M+H]+ 
724.411 167.417 PS 32:6; [M+H]+ 
557.242 248.783 PI 14:0; [M-H]- 
718.634 218.244 DG 42:4; [M+NH4]+ 
478.320 251.065 CerP 24:0; [M-H]- 
786.701 571.528 DG 47:5; [M+NH4]+ 
828.653 464.336 PE 42:1; [M-H]- 
 290 
   
 
Normal and low femoral neck BMD showed a similar range of lipid levels (Figure 
3). However, PA, PS, PI and PE compounds showed a higher level in the low 
group compared with the normal BMD group.  
 
 
Figure D.2: Boxplots showing normalised peak intensities from original LC-MS 
data of lipids between postmenopausal women with low and normal BMD. PS 
(phosphatidylserine), PA (phosphatidic acid), DG (diacylglycerol), plasmenyl-PE 
(phosphatidylethanolamine), Cer-P (ceramide-1-phosphate), PE 
(phosphatidylethanolamine) and PI (phosphatidylinositol). 
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Metabolites 
Entire cohort 
 
Table D.3: Significant polar metabolites associated to postmenopausal women 
with normal and low femoral neck BMD in univariate and multivariate approaches.  
m/z RT 
(sec) 
Compound 
104.070 628.58 4-Aminobutyric acid 
200.031 936.972 Threonine 
293.091 888.961 Asn-Gly-Cys 
381.026 886.248 Turanose 
 
 
Normal and low femoral neck BMD showed a similar range of 4 aminobutyric 
acid, threonine, Asn- Gly-Cys and turanose concentratios (Figure 5  
 
 
Figure D.3: Boxplots showing normalised peak intensities from original LC-MS 
data of polar metabolites between postmenopausal women with low and normal 
BMD.  
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Subset 
Table D.4: Significant polar metabolites associated to a subset of selected 
postmenopausal women with normal (n =15) and low femoral neck BMD (n =15) 
in univariate and multivariate approaches.  
 
m/z RT 
(sec) 
Compound 
116.070 731.838 Proline 
71.060 642.821 Aminopropionitrile 
200.031 936.972 Threonine 
150.058 654.108 Methionine 
293.091 888.961 Asn-Gly-Cys 
 
Results from boxplots of the plasma polar metabolomic analysis showed lower 
range of proline, aminopropionitrile and threonine in the low BMD group (Figure 
D.4). 
 
Figure D.4: Boxplots showing normalised peak intensities from original LC-MS 
data of polar metabolites between postmenopausal women with low and normal 
BMD.  
